




EASL CONGRESS

7-10 May 2025

Amsterdam, the Netherlands



ABSTRACT BOOK

#EASLCongress

easlcongress.eu



Contents

Acute liver failure and drug induced liver injury - Basic	3
Acute liver failure and drug induced liver injury - Clinical	6
Alcohol-related liver disease and MetALD - Basic.....	7
Alcohol-related liver disease and MetALD - Clinical	9
Cirrhosis and its complications: ACLF and Critical illness	14
Cirrhosis and its complications: Experimental and pathophysiology.....	20
Cirrhosis and its complications: Other clinical complications except ACLF and critical illness ..	26
Cirrhosis and its complications: Portal Hypertension	37
Fibrosis / Stellate cell biology.....	47
Gut microbiota and liver disease / Liver-organ crosstalk.....	50
Hepatocyte biology.....	54
Immune-mediated and cholestatic disease: Clinical aspects.....	55
Immune-mediated and cholestatic: Experimental and pathophysiology	65
Liver development and regeneration.....	68
Liver immunology	70
Liver transplantation and hepatobiliary surgery - Basic.....	75
Liver transplantation and hepatobiliary surgery - Clinical	76
Liver tumours: Clinical aspects except therapy	83
Liver tumours: Experimental and pathophysiology	90
Liver tumours: Therapy	100
MASLD: Clinical aspects except therapy.....	105
MASLD: Diagnostics and non-invasive assessment.....	115
MASLD: Experimental and pathophysiology	128
MASLD: Therapy	139
Non-invasive assesment of liver disease except MASLD.....	145
Nurses and Allied Health Professional.....	147
Public Health: Except Viral Hepatitis	150
Public Health: Viral Hepatitis	156
Rare liver diseases (including paediatric and genetic) - Basic	163
Rare liver diseases (including paediatric and genetic) - Clinical	166

Viral hepatitis A/E: Clinical aspects	173
Viral hepatitis B and D: Clinical aspects	173
Viral Hepatitis B and D: Current therapies	181
Viral Hepatitis B and D: New therapies, unapproved therapies or strategies	186
Viral Hepatitis C: Clinical aspects including follow up after SVR	189
Viral hepatitis C: Therapy and resistance	192
Viral Hepatitis: Experimental and pathophysiology.....	193

Acute liver failure and drug induced liver injury - Basic

181

Longitudinal assessment of liver stiffness for up to 96 weeks by magnetic resonance elastography and correlation with fibrosis markers in alpha-1 antitrypsin deficiency-associated liver disease: results from phase 2 studies of fazirsiran

Poster presentation

Presenter: Rohit Loomba

259

Abrogation of hepatic TRb action protects the liver from acute liver injury

Poster presentation

Presenter: Denise Zwanziger

422

Adrenomedullin as an immunomodulator of CD14+MerTK+ circulating monocytes in liver failure syndromes

Poster presentation

Presenter: Francesca Maria Trovato

527

The PPAR agonists Saroglitazar and Rosiglitazone provide hepatoprotection after APAP-induced liver injury in E2f1-/- mice

Poster presentation

Presenter: Paul Gomez-Jauregui

602

Gadoxetate-enhanced MRI detects acute rifampicin-induced inhibition of hepatocellular transporter function in rats and normalization of function after chronic dosing

Poster presentation

Presenter: Paul Hockings

651

Single-cell RNA sequencing reveals a fundamental role of LCN2+ neutrophils in the innate immune response in drug-induced acute-on-chronic liver failure

Poster presentation

Presenter: Yang Zhi

727

ECM1 mitigates PAs-induced hepatic sinusoidal obstruction syndrome in mice by interacting with MMP9

Poster presentation

Presenter: Jiamei Chen

767

A comparison of the protective effects of Rimforegtide (HTD4010) and DUR-928 on acute liver failure in mice

Poster presentation

Presenter: Ru Bai

1078

Drug-induced liver injury in biopsy-scaled precision-cut liver slices

Poster presentation

Presenter: Milan Lobo

1212

Prognostic significance of very high and towering peak alanine aminotransferase (ALT) values with normal or near normal total bilirubin in patients with idiosyncratic drug-induced liver injury

Poster presentation

Presenter: Naga Chalasani

1415

Biomimetic ceria lipoprotein nanoparticle enable NAC-enhanced macropinocytosis-dependent liver-targeting delivery for the treatment of APAP-induced liver injury

Poster presentation

Presenter: Yaoxing Chen

1434

Flavin-containing monooxygenase 3 (Fmo3) knockout mouse reveals the role of Fmo3 in female tolerance to acetaminophen-induced liver injury

Poster presentation

Presenter: Chibuisi Alimba

1497

Signaling interaction between TGF- β and EGF controls LPC proliferation and performing liver function in ALF

Poster presentation

Presenter: Chenhao Tong

1507

Lipid metabolites in acute and chronic liver damage: Do N-acyl taurines protect the liver?

Poster presentation

Presenter: Anna Hassing

1660

Brown adipose tissue-derived extracellular vesicles administration alleviates liver injury in mice

Poster presentation

Presenter: Leyu Zhou

1955

Metabolomic profiling to differentiate drug-induced liver injury from other liver diseases using machine learning models

Poster presentation

Presenter: Daniel E. Di Zeo-Sánchez

1970

Dynamic transition of hepatocyte subtypes highlights novel repair pathways in acute liver failure after hBMSCT transplantation

Poster presentation

Presenter: Jun Li

2237

Elevated plasma chenodeoxycholic acid as a prognostic marker and therapeutic target in acute liver failure: role of bacteroides intestinalis AM1 intervention in bile acid modulation and mitigation of liver injury

Oral presentation

Presenter: Sushmita Pandey

2300

miR148a-3p may play a direct role in regulating inflammatory responses in bacterial infection related acute-on-chronic liver injury

Poster presentation

Presenter: Ersin Karatayli

2451

Chronic plus binge ethanol feeding impact on cholesterol metabolism in liver- and intestine-specific Abcg5/g8 knockout mice

Poster presentation

Presenter: Senem Ceren Karatayli

2483

Patients with acute decompensation of cirrhosis present a unique methylation signature associated with their outcome

Oral presentation

Presenter: Estefania Huergo

2531

Enhanced prediction of drug-induced liver injury in keratinocyte-based high-content single-cell screening integrating machine learning

Poster presentation

Presenter: Ángela Remesal-Doblado

2552

Genetic polymorphisms associated with idiosyncratic drug-induced liver injury: a systematic review and bioinformatic analysis

Poster presentation

Presenter: Gonzalo Matilla-Cabello

2582

Drug-induced hepatic sinusoidal obstruction syndrome: clinical characteristics analysis and preliminary exploration of mechanisms

Poster presentation

Presenter: Mingyan Ji

2810

Coordinated liver tissue regeneration becomes ineffective with increasing injury in patients with acute indeterminate liver failure

Poster presentation

Presenter: Richard Sittner

2933

Validation of markers of hepatocyte senescence for the prognosis of patients with severe acute hepatitis

Poster presentation

Presenter: MohammadMahdi Saeidinejad

2974

Targeting cGAS/STING pathway and ferroptosis for protection against hepatic ischemia-reperfusion injury

Poster presentation

Presenter: Yasmeen Attia

2999

Serum levels of immune checkpoints in drug-induced liver injury and metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Juan Pedro Toro Ortiz

Acute liver failure and drug induced liver injury - Clinical

583

Haemophagocytic lymphohistiocytosis – a rare but deadly cause of acute liver failure

Poster presentation

Presenter: Esme Gardiner

935

Increased risk of hepatic steatosis in young adults treated for first-episode psychosis; a retrospective study

Poster presentation

Presenter: Tristan Rocheleau

952

Polyreactive immunoglobulin G is elevated in autoimmune hepatitis and acute liver failure

Poster presentation

Presenter: Theresa Kirchner

1214

Therapeutic plasma exchange improves outcomes in Amanita phalloides induced acute liver failure – results from an interim analysis of the Amanita-PEX study

Poster presentation

Presenter: Alejandro Campos Murguía

1304

Evaluation of different large language models' performance in answering common questions from drug-induced liver injury patients

Poster presentation

Presenter: Yinuo Dong

1391

Effects of universal early antimicrobial treatment in acute liver failure patients at a large volume transplant centre in the United Kingdom

Poster presentation

Presenter: Gladson Thomas

1550

Therapeutic and clinical outcomes of continuous renal replacement therapy and plasma exchange in acute liver failure patients

Poster presentation

Presenter: Anshuman Das

1637

Liver injury induced by CDK4/6 inhibitors for metastatic breast cancer: characterization and management. Data from a multicenter study

Oral presentation

Presenter: Mar Riveiro-Barciela

2543

Plasma exchange to treat severe acute liver injury: opportunity to improve native liver survival

Poster presentation

Presenter: Vijay Alexander

2790

Combination therapy with plasma exchange and continuous renal replacement therapy improves transplant free outcomes in acute liver failure: a tertiary care center experience

Poster presentation

Presenter: Manasa Alla

2989

Checkpoint inhibitor-induced liver injury in patients with advanced skin cancer: a single center experience

Poster presentation

Presenter: Sebastiano Archilei

3058

ESSENTIAL: Efficacy and safety of non-transplant therapies for acute liver failure syndromes due to infective etiologies

Poster presentation

Presenter: Ramit Mahajan

Alcohol-related liver disease and MetALD - Basic

594

Gut microbiota derived immunological signature in metabolic alcohol associated liver disease

Poster presentation

Presenter: Jung A Eom

762

Digital pathology biomarkers describe fibrosis severity and disease activity in the FAT-MASH murine model and response to preventative treatment with mannose

Poster presentation

Presenter: Jaime Chu

809

The role of aryl hydrocarbon receptor across different cellular targets in pectin's improvement of alcohol-associated liver disease

Poster presentation

Presenter: Wanchao Hu

984

Potential therapeutic target for the treatment of alcohol-related liver disease through magnesium homeostasis

Poster presentation

Presenter: Irene González-Recio

1144

Cytokine release assay QuantiFERON Monitor predicts 90-day mortality in patients with severe alcohol-related hepatitis

Poster presentation

Presenter: Paula Boeira

1437

Liver-targeted mRNA therapeutics through fibroblast growth factor 21 and apolipoprotein A1 delivery in experimental acute pancreatitis

Poster presentation

Presenter: Matías A Avila

1614

Metabolomic and transcriptomic insights into gender-specific PFAS effects on liver disease
Poster presentation
Presenter: Shashank Gupta

1648
A new translational dietary rat model allows studying MetALD natural history and assessing the efficacy of various therapeutic interventions
Poster presentation
Presenter: María Martínez-Gómez

1987
Plasma exosome antigens as prognostic biomarkers in alcohol-associated hepatitis
Poster presentation
Presenter: Anna Brujats

1994
The anticoagulant Edoxaban improves portal hypertension and liver injury in progressive liver disease
Poster presentation
Presenter: Katharina Bonitz

2025
Prevalence, genetic risks, and cardiovascular outcomes of Met-ALD in a longitudinal multiethnic U.S. cohort
Poster presentation
Presenter: Jie Yao

2061
Disruption of receptor-interacting protein kinase 1 post-translational modifications in alcohol-associated liver disease
Poster presentation
Presenter: Laura Nagy

2264
Bio-molecular characterization of albumin identifies predictors of disease severity and early mortality in severe alcohol associated hepatitis
Poster presentation
Presenter: Sushmita Pandey

2350
Hepatocyte-neutrophil interaction in the liver via SAA-FPR2 is key in the pathogenesis of alcohol-associated hepatitis
Oral presentation
Presenter: Alicia Martínez-Álvarez

2485
Altered high density lipoprotein 3 and associated proteins signatures contribute to immune dysfunction in alcohol associated liver cirrhosis
Poster presentation
Presenter: Shivani Gautam

2490
PNPLA3 risk variant and shortened telomere are independent risk factors for alcohol related liver disease: an indian cohort study
Poster presentation
Presenter: Vaishali Yadav

2752

Single-cell RNA sequencing and lipidomics identify synergistic effects of alcohol and PNPLA3 I148M on hepatic pathology

Poster presentation

Presenter: Stephen Hoang

2822

Ethanol-induced hepatic immune-metabolic dysregulation exacerbates atherosclerosis progression in Ldlr^{-/-} mice

Poster presentation

Presenter: Constanze Hoebinger

3027

Outcomes in a real-world patient group started on Acamprosate for alcohol use disorder (AUD) with co-existent advanced fibrosis: adherence, efficacy and clinical impact over 24 months

Poster presentation

Presenter: Helen White

Alcohol-related liver disease and MetALD - Clinical

40

The Mediating role of body mass index in the association between alcohol consumption and elevated liver enzyme levels in adults attending a tertiary care hospital in Chennai, South India

Poster presentation

Presenter: Arivarasan Barathi

194

Rising proportion of young adults and women on the U.S. liver transplant waitlist for end-stage liver disease attributed to rising alcohol-associated liver disease following the COVID-19 pandemic

Poster presentation

Presenter: Shyam Patel

227

Comorbidities at diagnosis of alcohol-related liver cirrhosis compared to the general population: a population-based case-control study of 11,989 patients

Poster presentation

Presenter: Gustav Jakobsson

336

Maintaining a low to moderate alcohol consumption over time in MASLD patients increases the risk of fibrosis progression over moderate drinkers and MetALD patients

Poster presentation

Presenter: Ares Villagrana

371

Monitoring hepatic function at 90 days of abstinence predicts recompensation and reduced liver-related mortality in patients with decompensated alcohol-related cirrhosis

Poster presentation

Presenter: Jan Embacher

456

Validating the association between alcohol-related hepatitis and alcohol-related cirrhosis: a population-based study

Poster presentation

Presenter: Lucy Wilson

468

Prevalence and predictors of early re-hospitalization or death among a national cohort of veterans hospitalized for alcohol-associated hepatitis in the United States

Poster presentation

Presenter: Robert Wong

534

Performance of six biomarkers compared to histological fibrosis stage as surrogate markers of clinical endpoints in drug trials of patients with MetALD and ALD - a dual biopsy study

Poster presentation

Presenter: Ellen Lyngbeck Jensen

552

Steatosis independent of fibrosis predict hepatic decompensation and mortality in patients with MetALD and ALD

Poster presentation

Presenter: Mette Lehmann Andersen

610

A call to action - shortfalls and variation in care for inpatients with alcohol related liver disease in the UK: results of the ALERT UK national audit

Poster presentation

Presenter: Laura Burke

706

Liver death trajectories differ in patients with alcohol consumption and/or metabolic syndrome: a 13-year nationwide study

Poster presentation

Presenter: Claire Delacôte

722

High-risk PNPLA3 rs738409 genotype is associated with higher CCL2 concentrations in liver transplant candidates with alcohol - related liver disease

Poster presentation

Presenter: Tomislav Kelava

741

Comparative perioperative morbidity and mortality of transplantation for alcohol-related hepatitis or liver disease: data from the QuickTrans study

Oral presentation

Presenter: Line Carolle Ntandja Wandji

846

Performance of MELD 3.0 in predicting 90- and 180-day mortality in alcoholic hepatitis

Poster presentation

Presenter: Ana Suárez-Saro Fernández

906

Alcohol as a mediator of genetic and metabolic risk for fibrosis and steatosis in SLD

Poster presentation

Presenter: Jan Embacher

958

Routine, pre-emptive anti-craving treatment to prevent alcohol relapse after liver transplantation

Poster presentation
Presenter: Pedro de Borba Engster

995

Discrepancies between self-reported alcohol intake and phosphatidylethanol in 2,925 individuals at risk of steatotic liver disease

Oral presentation
Presenter: Katrine Bech

1196

Impact of alcohol binge duration and metabolic features on liver stiffness in steatotic liver disease

Poster presentation
Presenter: Frances Lee

1209

Prospective study of phosphatidylethanol as a quantitative, objective biomarker to detect under-reported alcohol use in steatotic liver disease

Poster presentation
Presenter: Federica Tavaglione

1280

Bacterial infections in patients with severe alcoholic hepatitis: drivers of organ failure and mortality

Poster presentation
Presenter: Laura Buttler

1386

Prospective evaluation of undiagnosed MetALD prevalence in MASLD patients using the ani score

Poster presentation
Presenter: Carlos Alventosa-Mateu

1566

Steatosis predicts poor abstinence rates in patients with alcohol use disorder

Poster presentation
Presenter: Queralt Herms

1626

ALD is diagnosed at more advanced stages of fibrosis as compared to MetALD and MASLD in the general population

Poster presentation
Presenter: Jordi Gratacós-Ginès

1633

Will individuals with alcohol use disorder participate in screening for chronic liver disease?

Poster presentation
Presenter: Pernille Dahlin

1651

MetALD has a higher rate of extrahepatic cancer and cardiovascular events compared to other subtypes of steatotic liver disease

Poster presentation
Presenter: Katrina Pekarska

1733

Urinary proteomics identifies complement as potential biomarkers in severe alcohol-associated hepatitis patients

Poster presentation
Presenter: Laura Nagy

1887
Unemployment and social isolation predict relapse in patients with alcohol related cirrhosis
Poster presentation
Presenter: Christopher Oldroyd

1948
A prospective study on hepatic fibrosis evaluation in an alcohol withdrawal unit of an university hospital: role of FIB-4 and elastometry. FIBRADDICT study
Poster presentation
Presenter: Armand Abergel

2011
Cause-specific mortality across the spectrum of steatotic liver disease: a nationwide cohort study
Poster presentation
Presenter: Pedro Ochoa-Allemant

2113
Fecal microbiota transplantation is associated with improvement in survival compared to standard of care in severe alcoholic hepatitis: systematic review and meta-analysis
Poster presentation
Presenter: Jakub Hoferica

2129
Colorectal cancer incidence in steatotic liver disease (MASLD, MetALD, and ALD)
Poster presentation
Presenter: Takefumi Kimura

2232
Misclassification of alcohol use disorder in MASLD and MetALD: prevalence, clinical characteristics, and outcomes
Poster presentation
Presenter: Hyo Young Lee

2286
Histological features predict response to corticosteroids and short-term survival in severe alcohol-associated hepatitis
Poster presentation
Presenter: Rudolf Stauber

2368
Younger, sicker, higher mortality; the burden of alcohol related liver disease in Ireland
Poster presentation
Presenter: Clare Foley

2387
Cardiac performance is impaired in patients with proven alcohol related hepatitis and predicts 3-month mortality in this patient population
Poster presentation
Presenter: Shantha Valainathan

2443
Fibroblast activation assessed by PRO-C3 and PRO-C6 is associated to accumulation of key bile acids - A hallmark of fibrosis initiation and mortality in alcohol-related liver disease

Poster presentation

Presenter: Andressa de Zawadzki

2471

Hot & cold fibrosis: fibro-inflammatory biomarkers as prognostic tools in alcohol-related liver disease

Poster presentation

Presenter: Andressa de Zawadzki

2475

Corticosteroids are ineffective in individuals with severe alcohol-associated hepatitis and early spontaneous improvement: a multicenter randomized controlled trial

Oral presentation

Presenter: Christophe Moreno

2533

Impact of diabetes mellitus on mortality in alcohol-related acute-on-chronic liver failure: a study from the AARC database

Poster presentation

Presenter: Ashish Kumar

2632

Efficacy and safety of fecal microbiota transplantation in patients with severe alcohol-related hepatitis or decompensated liver cirrhosis: a systematic review and meta-analysis

Poster presentation

Presenter: Nabil El Hage Chehade

2642

ELIBIO MRI-based Digital liver biopsy correlates with elastography and blood test in patients with chronic liver diseases (CLD)

Poster presentation

Presenter: Juliette Foucher

2765

Augmenter of liver regeneration as a novel biomarker in alcohol-related liver disease: insights into disease progression and prognosis

Poster presentation

Presenter: Pratibha Garg

2788

Feasibility and effectiveness of a liver health check clinic in community alcohol services

Poster presentation

Presenter: Daniel Gutmann

2843

Plasma exchange as a rescue therapy for patients with severe alcohol-associated hepatitis

Poster presentation

Presenter: Anand Kulkarni

2847

Stratification of liver fibrosis in individuals at-risk of metabolic dysfunction and alcohol-associated liver disease (MetALD)

Poster presentation

Presenter: Luis Antonio Diaz

2977

Disease severity is more important than age and underlying cirrhosis at predicting mortality from alcohol related hepatitis
Poster presentation
Presenter: Huw Purssell

3075
Predictors of alcohol relapse in patients with alcohol-associated liver disease after liver transplant evaluation
Poster presentation
Presenter: Mohamad Ali Ibrahim

Cirrhosis and its complications: ACLF and Critical illness

61
Time-varying effect of acute-on-chronic liver failure on post-liver transplant survival accounting for selection bias
Poster presentation
Presenter: Tomohiro Tanaka

137
Interleukin-22 is a predictor for pre-ACLF and short-term mortality in cirrhosis
Poster presentation
Presenter: Nikola Mareljic

209
Real-world evidence on clinical outcomes and microbiome changes after healthy donor stool transplantation as palliative therapy compared to best supportive care in patients with unstable decompensations in alcohol-related end-stage liver disease
Poster presentation
Presenter: Cyriac Philips

294
Plasma interleukin-33 as a novel diagnostic marker for invasive pulmonary aspergillosis in patients with acute-on-chronic liver failure: a prospective study
Poster presentation
Presenter: Lanyue Huang

370
Prevalence of advanced liver fibrosis and accuracy of non-invasive tests in primary, secondary and tertiary care in Austria
Poster presentation
Presenter: Paul Thöne

465
HDL-C, Cholesterol and the ALT/HDL-C ratio are predictors of survival in patients with acute-on-chronic liver failure
Poster presentation
Presenter: Georg Kramer

466
Elevated lipase levels during acute-on-chronic liver failure are linked to increased mortality
Poster presentation
Presenter: Georg Kramer

491

Rifaximin use does not significantly affect the rate of 30-day mortality or liver transplant in patients with cirrhosis on Daptomycin in two national US-based cohorts

Poster presentation

Presenter: Jasmohan Bajaj

681

Acute-on-chronic kidney disease in cirrhosis- a global study

Oral presentation

Presenter: Jasmohan Bajaj

690

Outpatient sbp prophylaxis associates with higher sbp recurrence in a global cohort of cirrhosis inpatients with greatest impact in high- income countries

Poster presentation

Presenter: Jasmohan Bajaj

698

Pathophysiological basis of acute on chronic liver failure (ACLF) triggered by alcohol-related hepatitis or infection using circulating biomarkers of inflammation, circulatory dysfunction and albumin modifications

Poster presentation

Presenter: Julian Pohl

710

The AMMON-OHE model predicts liver-related complications in outpatients with cirrhosis: a prospective cohort study of the AMMON consortium

Poster presentation

Presenter: María Pilar Ballester

754

Benefit-to-risk profile in the label-specific population of patients with hepatorenal syndrome-acute kidney injury treated with terlipressin

Poster presentation

Presenter: Michael Curry

755

Intermediate-term survival in patients with hepatorenal syndrome-acute kidney injury treated with terlipressin

Poster presentation

Presenter: R. Todd Frederick

877

Integrated analyses of cytokine and metabolomics profiles uncover pathways regulating acute-on-chronic liver failure induced mortality

Poster presentation

Presenter: Hai Li

891

Predicting the risk of clinically relevant bleeding in patients with acute-on-chronic liver failure and acute decompensated liver cirrhosis

Poster presentation

Presenter: Sanna Norén

902

Intraperitoneal administration of VS-01 captures accumulated metabolites in patients with acutely decompensated liver cirrhosis

Poster presentation
Presenter: Berenice Alard

969
Human cytomegalovirus reactivation in cirrhotic individuals with acute decompensation
Poster presentation
Presenter: Changze Hong

977
Prevalence and characteristics of bacterial and fungal infections in end-stage liver disease: a multi-center, cross-sectional study from central China
Poster presentation
Presenter: Wei Liu

1002
Fibroblast growth factor 19 (FGF-19) predicts transplant free-survival in critically ill patients with acute-on-chronic liver failure
Poster presentation
Presenter: Maike Rebecca Pollmanns

1035
Oral anticoagulants are safe and may reduce risk of hepatic decompensation in patients with cirrhosis and atrial fibrillation
Poster presentation
Presenter: Axel Wester

1150
Yaq-001 positively impacts gut microbiome composition, virulence, antimicrobial resistance gene profile resulting in significant effects on ammonia, endotoxemia and inflammation in cirrhosis patients
Poster presentation
Presenter: Jinxia Liu

1159
AI-AD score: a novel machine learning-based model for predicting acute liver decompensation progression – a prospective observational study
Poster presentation
Presenter: Andrea Dalbeni

1169
Long term abdominal drains: a five-year study of safety and efficacy of long-term abdominal drains in a tertiary referral centre
Poster presentation
Presenter: Jemma Mickleburgh

1210
Establishment of a sarcopenia decline curve for patients with liver cirrhosis to develop hepatic rehabilitation medicine
Poster presentation
Presenter: Hiroteru Kamimura

1230
The presence of chronic kidney disease does not worsen 28- or 90-day survival in cirrhotic patients with acute on chronic liver failure
Poster presentation
Presenter: Saktivel Elangovan

1232

The burden of extrahepatic organ failures in European patients with cirrhosis

Poster presentation

Presenter: Wenyi Gu

1311

Dual plasma molecular adsorption system therapy in patients with acute-on-chronic liver failure: a non-randomized cluster-controlled study (PADSTONE)

Oral presentation

Presenter: Beiling Li

1332

APASL ACLF research consortium (AARC) liver failure score and first week (transplant window) defines the limits of medical management and time frame for liver transplant in acute on chronic liver failure patients

Poster presentation

Presenter: Sudhir Verma

1420

The etiology of chronic liver disease is an independent prognostic factor in patients with acutely deteriorated chronic liver disease

Poster presentation

Presenter: Do Seon Song

1425

Severe liver disease patients had dysfunctional platelets hypoergic to adenosine diphosphate

Poster presentation

Presenter: Jinjun Chen

1579

Modification of mortality risk scores with dynamic serum creatinine definition improves survival discrimination in patients with decompensated cirrhosis

Poster presentation

Presenter: Julian Allgeier

1615

Efficacy of Granulocyte Colony-stimulating factor in hepatitis B virus-associated acute-on-chronic liver failure patients: a multicenter study

Poster presentation

Presenter: Jinhua Hu

1649

Acute-on-chronic liver failure in Australia: a non-transplant centre experience

Poster presentation

Presenter: Annie Zhou

1656

Prediction of circulatory failure in patients with liver cirrhosis and acute-on-chronic liver failure on the intensive care unit

Poster presentation

Presenter: Hendrik Matthias Rogge

1754

A machine-learning algorithm using real-world data identified subpopulations at risk for adverse outcomes in patients with acute-on-chronic liver failure

Poster presentation

Presenter: Katharina Stauffer

1883

Outperformance of the COSSH diagnostic framework for acute-on-chronic liver failure: a global aetiology cohort

Poster presentation

Presenter: Jun Li

1928

Loss of hepatic leptin clearance is associated with development of acute-on-chronic liver failure

Poster presentation

Presenter: Frederike Krus

1944

Single-cell multimodal analysis reveals cellular dynamics underlying divergent immune response trajectories in HBV-ACLF progression

Poster presentation

Presenter: Jun Li

1957

Clinical impact of non selective beta-blockers in patients with cirrhosis and acute kidney injury: a post hoc analysis of the international club of ascites GLOBAL-AKI study

Oral presentation

Presenter: Simone Incicco

1961

Supporting unified management for patients with prior or first decompensation: evidence from three ACLF criteria

Poster presentation

Presenter: Meiqian Hu

1964

Multidrug-resistant organism colonization and outcomes in critically ill patients with cirrhosis: evidence from a tertiary care center

Poster presentation

Presenter: Iva Košuta

2053

One-week criteria of potential care inappropriateness for patients with acute-on-chronic liver failure not eligible for liver transplantation

Poster presentation

Presenter: Thierry Gustot

2155

Impact of blood cell count derived inflammatory markers on the outcome of critically ill cirrhotic patients

Poster presentation

Presenter: Paulo Bittencourt

2188

Development of an AI-driven predictive model and decision support system for managing acute-on-chronic liver failure: insights from the KACLIF cohort

Poster presentation

Presenter: Hyung Joon Yim

2216

Impact of home-based hepatology nurse-led care on disease knowledge in recently hospitalised patients with cirrhosis
Poster presentation
Presenter: Leya Nedumannil

2305
Non-acute decompensation of cirrhosis is a clinically and biologically distinct phenotype in cirrhosis
Poster presentation
Presenter: Nipun Verma

2400
A retrospective study of puncture counts and diagnostic accuracy in 119 patients undergoing transjugular liver biopsy
Poster presentation
Presenter: Asako Nogami

2478
Vasopressin is safe and effective as a second vasopressor in patients with cirrhosis and septic shock: results of the VITEL-C trial. NCT05315557
Poster presentation
Presenter: Rakhi Maiwall

2719
Pre-existing sarcopenia as the 7th organ failure and one of the leading predictors of 90-day mortality in acute decompensated cirrhosis
Poster presentation
Presenter: Yan Ling Ong

2758
Excess ICU mortality in septic patients with cirrhosis compared to a population without cirrhosis in two contemporary prospective cohorts
Poster presentation
Presenter: Natalia Jimenez-Esquivel

2795
Efficacy of 5% albumin versus plasmalyte in combination with 20% albumin for fluid resuscitation in cirrhosis with sepsis induced hypotension. A randomized controlled trial (ALPS Plus)
Poster presentation
Presenter: Ayush Jain

2897
An argument for risk-based case-finding in chronic liver disease
Poster presentation
Presenter: Sava Handjiev

2935
Loss of paraspinal skeletal muscle tissue is independently associated with increased 90-, but not 28-day mortality in patients with acute-on-chronic liver failure
Poster presentation
Presenter: Julian Pohl

2952
Interprofessional therapeutic drug monitoring of Piperacillin/Tazobactam enhances care for patients with acute-on-chronic liver failure in the ICU
Poster presentation
Presenter: Stephan Schmid

2953

Predictors of shock reversal and outcomes in acute-on-chronic liver failure with septic shock

Poster presentation

Presenter: Vishnu Girish

2966

The COPPTRIAHL randomized controlled study, a preliminary analysis

Poster presentation

Presenter: Rui Pereira

Cirrhosis and its complications: Experimental and pathophysiology

77

Propranolol reverses splanchnic β -adrenergic induced small intestinal barrier disruption stabilizing gut-liver axis in experimental cirrhosis

Poster presentation

Presenter: Elisa Castillo

87

Recombinant ADAMTS13 attenuates LPS-induced acute kidney injury and renal microangiopathy in mice with liver cirrhosis by cleaving vWF

Poster presentation

Presenter: Hiroyuki Masuda

151

Spleen Area affects the predictive performance of the platelet count-based non-invasive tools in MASLD

Poster presentation

Presenter: Marcello Dallio

189

Aurora Kinase A (AURKA): dual roles in liver disease progression and regulation of YAP1 and GSK-3 β dynamics

Poster presentation

Presenter: Clarissa Joy Garcia

245

A disintegrin and metalloproteinase with a thrombospondin type 1 motif 13 and von Willebrand factor axis regulates acute kidney injury in mice with liver cirrhosis

Poster presentation

Presenter: Norihisa Nishimura

298

Albumin as a therapeutic target for endothelial dysfunction in patients with decompensated cirrhosis

Poster presentation

Presenter: Susan Fischer

312

Hemodynamic and non-hemodynamic effects of non-selective beta-blockers in experimental and human acute-on-chronic liver failure

Oral presentation

Presenter: Vlad Taru

332

Downregulation of interleukine-6 receptors on ascitic T cells may shape the immune compartment in the peritoneal cavity
Poster presentation
Presenter: Helena Stadler

425
The in vitro immune response of mononuclear cells to Escherichia coli is not dependent on antibiotic multidrug resistance
Poster presentation
Presenter: Berta Cuyàs

549
Comparison of hepatocellular carcinoma risk scores in people with cirrhosis: concordance analysis of four prediction tools
Poster presentation
Presenter: Sude Yazar

566
Toll-like receptor 4 inhibition restores cytochrome C oxidase mitigating hyperammonemia-induced hepatocyte mitochondrial dysfunction
Poster presentation
Presenter: Supachaya Sriphoosanaphan

653
Bone morphogenetic protein 9 (BMP9): a novel therapeutic agent for the prevention of circulatory and renal failure in animal models of acute-on-chronic liver failure (ACLF)
Poster presentation
Presenter: Alexandra Phillips

719
Global trends in antimicrobial resistance in chronic liver disease patients with bacteremia: a systematic review and meta-analysis of observational studies
Poster presentation
Presenter: Ellis Paintsil

733
Immunocompetence in outpatients and hospitalized chronic liver disease patients: gene expression profiles and cell-type estimation from stimulated whole blood
Poster presentation
Presenter: Xiaomian Tan

769
Risk of hypoglycemia in people with cirrhosis without diabetes
Poster presentation
Presenter: Alan Hutchison

801
Associations between cardiorespiratory fitness and physical frailty in patients with cirrhosis
Poster presentation
Presenter: Alexis Couret

940
Efficacy of the apoptosis-signal-regulating kinase 1 (ASK1) inhibitor SRT-015 in in vivo and in vitro pathogen-associated molecular patterns (PAMPs)-induced disease models
Poster presentation
Presenter: Vanessa Legry

1042

NTZ alleviates stress-induced hepatocyte cell death through modulation of oxidative stress and DNA damage signaling pathways in ACLF models

Poster presentation

Presenter: Marie Bobowski-Gerard

1068

A new 3D coculture spheroid model to study advanced liver diseases such as ACLF

Poster presentation

Presenter: Jessica Dieudonne

1086

Plasma-induced neutrophil dysfunction is a novel approach to identification of acutely decompensated cirrhosis patients at risk of infection

Poster presentation

Presenter: Supachaya Sriphoosanaphan

1155

Cyclooxygenase-2 promote hepatic microvascular thrombosis and portal hypertension via AKT/mTOR-Thbs1 pathway in partial inferior vena cava ligation mice

Poster presentation

Presenter: Jisen Xu

1290

Immunometabolism of mononuclear cells from blood and ascites in patients with decompensated cirrhosis: compartment-specific features of metabolic dysfunction

Poster presentation

Presenter: Hasan Tarik Cosgun

1325

Mitochondrial transfer from mesenchymal stem cells to hematopoietic stem cells mitigates bone marrow failure and promotes liver regeneration in pre-clinical model of cirrhosis

Poster presentation

Presenter: Manisha Bhardwaj

1366

Comparative analysis of surrogate markers of intestinal permeability, bacterial translocation, and gut vascular barrier damage across different stages of cirrhosis

Poster presentation

Presenter: Haedge Frederic

1368

Single-cell RNA sequencing of peripheral blood mononuclear cells in patients with acutely decompensated cirrhosis reveals a specific monocyte subset associated with an increased risk of progression to ACLF

Oral presentation

Presenter: Theresa Hildegard Wirtz

1410

Expression signatures of IL-18 and IL-18BP characterize stages of cirrhotic decompensation

Poster presentation

Presenter: Aenne Harberts

1455

Ultrasound localization microscopy for diagnosis of clinically significant portal hypertension: a prospective multicenter study

Poster presentation

Presenter: Wei Zhang

1539

An antimicrobial peptide, melittin attenuates gut urease activity and ammonia production in experimental model of cirrhosis

Poster presentation

Presenter: Deepika Jakhar

1676

Activated intestinal fibroblasts induce inflammatory Th17 differentiation in experimental cirrhosis

Poster presentation

Presenter: Oriol Juanola

1683

The metabolome of patients with cirrhosis hospitalized with overt hepatic encephalopathy and association with clinical course

Poster presentation

Presenter: Anindro Bhattacharya

1697

Sex-specific estradiol signaling in liver cirrhosis and portal hypertension

Poster presentation

Presenter: Fabian Schachteli

1708

Sex-specific differences in preclinical models of advanced chronic liver disease and portal hypertension

Poster presentation

Presenter: Peio Aristu

1740

Hepatocyte derived extracellular vesicles promote endothelial dedifferentiation in chronic liver disease through the miR-153-3p – pyroptosis axis

Poster presentation

Presenter: Anabel Fernández-Iglesias

1762

MeCP2 as epigenetic mechanosensor of liver sinusoidal endothelial cells in cirrhosis

Poster presentation

Presenter: Manuel Prampolini

1807

TLR7-mediated immunomodulation in experimental liver fibrosis

Poster presentation

Presenter: Dimitrios Patseas

1841

CLM-022, a dual inhibitor of priming and activation steps of NLRP3 inflammasome, as a potential treatment for acute and chronic inflammatory late-stage liver diseases

Poster presentation

Presenter: Guillaume Vidal

1932

Recombinant insulin-like growth factor-1: a novel therapy for patients with cirrhosis and ACLF

Poster presentation
Presenter: Wenting Tan

1967
Novel potential metabolomic mechanisms for albumin-related improvement in cognitive function in patients with patients with hepatic encephalopathy
Poster presentation
Presenter: Jasmohan Bajaj

2086
Neuropathological basis of brain failure in acute-on-chronic liver failure (ACLF): insights into the roles of hyperammonaemia and neuroinflammation
Poster presentation
Presenter: Tingting Qi

2094
Aberrant monocyte function promotes systemic inflammation in decompensated advanced chronic liver disease and can be therapeutically targeted
Poster presentation
Presenter: Malgorzata Grzelka

2215
Liver sinusoidal endothelial cell BRD4 drives inflammatory angiocrine signaling in liver fibrosis
Oral presentation
Presenter: Can Gan

2227
Matrix remodeling and versican upregulation in mesenteric lymph nodes modulate bacterial phagocytosis and migration of activated CD4+ T cells, fueling systemic bacterial infections in cirrhosis
Poster presentation
Presenter: Pinky Juneja

2262
Mesenchymal stem cells restore gut-liver axis integrity by targeting intestinal barrier dysfunction and MLN inflammation in cirrhotic mice
Poster presentation
Presenter: Sandeep Kumar

2267
Statins as an alternative therapy to improve the cardiac chronotropic dysfunction in cirrhotic cardiomyopathy in cirrhotic rats
Poster presentation
Presenter: Muhammad Shafique

2341
Epigenetic regulation of LSECtin in hepatic antigen presenting cells during experimental cirrhosis
Poster presentation
Presenter: Enrique Ángel-Gomis

2366
Proximity extension assay-based proteomics: a reliable tool for prediction of major adverse liver outcomes
Poster presentation
Presenter: Katharina Remih

2386
Characterization of the muscle-liver axis in a murine model of liver injury

Poster presentation
Presenter: Karen Rischmüller

2419
Synergy between ornithine phenylacetate and strategies targeting endotoxemia with either a toll-like receptor 4 antagonist (TAK-242) or Yaq-001 for the treatment of hyperammonemia in cirrhosis and ACLF
Poster presentation
Presenter: Tingting Qi

2440
Albumin infusion improves albumin binding capacity in patients with cirrhosis and MHE on gut-specific therapy
Poster presentation
Presenter: Anna Mestre

2466
Attenuation of inflammatory bystander CD8+ T cell activation in decompensated cirrhosis via non-selective beta-blockers
Poster presentation
Presenter: Ayesha Lietzau

2468
Transcriptomic and metabolic insights into hyperammonemia: the complementary therapeutic roles of toll-like receptor 4 inhibitor and ornithine phenylacetate
Poster presentation
Presenter: Supachaya Sriphoosanaphan

2476
Glycated albumin is increased in patients with cirrhosis and hepatic encephalopathy already on gut-directed therapy and links with cognitive and quality of life impairment
Poster presentation
Presenter: Anna Mestre

2515
Clinical relevance of the evaluation of cardiorespiratory fitness in patients with cirrhosis: a systematic review with meta-analysis
Poster presentation
Presenter: Alexis Couret

2516
Endotoxin induced Liver sinusoidal endothelial cell metabolic reprogramming promotes vascular dysfunction and contribute to portal hypertension in experimental cirrhosis
Poster presentation
Presenter: Vaibhav Tiwari

2698
Characterising renal dysfunction in chronic liver disease rodent models
Poster presentation
Presenter: Olivia Greenham

2750
Profiling of intestinal blood vessel-associated macrophages in cirrhosis
Poster presentation
Presenter: Lena Smets

2768

HBV-specific metabolic footprints and impact on mortality in patients with HBV reactivation and acute-on-chronic liver failure
Poster presentation
Presenter: Mirco Glitscher

2859
Siglec-5 is a functional biomarker that contributes to poor prognosis in patients with liver cirrhosis
Poster presentation
Presenter: Sachiyo Yoshio

2919
Development and validation of dimethylarginines (DAS) as a novel biomarker to identify pre-ACLF and predict outcomes following acute decompensation of cirrhosis in two prospective multicentre european cohorts
Poster presentation
Presenter: Kohilan Gananandan

2939
Early detection of hepatic encephalopathy using wearable sensors: preliminary data
Poster presentation
Presenter: Clelia Asero

2957
A biliary organoid model to investigate the malignant transformation of primary sclerosing cholangitis to cholangiocarcinoma
Poster presentation
Presenter: Noah Sendtner

Cirrhosis and its complications: Other clinical complications except ACLF and critical illness

45
Smoking aggravates inflammation, fibrogenesis, angiogenesis and cancer risk in patients with cirrhosis
Poster presentation
Presenter: Nina Dominik

127
Cirrhotic cardiomyopathy: Prevalence and clinical impact on liver cirrhosis outcomes
Poster presentation
Presenter: Takashi Kitagataya

139
Increasing 'Liver Frailty Index' scores are associated with increased mortality and unplanned hospital admission in patients with cirrhosis: a retrospective cohort study
Poster presentation
Presenter: Isobel Phillips

192
SHiNE-UK: a national evaluation of hepatocellular carcinoma surveillance and treatment pathways
Poster presentation
Presenter: Christopher Mysko

273

Obesity decreases liver-related death in patients with cirrhosis: a retrospective, propensity score-matched study

Poster presentation

Presenter: Kei Endo

311

Biomarker-based profiling of pathomechanisms across distinct clinical stages of cirrhosis

Poster presentation

Presenter: Vlad Taru

340

Periodontal diseases in cirrhosis: prevalence, microbiome profile and dental assessment safety and tolerability

Poster presentation

Presenter: Ji Jade King

356

Regulation and prognostic value of Fibroblast Growth Factor 23 in advanced chronic liver disease

Poster presentation

Presenter: Clemens Renhardt

375

Risk of hepatocellular carcinoma and cirrhosis decompensation in a large retrospective cohort of cirrhotic patients with autoimmune hepatitis

Poster presentation

Presenter: rawi hazzan

392

Liver cirrhosis detection by canine olfaction using randomized controlled blinded testing: a proof-of-concept study

Poster presentation

Presenter: suwadee aramwittayanukul

461

A metagenomics approach to frailty in patients with cirrhosis undergoing a multifactorial intervention

Poster presentation

Presenter: German Soriano

542

Prognostic performance of MELD and MELD 3.0 in 777 patients hospitalized with an acute decompensation of cirrhosis

Poster presentation

Presenter: Nikolaj Torp

545

Over the years, diagnostic problems in cirrhosis continue, but its etiology changes: chronic viral hepatitis is decreasing, steatotic liver disease is increasing

Poster presentation

Presenter: Zülal İstemihan

587

Physical frailty is associated with myosteatorsis and physical frailty assessment tools may predict the presence of myosteatorsis in liver cirrhosis

Poster presentation

Presenter: Alexandra Alexopoulou

604

The association between familial mediterranean fever and incidence liver cirrhosis: a population based matched cohort study

Poster presentation

Presenter: Michal Carmiel-Haggai

636

Clinical and hemodynamic factors associated with hemoglobin levels in patients with liver cirrhosis

Poster presentation

Presenter: Natalia Jimenez-Esquivel

693

Adherence to a remote monitoring platform for the liver cirrhosis population, a multicenter feasibility study

Poster presentation

Presenter: Britt van Ruijven

702

Phase angle as a predictive factor for mortality in hospitalized patients with cirrhosis

Poster presentation

Presenter: Fajardo Ordóñez Javier

752

Direct oral anticoagulants for Budd-Chiari syndrome following percutaneous angioplasty in a chinese cohort

Poster presentation

Presenter: Chengjian Wu

774

A novel non-invasive diagnostic model for high-risk varices in cirrhosis: a multicenter retrospective and prospective study

Poster presentation

Presenter: Junliang Fu

793

Novel sex-specific cut-offs for subcutaneous adipose tissue radiointensity in patients with cirrhosis: a post-hoc analysis

Poster presentation

Presenter: Simone Di Cola

799

Management of ascites in elderly patients with cirrhosis: results of an italian survey

Poster presentation

Presenter: Simone Di Cola

814

Identification of sarcopenia in patients with liver cirrhosis by combining anthropometry and ultrasound of thigh and psoas

Poster presentation

Presenter: Isabel Campos-Varela

834

An optimized diagnostic strategy for MHE in cirrhotic patients based on PHES normalization and Stroop-CN: a prospective multicenter study

Poster presentation

Presenter: Junliang Fu

920

Neurofilament light chains and glial fibrillary acidic protein in serum for predicting post-TIPS hepatic encephalopathy

Poster presentation

Presenter: Simon Johannes Gairing

953

Hepatic perfusion measured with ¹⁵Oxygen-water-Positron emission tomography/computed tomography correlates with severity of cirrhosis

Poster presentation

Presenter: Paul Runeson

1036

Highly variable antibiotic prescribing practices in a real world cohort of patients in the United Kingdom with decompensated cirrhosis

Poster presentation

Presenter: Gemma Wells

1039

Determinants of muscle mass in patients with liver cirrhosis

Poster presentation

Presenter: Martin Philipp

1044

Epidemiology and Risk factors for development of AKI-HRS based on the new consensus definition

Poster presentation

Presenter: Jeanette Pei Xuan Ng

1055

Prevalence and prognosis of cirrhotic cardiomyopathy in hospitalized patients with decompensated cirrhosis

Poster presentation

Presenter: Judith Cortada

1215

Branched-chain amino acids in liver cirrhosis and hepatic encephalopathy: a meta-analysis of clinical evidence

Poster presentation

Presenter: Luise Aamann

1224

Improved glycaemic control over time in patients with type 2 diabetes mellitus (T2DM), with and without cirrhosis: a territory-wide cohort study of 1.2 million patients in Hong Kong

Poster presentation

Presenter: Mary Yue Wang

1237

Cirrhotic cardiomyopathy: diagnostic challenges and debating role in mortality prediction in cirrhosis

Poster presentation

Presenter: Burcu Gurbuz

1241

Liver frailty index: a prognostic tool for predicting mortality in cirrhotic patients

Poster presentation

Presenter: Burcu Gurbuz

1252

Comparative study on the efficacy of TIPS versus Non-TIPS treatments for hepatic portal vein thrombosis complicated by upper gastrointestinal hemorrhage

Poster presentation

Presenter: Rongjiong Zheng

1267

Impact of parenteral nutrition on the risk of infections and the disease course of malnourished patients with decompensated liver cirrhosis

Poster presentation

Presenter: Laura Buttler

1279

Oral health and microbiome: do they influence cirrhosis outcomes? A comparison of cirrhotic patients with periodontitis versus those with good oral health

Poster presentation

Presenter: Ji Jade King

1297

To construct a prediction model of recompensation in HBV-related decompensated cirrhosis patients combined with the inflammation index MLR

Poster presentation

Presenter: Xu huaqian

1298

Impact of PPIs, PCABs, and Rifaximin on SBP risk in cirrhotic patients with moderate-to-severe ascites

Poster presentation

Presenter: Satoshi Miuma

1309

High mortality of further decompensation of liver cirrhosis: validation study

Poster presentation

Presenter: Petra Dinjar Kujundžić

1345

Randomized, open-label, phase 2a comparator study to assess the pharmacodynamics, safety and pharmacokinetics of oral administration of mnk6106 (l-ornithine phenylacetate) vs. rifaximin in subjects with hepatic cirrhosis and a previous history of hepatic

Poster presentation

Presenter: Rajiv Jalan

1364

Development and validation of the modified hepatic encephalopathy staging tool (mHEST) for grading of hepatic encephalopathy for accurate assessment and regulated clinical trials

Poster presentation

Presenter: Rajiv Jalan

1412

Prevalence and determinants of reduced muscle status among adults with cirrhosis attending liver clinics

Poster presentation

Presenter: Damian Harding

1429

Reduced COVID-19 vaccination effectiveness and clinical outcomes for decompensated cirrhosis: a nationwide population-based study

Poster presentation

Presenter: Won Sohn

1443

5-year outcomes of a dedicated, multidisciplinary clinic for decompensated cirrhosis

Poster presentation

Presenter: Alexander Mitropoulos

1472

Rehabilitation classes for sarcopenic cirrhotics, a proof of concept

Poster presentation

Presenter: Mariana Machado

1476

Specialist palliative care is under-utilized at end of life in chronic liver disease, especially in patients without liver cancer

Poster presentation

Presenter: Maria Valjus

1495

Transjugular intrahepatic portosystemic shunt implantation is associated with resolution of hepatopulmonary syndrome

Poster presentation

Presenter: Jim Benjamin Mauz

1525

Economic evaluation of LivR Well, a multidisciplinary, multimodal, home-based program for acute hepatic decompensation: interim analysis

Poster presentation

Presenter: Natalie Ngu

1624

Transcatheter closure of acquired portosystemic shunts for the management of refractory hepatic encephalopathy. A case-series

Poster presentation

Presenter: Natalie Ngu

1703

History of overt hepatic encephalopathy is associated with worsen cognitive tests and cerebral atrophy in a prospective cohort of outpatients with cirrhosis with multimodal evaluation and brain magnetic resonance imaging with diffusion tensor imaging

Poster presentation

Presenter: Lyès Kheloufi

1739

A study of clinical characteristics in 43 patients with porto-sinusoidal vascular disease

Poster presentation

Presenter: Chengjian Wu

1745

Urinary neutrophil gelatinase-associated lipocalin (NGAL) as a diagnostic and prognostic biomarker of acute kidney injury in patients with decompensated cirrhosis: an individual patient data meta-analysis

Oral presentation

Presenter: María José Moreta

1829

Factors associated with AKI development and external validation of the AKI prediction score

Poster presentation
Presenter: Jeanette Pei Xuan Ng

1832
Daily step count using pedometer for sarcopenia management in patients with cirrhosis: a randomized controlled trial
Poster presentation
Presenter: Witchuta Niamsanit

1849
A retrospective review of reduced dose argatroban in liver impairment
Poster presentation
Presenter: Sarah Sawieres

1875
Loculated ascites in the setting of spontaneous bacterial peritonitis is associated with increased morbidity and mortality
Poster presentation
Presenter: Anita Mahadevan

1893
Identification of prognosis determining risk factors in outpatients with cirrhosis
Poster presentation
Presenter: Clara Guntlisbergen

1988
Quantitative measurements of prothrombin in patients with cirrhosis and ascites: a validation study
Poster presentation
Presenter: Markus Maagaard

2005
Natural history of overt hepatic encephalopathy defining factors associated with progression, resolution and mortality
Poster presentation
Presenter: María Pilar Ballester

2007
Factors predicting response to long-term albumin administration and impact on survival in patients with decompensated cirrhosis. A single-centre real-world experience
Poster presentation
Presenter: Isabel Payeras

2013
High incidence of diuretic derived complications among patients with refractory ascites undergoing either TIPS implantation or insertion of tunneled peritoneal catheter
Poster presentation
Presenter: Sarah Lisa Schütte

2020
The novel classification as acute vs. non-acute decompensation provides prognostic value in cirrhosis patients developing ascites
Poster presentation
Presenter: Lucie Simonis

2027
Use of light-EEG to rule out covert hepatic encephalopathy in advanced chronic liver disease

Poster presentation
Presenter: Juliana Goediker

2031
Optimising management of patients discharged from hospital following an acute decompensation of cirrhosis – a multicentre UK perspective
Poster presentation
Presenter: Giovanna McGinty

2036
COVID-19 pandemic significantly increased anxiety and depression in patients with cirrhosis, but not in patients without liver disease
Poster presentation
Presenter: Greta Priebe

2039
Chronic Liver Disease and Autoimmune Haemolytic Anaemia: A Case Series
Poster presentation
Presenter: Dorien Pint

2041
Detection of Candida species via shotgun sequencing in patients with decompensated cirrhosis is associated with impaired survival and higher risk of acute-on-chronic liver failure
Poster presentation
Presenter: Sarah Lisa Schütte

2056
L-ornithine-L-aspartate improves quality of life and ammonia levels but not microbiome dysbiosis in cirrhosis: results of a phase 4 study
Poster presentation
Presenter: Vanessa Stadlbauer

2059
Dynopenia predicts mortality in patients with liver cirrhosis and hepatocellular carcinoma
Poster presentation
Presenter: Paolo Gallo

2070
Urinary microbiome alterations in patients with cirrhosis: a link to an increased urinary tract infection risk
Poster presentation
Presenter: Vanessa Stadlbauer

2157
The most common bacterial isolates in spontaneous bacterial peritonitis in a tertiary hospital center in Croatia and their antibiotic resistance
Poster presentation
Presenter: Sanja Stojšavljević Šapeski

2161
Role of renal biomarkers on sarcopenia and frailty in patients with cirrhosis
Poster presentation
Presenter: Won Sohn

2171
Functional and structural evaluation of patients with cirrhosis to consider recompensation

Poster presentation
Presenter: Jose Luis Perez Hernandez

2240
DOACs offer superior safety and survival over traditional agents in anticoagulant therapy for cirrhosis
Poster presentation
Presenter: Eun Young Cho

2241
Acute kidney disease in acutely decompensated cirrhosis: impact on clinical outcomes
Poster presentation
Presenter: Alberto Calleri

2269
Comparison of the animal naming test 1 minute versus 2 minutes for the screening of covert hepatic encephalopathy in a prospective cohort of outpatients with cirrhosis
Poster presentation
Presenter: Clara Modolo

2323
Current incidence of decompensating events, HCC and their prognostic impact on patients with compensated advanced chronic liver disease
Poster presentation
Presenter: Susana G. Rodrigues

2347
Clinical trajectories of patients with cirrhosis and ascites receiving long-term albumin. A proposal for a personalized management based on real-world experience
Poster presentation
Presenter: Enrico Pompili

2373
Impact of infections on the natural history of compensated advanced chronic liver disease: data from an individual patient data meta-analysis
Poster presentation
Presenter: Susana G. Rodrigues

2385
Prevalence and clinical impact of rectal colonization by multidrug-resistant (MDR) bacteria in patients with acute decompensation of cirrhosis
Poster presentation
Presenter: Nicola Zeni

2448
Gut colonization guided versus routine empiric antimicrobial therapy to manage infections in patients with cirrhosis: a pragmatic randomized trial
Oral presentation
Presenter: Jayant Agarwal

2473
Community-acquired infections requiring hospitalization in patients with alcohol-related cirrhosis
Poster presentation
Presenter: Clara Stenderup

2484

Variables associated with postoperative mortality in advanced chronic liver disease patients undergoing urgent or elective surgery. a multicentre spanish cohort
Poster presentation
Presenter: Lidia Canillas

2532
Muscle mass assessed by rectus femoris ultrasound predicts clinical outcomes in cirrhosis: a step beyond the "black-and-white" classification of sarcopenia
Poster presentation
Presenter: Roberta Gagliardi

2580
Hospital acquired infection is associated with higher mortality in patients hospitalised with acute decompensation of liver cirrhosis and infection
Poster presentation
Presenter: Gemma Wells

2604
A systematic review and meta-analysis of the ability of novel biomarkers to differentiate subtype of acute kidney injury and predict response to terlipressin treatment
Poster presentation
Presenter: Olivia Greenham

2610
A multicentre randomised double-blind placebo-controlled phase 1b clinical trial evaluating the safety and mechanism of action of EBX-102, an oral pooled intestinal microbiota product, in liver cirrhosis: the IMPuLCE trial
Oral presentation
Presenter: James McIlroy

2611
Evaluation of the clinical utility of wearable fitness tracking devices to diagnose frailty in patients with liver cirrhosis – A proof-of-concept study
Poster presentation
Presenter: Jonna Friederike Zimmermann

2650
Attitudes towards exercise among patients with advanced chronic liver disease: a survey
Poster presentation
Presenter: Matthew McKenna-Barry

2676
Sustained improvement in minimal hepatic encephalopathy and quality of life in patients with cirrhosis through two-session fresh fecal microbiota transplantation: An open-label pilot randomized controlled trial (The FLAME trial)
Poster presentation
Presenter: Ankit Agarwal

2697
Identifying potential baseline risk factors for further decompensation in patients with cirrhosis and early decompensation: analysis of data from a phase 2 randomized trial
Poster presentation
Presenter: Nancy S. Reau

2710
The prognostic role of LiverRisk score in patients with compensated cirrhosis

Poster presentation
Presenter: Marta Tonon

2727

FastPHES offers a rapid but valid alternative for the detection of cognitive impairment in patients with liver cirrhosis

Poster presentation
Presenter: Julius Egge

2730

Effect of exercise based regimen on frailty in children with liver disease-a randomized controlled trial

Poster presentation
Presenter: Deepika Yadav

2736

Lipopolysaccharide-binding protein indicates risk for infections and liver-related death in patients with compensated and decompensated liver cirrhosis

Poster presentation
Presenter: Rhea Veelken

2770

Impact of growth hormone therapy on complications, disease severity, and frailty in decompensated cirrhosis: a randomized controlled trial

Poster presentation
Presenter: Parminder Kaur

2789

Mortality in patients hospitalised with decompensated cirrhosis and infection is associated with higher baseline measures of infection and organ dysfunction

Poster presentation
Presenter: Gemma Wells

2813

Hybrid care models in liver disease management: lessons from telemedicine during the COVID-19 pandemic

Poster presentation
Presenter: Nada Abedin

2815

The impact of anticoagulant therapy on safety of variceal ligation in cirrhotic patients: a systematic review and meta-analysis

Poster presentation
Presenter: Madeleine Corkery-Hayward

2879

Effect of human albumin solution on coagulation parameters in decompensated cirrhosis (CoPA-D): an open-label randomized control trial

Poster presentation
Presenter: Omkar Rudra

2885

Elevated serum ammonia is a poor prognostic marker for 1 year liver related outcomes and external validation of AMMON-OHE prediction model in stable outpatient cirrhosis

Poster presentation
Presenter: Pooi Ling Loi

2890

Impact of diabetes mellitus on clinical outcomes in patients with acutely decompensated cirrhosis

Poster presentation

Presenter: Mimma Bonomo

2956

Minimal serum creatinine fluctuations impact on prognosis in acutely decompensated cirrhosis

Poster presentation

Presenter: Marco Tizzani

3037

Predictive value of systemic inflammation biomarkers towards recompensation versus progression to further decompensation in patients with decompensated cirrhosis

Poster presentation

Presenter: Dalila Costa

3048

Micronutrients supplementation in patients with liver cirrhosis: a single-arm prospective cohort study

Poster presentation

Presenter: Rohit Sawhney

Cirrhosis and its complications: Portal Hypertension

27

Right heart function on hemodynamic alterations and survival outcomes after transjugular intrahepatic portosystemic shunt

Poster presentation

Presenter: Yaozu Liu

32

Deep learning allows prediction of portal hypertension from liver biopsies

Poster presentation

Presenter: Thomas Sorz-Nechay

48

The safety and efficacy of trans-splenic portal vein recanalization-assisted TIPS for the treatment of portal vein obliteration: a multicenter retrospective study

Poster presentation

Presenter: Yaozu Liu

64

A multicentre randomised controlled trial of carvedilol versus variceal band ligation in primary prevention of variceal bleeding in liver cirrhosis (CALIBRE trial)

Oral presentation

Presenter: Dhiraj Tripathi

174

Impact of physical exercise and protein-enriched nutritional support on the development of post-TIPS hepatic encephalopathy

Poster presentation

Presenter: Anna Baiges

243

Incidence and clinical implications of abstinence-induced hepatic recompensation in decompensated alcohol-related cirrhosis
Poster presentation
Presenter: Benedikt Hofer

244
Dynamics in hepatic venous pressure gradient (HVPG) during the course of recompensated alcohol-related cirrhosis
Poster presentation
Presenter: Benedikt Hofer

270
Vibration-controlled transient elastography of the liver and the spleen for hepatic decompensation risk stratification in a european multicentre study of contemporary cACLD patients
Poster presentation
Presenter: Mathias Jachs

271
CT-based clinically significant portal hypertension: predicting complications in HCC hepatectomy
Poster presentation
Presenter: Subin Heo

323
Copeptin decrease after TIPS is linked to portal pressure and kidney function
Poster presentation
Presenter: Lukas Hartl

335
The efficacy of HCP407 in reducing dysphagia and chest pain following esophageal variceal ligation in patients with cirrhosis. Preliminary results of a prospective randomized study
Poster presentation
Presenter: Andres Cardenas

344
A novel MELD-copeptin score accurately predicts ACLF and liver-related death in patients with decompensated cirrhosis
Poster presentation
Presenter: Marlene Hintersteininger

454
Effect of albumin treatment duration on response rates and outcomes in patients with cirrhosis and acute kidney injury
Oral presentation
Presenter: Eva Maria Schleicher

463
Influence of low-dose acetylsalicylic acid on renal function in patients with liver cirrhosis and ascites
Poster presentation
Presenter: Henrik Karbanek

464
Validation of the blood-based Vienna 3P/5P portal hypertension risk models in patients with compensated advanced chronic liver disease
Poster presentation
Presenter: Georg Kramer

479

Biomarkers of pathophysiological mechanisms identify stage-specific drivers of disease progression in ACLD

Poster presentation

Presenter: Georg Semmler

481

Incidence and clinical significance of recompensation after HCV-cure

Poster presentation

Presenter: Georg Semmler

510

Prognostic performance of the enhanced liver fibrosis (ELF) test in patients with advanced chronic liver disease in tertiary care

Poster presentation

Presenter: Georg Kramer

526

Development and validation of a novel fibrosis digital pathology biomarker to predict portal pressure in patients with MASH cirrhosis

Poster presentation

Presenter: Mathieu Petitjean

541

Prognostic performance of MELD variants and CLIF-C AD in 958 patients with cirrhosis and ascites

Poster presentation

Presenter: Nikolaj Torp

585

Changes in spleen stiffness as assessed via vibration-controlled transient elastography at 100Hz reflect acute hepatic venous pressure gradient response to i.v. propranolol: a european multicenter study

Poster presentation

Presenter: Paul Thöne

671

Endoscopic ultrasound-guided portal pressure gradient predicts hepatic decompensation in compensated cirrhosis

Poster presentation

Presenter: Michael Yu

712

The role of hepatic venous pressure gradient in patients with porto-sinusoidal vascular disease

Poster presentation

Presenter: Xiaofeng Zhang

736

Role of spleen stiffness measurement by vibration-controlled transient elastography at 100Hz in guiding invasive hemodynamic reassessments after underdilated TIPS

Poster presentation

Presenter: Dario Saltini

753

Descriptive study of the impact of using non-cardioselective beta-blockers in cirrhotic patients after a first episode of ascites

Poster presentation

Presenter: Alejandro Fernandez Soro

790

Cardiopulmonary hemodynamics and liver stiffness changes in predicting cardiac decompensation after TIPS: a prospective study

Poster presentation

Presenter: Dario Saltini

800

Predicting post-TIPS hepatic encephalopathy risk in patients with cirrhosis and refractory ascites: a proof-of-concept study using a 4D MRI perfusional model

Poster presentation

Presenter: Dario Saltini

804

Real-world outcomes and treatment response to terlipressin in patients with hepatorenal syndrome - acute kidney injury: a multicenter study from the German cirrhosis/Terli-CKD study group

Poster presentation

Presenter: Eva Maria Schleicher

848

Prognostic performance of MELD 3.0 in patients undergoing transjugular intrahepatic portosystemic shunt placement - a retrospective multicentre study

Poster presentation

Presenter: Markus Kimmann

850

Unveiling the economic burden of decompensated cirrhosis: a comprehensive cost analysis

Poster presentation

Presenter: Mariana Esteves

889

Prognostic scores and clinical outcomes after covered TIPS placement: analysis of 987 cirrhotic patients from the multicenter international EASL-endorsed EuroTIPS registry

Oral presentation

Presenter: Anna Baiges

918

Advanced chronic liver disease in the context of further decompensation & recompensation – a multistate analysis of a contemporary prospective study

Poster presentation

Presenter: Georg Semmler

927

Ultrasound muscular thickness-based model to identify sarcopenia in patients with portal hypertension (PH): a cross-sectional single-center observational study

Poster presentation

Presenter: Martina Lucà

930

Machine and deep learning for non-invasive detection of esophageal varices in hepatocellular carcinoma patients

Poster presentation

Presenter: Asier Rabasco Meneghetti

964

Baveno VII algorithm was able to stratify the risk of portal hypertension-related events in patients with HBV-related cirrhosis
Poster presentation
Presenter: Haiyu Wang

971

Endoscopic ultrasound-guided therapies versus standard and modified balloon-occluded retrograde transvenous obliteration for management of fundal varices – a multicentric propensity-matched analysis
Poster presentation
Presenter: Suprabhat Giri

1032

Nutritional therapy prevents overt hepatic encephalopathy (OHE) in patients with cirrhosis after transjugular intrahepatic portosystemic shunt (TIPS): a randomized controlled trial
Oral presentation
Presenter: Ying Li

1058

Treatment response to terlipressin in patients with acute kidney injury - hepatorenal syndrome and preexisting chronic kidney disease – the german liver cirrhosis / CKD-Terli study group
Poster presentation
Presenter: Frank Erhard Uschner

1126

ANT at discharge can predicts further development of overt hepatic encephalopathy after elective TIPS placement
Poster presentation
Presenter: Mélisande Jorus

1127

Three-dimensional computed tomography angiography-based computational fluid dynamics simulation for noninvasive assessment of portal hypertension in patients with cirrhosis
Poster presentation
Presenter: Yang Tai

1165

Cirrhotic cardiomyopathy in patients underwent transjugular intrahepatic portosystemic shunt (TIPS): clinical impact of the updated diagnostic criteria for diastolic dysfunction
Poster presentation
Presenter: Chiara Becchetti

1177

Cardiac failure following transjugular intrahepatic portosystemic shunt patients with cirrhosis
Poster presentation
Presenter: Shu mei Du

1327

Determining the optimal portal pressure gradient after small-diameter TIPS for ascites: a cohort study
Poster presentation
Presenter: Guofeng Liu

1329

Factors associated with clinical deterioration in patients with ascites that may be preventable by TIPS
Poster presentation
Presenter: Lorenz Balcar

1334

Inter-assay/inter-laboratory comparison of von Willebrand Factor antigen as diagnostic and prognostic biomarker in advanced chronic liver disease

Poster presentation

Presenter: Lorenz Balcar

1417

A metabolomic model based on portal venous functional metabolites for predicting post-TIPS overt hepatic encephalopathy using machine learning methods

Poster presentation

Presenter: Xiaoze Wang

1424

Rate of recurrent gastrointestinal bleeding and outcomes in patients undergoing balloon-occluded retrograde obliteration (BRTO) versus transjugular intrahepatic portosystemic shunt (TIPS) for gastric variceal bleeding

Poster presentation

Presenter: Cristina Angelo

1454

TIPS for portal hypertensive gastropathy bleeding reduces further decompensation and mortality

Poster presentation

Presenter: Zeyu Wang

1547

Assessment of impact of ascitic fluid polymorphonuclear count on development of spontaneous bacterial peritonitis and survival in patients with liver cirrhosis and ascites

Poster presentation

Presenter: Sanjeev Jha

1620

Growth differentiation factor 11 increases after TIPS insertion, correlates with muscle mass and is an independent predictor of survival

Poster presentation

Presenter: Martin Kabelitz

1647

Risk factors of post-banding ulcer bleeding in patients with cirrhosis at a large tertiary center in Switzerland

Poster presentation

Presenter: Maria De Brito Nunes

1679

Targeted nutrition intervention improves frailty and quality of life in patients with liver cirrhosis

Poster presentation

Presenter: Saniya Khan

1704

CT-based imaging indices predict hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients

Poster presentation

Presenter: Xinyu Chen

1744

Dedicated stent decreases the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients

Poster presentation
Presenter: Shu mei Du

1746

Frailty, malnutrition, and sarcopenia are prevalent among patients with liver disease and are associated with worse health-related quality of life and complications of cirrhosis

Poster presentation
Presenter: Maria Dezan

1755

Prevention of hepatic encephalopathy following transjugular intrahepatic portosystemic: lactulose plus rifaximin vs. lactulose monophylaxis

Poster presentation
Presenter: Shu mei Du

1770

The Impact of lactulose on the gut microbiome and barrier function in patients with decompensated cirrhosis

Poster presentation
Presenter: Patricia Bloom

1793

Cirrhotic patients with acute variceal bleeding and an indication for preemptive-TIPS: real-life results

Poster presentation
Presenter: Jiajia He

1844

Prophylactic antibiotics cannot prevent infection in patients undergoing trans jugular intrahepatic portosystemic shunt or plug assisted retrograde transvenous obliteration electively for portal hypertension complications- a double-blind pilot randomized

Poster presentation
Presenter: Aashika Bhashyakarla

1871

Anemia following portal hypertension-related bleeding in liver cirrhosis: incidence and impact on prognosis

Poster presentation
Presenter: Asunción Ojeda

1878

Utility of spleen elastography in predicting transjugular intrahepatic porto-systemic shunt dysfunction in patients with liver cirrhosis

Poster presentation
Presenter: Asunción Ojeda

1923

Shunt cross-sectional area is a better predictor of overt hepatic encephalopathy than minimal hepatic encephalopathy

Poster presentation
Presenter: Elise Humerfelt

2066

Assessing portal hypertension with endoscopic ultrasound portal pressure gradient (eus-ppg): clinical correlations and procedural outcomes

Poster presentation
Presenter: Francesco Martini

2082

Frequency and impact of early and sustained hepatic recompensation after TIPS

Poster presentation

Presenter: Sophia Geißelbrecht

2126

Long-term outcomes of patients with porto-sinusoidal vascular liver disorder. A single-centre 10 year-follow-up study

Poster presentation

Presenter: Sanchit Sharma

2274

Benchmarking spleen stiffness in assessing response to beta-blocker therapy for secondary prophylaxis of acute variceal bleed- BE-RESPONSE study (NCT05166317)

Oral presentation

Presenter: Akhil Deshmukh

2292

Clinical outcomes of cirrhotic patients undergoing balloon-occluded retrograde transvenous obliteration for prevention of gastric variceal rebleeding

Poster presentation

Presenter: Luo Xuefeng

2344

Personalized biomarkers scores outperform established scores in the short- and long-term prediction of hepatocellular carcinoma and decompensation

Poster presentation

Presenter: Rosina Maria Critelli

2395

Non-invasive evaluation of portal hypertension in patients with advanced chronic liver disease undergoing major abdominal surgery

Poster presentation

Presenter: Lidia Canillas

2414

Exploring point-of-care ultrasound for diagnosis of spontaneous bacterial peritonitis in patients of decompensated cirrhosis - proof of concept study

Poster presentation

Presenter: Sunil Taneja

2545

Early need for paracentesis after TIPS is linked to further ascitic decompensation and impaired survival

Poster presentation

Presenter: Martin Kabelitz

2607

External validation of prognostic scores for post-TIPS mortality in a contemporary, Australian cohort

Poster presentation

Presenter: Nirbaanjot Walia

2693

The GEMA score predicts mortality in patients undergoing TIPSS for ascites

Poster presentation

Presenter: Jemima Finkel

2701

TIPS for hydropic decompensation improves short-term outcome: a case-control study

Poster presentation

Presenter: Eduardo Cervantes-Alvarez

2702

Effectiveness of carvedilol plus variceal band ligation compared to carvedilol alone in primary prophylaxis of variceal bleed in cirrhosis with high-risk oesophageal varices

Poster presentation

Presenter: Jata Shankar Kumar

2705

Limited value of liver frailty index to predict symptom control after insertion of a transjugular intrahepatic portosystemic shunt

Poster presentation

Presenter: Jonna Friederike Zimmermann

2707

A prospective multicenter study for comparison of standard-dose repeated bolus injection vs. low-dose continuous intravenous infusion of terlipressin for acute esophageal variceal bleeding in patients with liver cirrhosis

Poster presentation

Presenter: Hyung Joon Yim

2799

Long-term albumin treatment improves outcomes in patients with cirrhosis and ascites

Poster presentation

Presenter: Valeria Santori

2820

Colonization with multidrug resistant organisms is associated with poor outcomes in patients with decompensated cirrhosis of liver: a tertiary care center experience

Poster presentation

Presenter: Manasa Alla

2821

A pan-elastographic machine learning model for non-invasive diagnosis of clinically significant portal hypertension

Poster presentation

Presenter: Mauro Giuffrè

2857

Role of splenic stiffness in predicting outcomes in decompensated cirrhosis: an ambispective cohort study

Poster presentation

Presenter: Ayush Agarwal

2861

The AMMON-OHE model predicts post-TIPS overt hepatic encephalopathy

Poster presentation

Presenter: María Pilar Ballester

2886

Resolution of portal hypertension by transjugular intrahepatic portosystemic shunt (TIPS) implantation reverses markers of gut-barrier dysfunction, systemic inflammation and anti-inflammatory monocyte alterations in patients with decompensated liver cirrh

Poster presentation
Presenter: Felix Piecha

2906
Outcomes following transjugular intrahepatic portosystemic shunt in patients with hepatorenal syndrome and acute-on-chronic liver failure
Poster presentation
Presenter: Anand Kulkarni

2909
De novo decompensation and portal vein thrombosis are both linked to similar pathophysiologic alterations associated with advanced liver disease
Poster presentation
Presenter: Erica Villa

2912
Safety of seladelpar in primary biliary cholangitis patients with cirrhosis and clinical signs of portal hypertension: data from the ENHANCE and RESPONSE studies
Poster presentation
Presenter: Aliya Gulamhusein

2996
Hormone dysregulation in young people with liver disease and portal hypertension: an unrecognised problem that requires attention
Poster presentation
Presenter: Marianne Samyn

3009
Non-invasive prediction of clinically significant portal hypertension in patients with compensated advanced chronic liver disease of different aetiologies
Poster presentation
Presenter: Giulia Francesca Manfredi

3017
Evaluation of the Baveno VII criteria for predicting liver-related events in patients with advanced chronic liver disease – a single centre retrospective study
Poster presentation
Presenter: Rohit Sawhney

3053
Association between body mass index and adverse outcomes in patients with compensated cirrhosis
Poster presentation
Presenter: Abhinav Rao

3054
Multiparametric ultrasound for the prediction of the outcomes of endoscopic ligation of esophageal varices
Poster presentation
Presenter: Valentin Calvez

3107
Long-term outcome of interventional radiological management of Budd-Chiari syndrome: a retrospective, multicenter survey of 10 years
Poster presentation
Presenter: Guohong Han

Fibrosis / Stellate cell biology

44

Sex differences in aging rates and superoxide dismutase activity in patients with metabolic dysfunction-associated steatotic liver disease: implications for fibrosis risk

Poster presentation

Presenter: Anastasiia Radchenko

285

Blockage of microfibrillar-associated protein 4 (MFAP4) decreases liver fibrosis in two murine models of steatotic liver disease

Poster presentation

Presenter: Maximilian Joseph Brol

517

Neo-epitope biomarkers for fibrogenesis and neutrophil activity predict liver-related events in advanced chronic hepatitis C infection

Poster presentation

Presenter: Emilie Skovgaard

550

Single cell fixed RNA-seq revealed HSCLMCD1+LIMK2+ is a driver of liver fibrosis by modulating SMAD3-AKT-PRAS40-4EBP1

Poster presentation

Presenter: Pham Minh Duc

562

Use of the LiverRisk score for prediction of moderate to advanced liver fibrosis in United States adults

Poster presentation

Presenter: Mary E. Rinella

612

Defective autophagy in CD4 T cells drives liver fibrosis via type 3 inflammation

Oral presentation

Presenter: Rola Al Sayegh

806

Integrating spatial lipidomics with imaging mass cytometry: a novel approach for metabolic profiling of liver fibrosis

Poster presentation

Presenter: Aleksandra Gruevska

898

CCN5 promotes fibrogenic activation of hepatic stellate cells and serves as a biomarker for liver fibrosis

Poster presentation

Presenter: Yunhao Duan

960

Extracellular vesicle-dependent crosstalk between hepatic stellate cells and Kupffer cells promotes their mutual activation

Poster presentation

Presenter: Junyu Wang

1015

Engineering liver fibrosis in a three-dimensional, extracellular matrix-hydrogel, ex-vivo disease model

Poster presentation
Presenter: Frederik Højbjerg Svejsø

1017

A composite score of PRO-C6 and platelet count is prognostic for liver-related outcomes in patients with chronic hepatitis C

Poster presentation
Presenter: Thomas Wiggers

1202

Femoral vs hepatic vein plasma levels of collagen biomarkers confirm Pro-C3 as true marker of collagen synthesis in the fibrotic/cirrhotic liver

Poster presentation
Presenter: Rambabu Surabattula

1381

Dual inhibition of glutaminolysis and de novo amino acid synthesis underpins Pirfenidone's suppression of hepatic stellate cell activation

Poster presentation
Presenter: Jia Li

1383

A simple lab based machine learning model (FAET) predicts advanced Liver Fibrosis more accurately in MASLD patients

Poster presentation
Presenter: Shobha Sharma

1450

A human-like bile salt pool critically modulates liver fibrosis in bile duct ligation-challenging mice

Poster presentation
Presenter: Jingguo Li

1462

Endothelial Heg1 promotes liver sinusoidal endothelial cells capillarization to aggravate liver fibrosis

Oral presentation
Presenter: Yuting Zhang

1475

Investigating the role of Fn14 in metabolic associated steatohepatitis: effects on fibrosis, inflammation, and proliferation in a mouse model

Poster presentation
Presenter: Anouk Oldenburger

1546

Insulin-like growth factor binding protein 7 promotes the development of metabolic dysfunction-associated steatotic liver disease-related hepatic fibrosis and induces decreased cardiac function

Poster presentation
Presenter: Wenjing Ni

1616

The mechanisms of transcription factor ZEB2 in regulating hepatic stellate cell activation and liver fibrosis

Poster presentation
Presenter: Qianwen Zhao

1629

Targeting metabolic dysfunction-associated steatohepatitis with microRNA therapeutics

Poster presentation
Presenter: Cinzia Chinnici

1723

Nuclear factor I-B delays liver fibrosis by inhibiting chemokine ligand 5 transcription
Poster presentation
Presenter: Qianwen Zhao

1842

PPAR-alpha agonist GW7647 targeted to macrophages using dendrimer-graphite nanoparticles reduces liver fibrosis
Oral presentation
Presenter: Blanca Simón-Codina

1940

Inhibition of Adipocyte triglyceride lipase (ATGL) reduces fibrosis and portal hypertension in murine CCl4 liver fibrosis
Poster presentation
Presenter: Henriette Horstmeier

2164

Bortezomib improves advanced fibrosis by selectively inducing stellate cell apoptosis via downregulation of LGALS2 and CDH3 expression
Poster presentation
Presenter: Ling Wu

2199

CD8+ tissue-resident memory T cells promotes liver fibrosis resolution and are regulated by intestinal microbiota
Oral presentation
Presenter: Yuzo Koda

2461

The study of pathogenesis of the progression of liver cirrhosis
Poster presentation
Presenter: Oksana Shapoval

2479

Patients with chronic liver disease present elevated plasma levels of peptidylprolyl isomerase C associated with the degree of fibrosis
Poster presentation
Presenter: Ana Blas-García

2512

Cell-type specific roles of TGF- β 2 signaling in cholestatic liver disease progression and therapeutic targeting
Poster presentation
Presenter: Ida Harst

2588

Characterizing the differentiation and cellular heterogeneity of hepatic stellate cells derived from induced pluripotent stem cells
Poster presentation
Presenter: Zhengqing Xu

2601

Lycorine reduces liver fibrosis by inactivating hepatic stellate cells (HSCs) in mouse models of metabolic dysfunction-associated steatohepatitis (MASH)

Poster presentation

Presenter: Alma Diaz Ruiz de Zarate

2654

Human umbilical cord mesenchymal stem cells attenuate liver fibrosis in mice and inhibit hepatic stellate cell activation via secreting soluble factors

Poster presentation

Presenter: Qi Zhou

2700

Disease-specific human ECM composition and bioactivity in MASH liver fibrosis

Poster presentation

Presenter: Lisa Longato

2766

EmTPx promotes liver fibrosis via enhancing IL-33 secretion from macrophage

Poster presentation

Presenter: Tuerhongjiang Tuxun

2783

Novel natural killer cell immunotherapy through synthesized Neuroligin-4 peptides improved liver fibrosis

Poster presentation

Presenter: Johnny Amer

3089

Efficacy of CRV431 and Semaglutide on liver fibrosis in a mouse model of MASH

Poster presentation

Presenter: Asha Goodman

Gut microbiota and liver disease / Liver-organ crosstalk

157

Deep insights on gut bacterial associations with long-term clinical events, host immunology, and inflammatory cytokines in hospitalized Indian cohort of patients with cirrhosis

Poster presentation

Presenter: Cyriac Philips

158

The intestinal virome related clinical outcomes, systemic inflammation and immune functions in hospitalized cirrhosis patients – the foremost work in an indian patient cohort

Poster presentation

Presenter: Cyriac Philips

177

A single center experience from India on associations of fungal microbiota (mycobiome) in cirrhosis - orally-predominant fungal dysbiosis in the gut and immune-escaping Candida species drive outcomes in hospitalized patients

Poster presentation

Presenter: Cyriac Philips

254

Targeting the gut-liver crosstalk: the role of Gardenin A in alleviating alcohol-associated liver disease

Poster presentation
Presenter: Prashsti Chadha

266

Quantification of genes encoding bacterial sialidases and enzymes of the nan cluster in combination with cutaneous T cell-attracting chemokine (CTACK) in bile for the early detection of cholangiocellular carcinoma in patients with primary sclerosing chola

Poster presentation
Presenter: Antonia Triefenbach

412

Absence of cholesterol gallstone formation in male C57BL/6 mice by abrogation of hepatic thyroid hormone action

Poster presentation
Presenter: Denise Zwanziger

496

Gut microbial antibiotic resistance genes in clinicians taking care of cirrhosis patients shows wide variation according to country income and could be a risk factor for bidirectional transmission

Poster presentation
Presenter: Jasmohan Bajaj

591

Veillonella dispar-mediated l-arginine depletion induces leydig cell mitochondrial apoptosis and suppresses testosterone synthesis to drive primary biliary cholangitis

Poster presentation
Presenter: Qing-Qing Xing

779

Role of alcohol-associated gut microbiota in driving liver fibrosis via tgfr1 kinase alterations in alcohol associated liver disease

Poster presentation
Presenter: Manisha Yadav

797

Next-generation beneficial bacteria combined with fructo-oligosaccharides and fecal microbiota transplantation attenuates diet-induced metabolic dysfunction-associated steatohepatitis in mice

Poster presentation
Presenter: Quinten Augustijn

910

Targeting gut-liver axis crosstalk with probiotic Lactobacillus rhamnosus attenuates ductular reaction in Mcp1-deficient mice

Poster presentation
Presenter: Katarzyna Trzos

934

Gut-oral microbial translocation promotes ammonia metabolism in liver cirrhosis

Poster presentation
Presenter: Yi Jin

967

Chronic exposure to microplastics and nanoplastics exacerbates western diet-induced metabolic dysfunction-associated steatohepatitis: the role of gut microbiota

Oral presentation
Presenter: Zhixin Fang

1037

Unravelling the therapeutic potential of novel peptides derived from the human gut microbiome in mouse models of MASLD and acute liver injury

Oral presentation

Presenter: Javier Martínez-García

1119

Microbial changes resulting from vertical sleeve gastrectomy attenuate obesity by modulating bile acid metabolism and the intestinal farnesoid X receptor–fibroblast growth factor 15/19 axis

Poster presentation

Presenter: Yi Xia

1122

PPAR α is a key molecule mediating the diurnal variation of sepsis in mice

Poster presentation

Presenter: Junzhou Zhao

1123

Fecal microbiota transplant activates hepatic PPAR- α resulting in remission of alcohol-related liver disease in murine model

Poster presentation

Presenter: Ashi Mittal

1188

Gut metagenomic profiles predict 90-day hospitalizations despite controlling for diet, demographics & cirrhosis details in a multi-country cohort of patients with cirrhosis

Poster presentation

Presenter: Jasmohan Bajaj

1260

Quantification of intestinal barrier dysfunction in vivo using confocal multiphoton microscopy in a mouse model of steatotic liver disease and acute-on-chronic liver failure

Poster presentation

Presenter: Joscha Vonderlin

1343

Enterohepatic circulation of microbial bile acid conjugates

Poster presentation

Presenter: Marta Romero

1444

Akkermansia muciniphila inhibits serotonin-induced fibrosis progression in liver injury mouse model

Poster presentation

Presenter: Sung-Min Won

1458

Myricetin alleviates steatotic liver disease through gut microbiota modulation and Wnt-signaling inhibition

Poster presentation

Presenter: Min Ju Kim

1461

Bacteroides caccae alleviates hepatic fibrosis by suppressing inflammation

Poster presentation

Presenter: Ki Tae Suk

1463

An integrative multi-omics and machine learning framework for diagnostic biomarker identification in patients with liver cirrhosis

Poster presentation

Presenter: In Gyu Park

1921

Gut fungi in liver cirrhosis: characterizing mycobiota alterations and links to disease stages

Poster presentation

Presenter: Juozas Kupcinskas

1946

Gut microbiota composition of obesity resistant mice protects from high fat diet-induced steatosis

Poster presentation

Presenter: Milos Vratarić

2051

Cathepsin B-mediated occludin degradation increases gut permeability and progression of alcohol-associated liver disease

Oral presentation

Presenter: Marcos F Fondevila

2291

Microbiota-derived S-equol ameliorates inflammatory pathway in metabolic dysfunction-associated fatty liver disease

Poster presentation

Presenter: Kwon Goo-Hyun

2374

Restoration of gut microbiome-nitrogen metabolism post oral administration of black carrot extracellular vesicles in hepatic encephalopathy

Poster presentation

Presenter: P Debishree Subudhi

2437

The role of the gut microbiota in high-fat diet-induced hepatic steatosis in juvenile and adult mice

Poster presentation

Presenter: Isidora Alempijević

2450

Dietary bacterial D-lactate modulates liver steatosis and ameliorate experimental MASLD

Poster presentation

Presenter: André Santos

2537

Microbially conjugated bile salts undergo hepatobiliary secretion in humans and mice

Poster presentation

Presenter: Frank Schaap

2633

Periodontitis drives steatotic liver disease progression via a microbiome-dependent oral-gut-liver circuit

Oral presentation

Presenter: Astrid Devriese

2667

Sex-specific effects of beta-blockers on the gut microbiome and metabolome in liver cirrhosis

Poster presentation
Presenter: Rosa Haller

2688

Gut multiomics links bacterial-driven increase in Lactate with the development of shock and identifies metabolite panel for prediction of adverse outcomes in ACLF patients

Poster presentation
Presenter: Gaurav Tripathi

2734

Fecal microbiota transplantation results in increased caproic acid which alleviates steatosis and reduces ethanol-induced hepatotoxicity (in vivo and in vitro)

Poster presentation
Presenter: Nishu Choudhary

2786

Association between gut fungal microbiota and subclinical coronary atherosclerosis in patients with MASLD

Poster presentation
Presenter: Pisit Tangkijvanich

2818

Baseline oral microbiome composition in liver transplant recipients can help predict graft dysfunction

Poster presentation
Presenter: Rosmy Babu

Hepatocyte biology

830

Regulation of thyroid hormone metabolism by HNF4A via modulation of deiodinase activity in hepatocytes

Poster presentation
Presenter: Xinru Zhang

944

Disruption of mitochondrial dynamics and stasis leads to liver injury, innate immune response and tumorigenesis

Poster presentation
Presenter: Wen-Xing Ding

968

The updated LiverSCA: a widespread and user-friendly cell atlas in human primary liver cancer and steatotic liver disease

Poster presentation
Presenter: Tina Suoangbaji

986

Unveiling the link between neddylation and hepatic zonation: key insights into liver metabolism and diseases

Oral presentation
Presenter: Giselle Abruzzese

1006

Rapid multiplex liver gene editing in mice using adeno-associated virus 8 or lipid nanoparticles

Poster presentation

Presenter: Dandan Wu

1166

10 year analysis and trends in liver biopsy; a single centre experience

Poster presentation

Presenter: Jennifer Cathcart

1248

rhTPO promotes hepatocyte proliferation in rats with acute liver failure through the MAPK and PI3K AKT signaling pathways

Poster presentation

Presenter: Jing Liang

1536

Dynamic hepatocyte adaptations in acute biliary hypertension: role of canalicular remodeling, mechanosensors activation and alternate bile transport

Poster presentation

Presenter: Himanshi Himanshi

2801

Effects of N-acylethanolamines in an in vitro model of metabolic stress: evidence on autophagy and related pathways in hepatic cells

Poster presentation

Presenter: Nicole Pia Navatti

Immune-mediated and cholestatic disease: Clinical aspects

206

Terminology, diagnosis and management of primary biliary cholangitis -autoimmune hepatitis variant syndrome (PBC-AIH): results from an international Delphi consensus process

Poster presentation

Presenter: Alessio Gerussi

208

Fibrosis stage is an independent predictor of liver-related complications in primary biliary cholangitis

Poster presentation

Presenter: Tadashi Namisaki

215

Research on the factors affecting hepatic recompensation and criteria for aetiological control in patients with primary biliary cholangitis

Poster presentation

Presenter: Li Shen

225

Efficacy, safety and long-term clinical outcomes of a low-dose versus high-dose prednisolone induction in autoimmune hepatitis: a propensity score matched analysis

Poster presentation

Presenter: Arnav Aggarwal

263

Sebepliasa alfa improves lipid metabolism and liver outcomes in pediatric patients with lysosomal acid lipase deficiency

Poster presentation

Presenter: Lorenzo D'Antiga

309

Clinical prediction model with good discriminative capacity for mortality risk in autoimmune hepatitis

Oral presentation

Presenter: Charlotte Slooter

310

Liver steatosis prevalence in primary sclerosing cholangitis

Poster presentation

Presenter: Imante Lasyte

327

Fixed-dose combination of obeticholic acid and bezafibrate vs bezafibrate monotherapy in patients with primary biliary cholangitis: 12-week results from 2 phase 2 trials with real-world outcomes from the GLOBAL PBC study group

Poster presentation

Presenter: Cynthia Levy

352

Clinical diagnostics of autoimmune hepatitis enabled by mass spectrometry-based proteomics

Poster presentation

Presenter: Anne-Sofie Houlberg Jensen

376

Advancements in autoimmune hepatitis epidemiology, treatment and complication – a 15-year retrospective study

Poster presentation

Presenter: rawi hazzan

385

Early assessment of treatment response in primary biliary cholangitis: key to timely management

Poster presentation

Presenter: Tomáš Koky

430

Direct nerve fiber recordings reveal functional alterations in cutaneous C-fibers linked to itch severity in cholestatic liver diseases

Poster presentation

Presenter: Miriam M. Düll

433

Epidemiology of primary sclerosing cholangitis in Canterbury, New Zealand, a population-based study

Poster presentation

Presenter: Samantha Benson-Pope

442

Latest liver stiffness measurements predict liver-related outcomes in primary biliary cholangitis patients with discordant biochemical and liver stiffness responses

Oral presentation

Presenter: Yu Jun Wong

450

Prognostic value of liver stiffness dynamics in patients with autoimmune hepatitis

Poster presentation

Presenter: Lukas Burghart

487

Misclassification of UDCA treatment response in patients with primary biliary cholangitis (PBC) in the real-life setting

Poster presentation

Presenter: Johannes Wiegand

618

Evaluation of the response criteria following second-line treatment with bezafibrate in patients with primary biliary cholangitis

Oral presentation

Presenter: Sergio Rodriguez-Tajes

622

Comprehensive exploration of disease-specific autoantigen candidates in autoimmune hepatitis through immunocomplexome analysis

Poster presentation

Presenter: Satoshi Matsuo

623

Direct visualization of fibroblast activation protein inhibitor expression in primary sclerosing cholangitis – a novel biomarker for disease activity and inflammation?

Poster presentation

Presenter: Laura Muana Wilhelm

645

Clinical outcomes of primary sclerosing cholangitis associated with inflammatory bowel disease after liver transplantation: a systematic review and meta-analysis

Poster presentation

Presenter: Jiangrong Zhou

661

Serum levels of IL-31 and autotaxin are independently associated with pruritus severity in patients with primary sclerosing cholangitis

Poster presentation

Presenter: Cynthia Levy

686

The risk of psychiatric disorders in patients with autoimmune hepatitis: a nationwide registry-based follow-up study

Poster presentation

Presenter: Lisbet Groenbaek

725

Quantitative morphometric analysis via artificial intelligence-driven image analysis in autoimmune hepatitis: a multi-center study

Poster presentation

Presenter: Giorgio Cazzaniga

742

Implementation of a clinical global impression severity scale for primary biliary cirrhosis: results of a hepatologist focussed training programme

Poster presentation

Presenter: Nasir Hussain

748

Validation of the clinical global impression severity scale for primary biliary cholangitis: a clinical trials outcome tool
Poster presentation
Presenter: Nasir Hussain

810
Efficacy and safety of odevixibat in adult patients with progressive familial intrahepatic cholestasis: results from the 72-week PEDFIC2 phase III, open-label study
Poster presentation
Presenter: Henkjan J. Verkade

843
Psychometric evaluation of the pruritus numeric rating scale in patients with primary biliary cholangitis with moderate-to-severe pruritus
Poster presentation
Presenter: Andreas E. Kremer

852
Safety and efficacy of inebilizumab in IgG4 related disease in participants with pancreatic, biliary, and hepatic involvement: results from the phase 3 MITIGATE trial
Oral presentation
Presenter: Emma Culver

857
Clinical meaningful change of pruritus numeric rating scale in adults with primary biliary cholangitis with moderate-to-severe pruritus
Poster presentation
Presenter: Cynthia Levy

864
Impact of non-classical phenotypes of primary biliary cholangitis on treatment response and long-term prognosis. Results from the ColHai registry
Poster presentation
Presenter: Pinelopi Arvaniti

909
Treatment with elafibranor has no impact on bone health in patients with primary biliary cholangitis
Poster presentation
Presenter: Jörn M. Schattenberg

966
Is the POISE really valid as a surrogate endpoint for patients with PBC treated with UDCA and PPAR agonist? – a retrospective validation study from the real-world data in Japan
Poster presentation
Presenter: Ryo Miura

970
Clinical characteristics of a large cohort of primary sclerosing cholangitis patients undergoing liver transplant for primary sclerosing cholangitis and biochemical predictors of recurrence
Poster presentation
Presenter: Natcha Cheewasereechon

976
Epidemiological trends of autoimmune hepatitis in South Korea: a population-based study from 2010 to 2023
Poster presentation

Presenter: Kyung-Ah Kim

980

Disparities in treatment response and liver decompensation by race and ethnicity in primary biliary cholangitis: results from the ELLA-PBC cohort

Poster presentation

Presenter: Lily Dara

989

Non-invasive tests for liver fibrosis are stable in patients with primary biliary cholangitis with two years of treatment with elafibranor

Poster presentation

Presenter: Marlyn J. Mayo

1029

Efficacy and safety of odevixibat in patients aged ≥ 10 years with Alagille syndrome: results from the 72-week ASSERT-EXT phase III, open-label extension study

Poster presentation

Presenter: Nadia Ovchinsky

1071

The PSC-DM: development and validation of a clinical diagnostic model to aid the diagnosis of primary vs. secondary sclerosing cholangitis

Poster presentation

Presenter: Miki Scaravaglio

1098

Appraising improvement in prediction of clinical outcomes based on different response criteria and liver stiffness measurements in patients with primary biliary cholangitis treated with second-line therapies

Poster presentation

Presenter: Antonio De Vincentis

1128

Optimization of corticosteroid treatment for acute severe autoimmune hepatitis: slow simmering shows better prognosis

Poster presentation

Presenter: Min Lian

1164

One-year efficacy and safety of tacrolimus in chronic autoimmune hepatitis

Poster presentation

Presenter: Armando Curto

1255

CM-101 impacts disease biomarkers in primary sclerosing cholangitis: assessment of the SPRING study pharmacokinetics and pharmacodynamics

Poster presentation

Presenter: Matthew Frankel

1256

Unveiling the cholangiopathy of critical COVID-19: unique imaging patterns on magnetic resonance cholangiography

Poster presentation

Presenter: Valéria Borges

1353

Low vitamin B6 status associates with cholangiocarcinoma in primary sclerosing cholangitis
Poster presentation
Presenter: Isma Sohail

1355
Screening for biliary dysplasia using brush cytology in PSC: Accuracy, risk factors and outcomes
Oral presentation
Presenter: Martti Färkkilä

1358
UK validation of the simple cholestatic complaints score: a patient reported outcomes measure in primary sclerosing cholangitis
Poster presentation
Presenter: Nasir Hussain

1363
Long-term evaluation of controlled attenuation parameter for steatosis monitoring in autoimmune hepatitis
Poster presentation
Presenter: Ignasi Olivas

1518
Exploring the spectrum of autoimmune hepatitis: acute, acute-on-chronic, and chronic forms
Poster presentation
Presenter: Dan Zhou

1545
Statins are associated with decreased risk of disease progression and death in non-cirrhotic patients with primary biliary cholangitis
Poster presentation
Presenter: Eirini Rigopoulou

1634
Long term efficacy, effectiveness and side effects of third line therapies in autoimmune hepatitis
Poster presentation
Presenter: Ilkay Ergenc

1742
Safety and efficacy of Upadacitinib in patients with primary sclerosing cholangitis and associated colitis
Poster presentation
Presenter: Ida Schregel

1747
Utility of splenic stiffness as a predictor for varices needing treatment in autoimmune hepatitis and primary biliary cholangitis
Poster presentation
Presenter: Marlene Padilla-Lopez

1774
Evaluating the 2023 EASL guidelines for intrahepatic cholestasis of pregnancy: risk stratification and outcomes in 4,000+ U.S. patients
Oral presentation
Presenter: Nina Rodriguez

1805
Analysis of histopathological diagnosis and clinical diagnosis of 1,752 patients undergoing liver biopsy

Poster presentation
Presenter: Airong Hu

1831

Epidemiological and clinical differences in primary sclerosing cholangitis between men and women in Spain: a multicenter analysis of 697 patients

Poster presentation

Presenter: Magdalena Salcedo

1839

Seladelpar treatment of patients with primary biliary cholangitis improves the GLOBE score and predicts improved transplant-free survival

Poster presentation

Presenter: Bettina Hansen

1865

Addressing primary biliary cholangitis symptoms during consultations: an international survey of those who see patients

Poster presentation

Presenter: Caz Canavan

1897

Extra-intestinal autoimmune conditions in patients with primary sclerosing cholangitis – does age matter?

Poster presentation

Presenter: Samantha Campbell

1909

Evaluation of the association between biomarkers and patient-reported outcomes in patients with primary biliary cholangitis

Poster presentation

Presenter: Alan Bonder

1922

Pruritus is not a clinical feature of early-onset primary sclerosing cholangitis during late teenage years

Poster presentation

Presenter: Jeremy Nayagam

1959

Efficacy and safety of seladelpar in patients previously treated with fibrates or OCA

Poster presentation

Presenter: Alejandra Villamil

1963

Diagnostic distribution of patients positive for anti-mitochondrial antibodies (subtype) , anti-sp100, and anti-gp210: pathological examination is necessary of PBC diagnosis: a retrospective study based on liver biopsy

Poster presentation

Presenter: Hongli Liu

1976

Change in pruritus in patients with primary biliary cholangitis and moderate-to-severe pruritus: a pooled analysis from the Response and Enhance studies

Poster presentation

Presenter: David E. Jones

2024

A larger decline of IgG after initiation of treatment in patients with AIH is associated with complete biochemical response despite having normal baseline IgG levels

Poster presentation

Presenter: Lorenz Grossar

2033

Does steatotic liver disease influence treatment response and clinical outcomes in primary biliary cholangitis?

Poster presentation

Presenter: Ellina Lytvyak

2103

Evolution of the United Kingdom's national immunoglobulin G4-related disease multidisciplinary meeting in guiding diagnosis and management of complex cases

Poster presentation

Presenter: Roshni Patel

2148

Atherosclerosis in primary biliary cholangitis – more common than previously thought

Poster presentation

Presenter: Suzanne Elshafey

2162

Efficacy of tioguanine and mycophenolate mofetil as second-line immunosuppressive treatment in autoimmune hepatitis management

Poster presentation

Presenter: Catherine Tian

2195

Alberta has the highest prevalence of primary biliary cholangitis in North America

Poster presentation

Presenter: Bryce Tkachuk

2203

Risk factors for post-liver transplantation patient and graft survival in autoimmune hepatitis: pioneering insights from a south american cohort

Poster presentation

Presenter: Pedro Passos

2261

Reviewing the utility of genetic cholestasis testing in adults with cholestatic liver disease

Oral presentation

Presenter: Inbal Hourii

2332

Evaluation of response to Ursodeoxycholic acid (UDCA) in a nationwide population with primary biliary cholangitis

Poster presentation

Presenter: Ellen Werner

2334

The association between metabolic comorbidities and clinical outcome in patients with primary biliary cholangitis

To be confirmed

Presenter: Ellen Werner

2356

Prevalence and impact of extrahepatic autoimmune disease in patients with primary biliary cholangitis
Poster presentation

Presenter: Gemma Weijsters

2391

The spectrum of adult cholestatic liver diseases related to ABCB4 gene mutations: genotype-phenotype correlation

Poster presentation

Presenter: Sandra Ribeiro Correia

2398

Analysis of bile microbiome profiles and bacterial metabolic pathways in primary sclerosing cholangitis, secondary sclerosing cholangitis and ischemic-type biliary lesions

Poster presentation

Presenter: Laura Muana Wilhelm

2438

Rituximab therapy for autoimmune hepatitis cirrhosis is associated with a high rate of complete biochemical response and improvement in MELD score

Poster presentation

Presenter: Mar Riveiro-Barciela

2592

Uncovering novel therapeutic targets for autoimmune hepatitis (AIH): detection via omics integration and validation in proof-of-concept clinical trial

Poster presentation

Presenter: Jan Philipp Weltzsch

2640

Predictors of response to steroids in children and adolescents with treatment naïve severe autoimmune hepatitis

Poster presentation

Presenter: Samannay Das

2690

FiOCA study: comparative analysis of transplant-free survival in primary biliary cholangitis patients treated with obeticholic acid or fibrates

Oral presentation

Presenter: Vincenzo Ronca

2691

Evidence-based digital support in hepatology: retrieval-augmented generation's role in autoimmune liver diseases management

Poster presentation

Presenter: Ernest Saenz

2718

Fibrates in primary sclerosing cholangitis: a multicenter retrospective observational study

Poster presentation

Presenter: Eugenia Nofit

2785

Real-world assessment of standard of care trends in primary biliary cholangitis and cholestatic pruritus in Europe

Poster presentation

Presenter: Lina Titievsky

2844

Prognosis of primary sclerosing cholangitis (PSC) in Hungary is independent of coexisting inflammatory bowel disease (IBD) and prognostic ability of the currently used PSC risk scores are limited

Poster presentation

Presenter: David Tornai

2860

The histological activity index is associated with disease severity and treatment response in patients with immune mediated liver injury from checkpoint inhibitors

Poster presentation

Presenter: Robert Fontana

2888

Prognostic factors in autoimmune hepatitis: a french multicenter study

Poster presentation

Presenter: Anna Sessa

2934

The differential, but significant, burden of pruritus, fatigue, and sicca across cholestatic liver diseases

Poster presentation

Presenter: Kristel Leung

2954

Impact of social determinants of health on outcome of autoimmune liver diseases: insights from the european reference network on hepatological diseases (ERN RARE-LIVER)

Poster presentation

Presenter: Franziska Stallbaum

2971

Combination obeticholic acid (OCA) and fibrate therapy is associated with greater probability of biochemical response than switching from OCA to a fibrate in primary biliary cholangitis

Poster presentation

Presenter: Nadir Abbas

2982

The Mayo-risk model predicts postsurgical transplant-free survival in patients with Primary sclerosing cholangitis

Poster presentation

Presenter: Johannes Chang

3010

Cholestasis as a predictor of PSC in inflammatory bowel disease: insights from a romanian cohort study

Poster presentation

Presenter: Matei Manda

3022

Non-invasive prediction of clinically significant portal hypertension in patients with compensated advanced primary biliary cholangitis

Poster presentation

Presenter: Giulia Francesca Manfredi

3033

Health-related quality of life and well-being of young patients with autoimmune hepatitis during transition of care from paediatric to adult site

Poster presentation
Presenter: Maciej Janik

3044

Introduction of an advanced pharmacist clinic leads to improved assessment and treatment of patients with PBC

Poster presentation
Presenter: Alison Boyle

Immune-mediated and cholestatic: Experimental and pathophysiology

97

Genetic ablation of interleukin 17A augments fibrosis in a mouse model of cholestatic liver injury

Poster presentation
Presenter: Takashi Kitagataya

193

Quantitative MRI metrics in the liver and pancreas for disease assessment in IgG4-related sclerosing cholangitis with autoimmune pancreatitis

Poster presentation
Presenter: Edward Jackson

449

A novel orally bioavailable small-molecule inhibitor of the sodium taurocholate co-transporting polypeptide (NTCP) prevents HBV infection and ameliorates cholestasis in humanized mice models

Poster presentation
Presenter: Stan F.J. van de Graaf

691

Epstein-Barr virus is targeted by converging T and B cell responses in primary sclerosing cholangitis

Poster presentation
Presenter: Hesham ElAbd

703

Active transport via bile salt export pump (Bsep/Abcb11) is not required for cholehepatic shunting and choleretic actions of Norucholic acid (NCA/norUDCA) in mice

Poster presentation
Presenter: Claudia Fuchs

842

Novel dual-acting ABCB4/MDR3 and ABCB11/BSEP positive functional modulator demonstrates anti-cholestatic and anti-cholangitis activity in two orthogonal models of hepatobiliary disease

Oral presentation
Presenter: Eric Bell

876

Amongst autoimmune liver diseases, primary sclerosing cholangitis demonstrates distinct methylation profiles on circulating DNA

Oral presentation
Presenter: Soumita Ghosh

991

Lack of CD1d on biliary epithelial cells protects from cholangitis

To be confirmed

Presenter: Kathrine Sivertsen Nordhus

1090

Protectin DX as a novel anti-inflammatory and anti-fibrotic therapeutic candidate for the treatment of autoimmune cholangitis

Poster presentation

Presenter: Audrey-Anne Lavoie

1225

Bioinformatic analysis of the spatial transcriptomes of inflamed portal tracts in human primary biliary cholangitis

Poster presentation

Presenter: Atsumasa Komori

1243

CCL24 blockade alters the proteomic profile of patients with primary sclerosing cholangitis and down-regulates central disease processes

Poster presentation

Presenter: Tom Snir

1552

Single-cell profiling reveals increased IGHG2+ memory and activated IGHA1+ intrahepatic B cells in primary sclerosing cholangitis

Poster presentation

Presenter: Lisa R. V. Brynjulfson

1593

Restoring gene function in cholangiocyte organoids through lentiviral transduction

Poster presentation

Presenter: Enya Amundsen-Isaksen

1600

Urinary proteomics: a new diagnostic approach for primary biliary cholangitis

Poster presentation

Presenter: Wei Jiang

1681

Therapeutic application of circular RNA aptamers in a mouse model of primary biliary cholangitis

Poster presentation

Presenter: kai zhang

1712

Identifying transporters of the solute carrier (SLC) group involved in cholangiocyte defense against toxic bile acids

Poster presentation

Presenter: Qinghong Li

1765

MUCIN1 positive biliary epithelial cell heterogeneity contributes to cholestatic liver injury and promotes early liver fibrosis

Poster presentation

Presenter: Aishwarya Bhatnagar

1956

Evaluation of the potential impact of seladelpar on the pharmacokinetics of midazolam, tolbutamide, simvastatin, rosuvastatin, and atorvastatin

Poster presentation
Presenter: Jin Zhou

1968

Pharmacokinetics, safety, and tolerability of seladelpar in people with renal impairment
Poster presentation
Presenter: Jin Zhou

1972

Integrative spatial proteomics and transcriptomics of patient liver tissues unravel Claudin-1 as a mediator and therapeutic target for primary sclerosing cholangitis
Oral presentation
Presenter: Fabio Del Zompo

2220

Single-cell profiles of intrahepatic and peripheral immune cells reveal AIH-specific CD8+ T cells promote disease progression through cytotoxicity and macrophage interactions
Poster presentation
Presenter: Xinghuan Fu

2280

ATP8B1 deficiency causes steatosis and PDE4-mediated glucagon resistance in liver
Poster presentation
Presenter: Jung-Chin Chang

2301

A cfChIP-seq liquid biopsy for the diagnosis of autoimmune hepatitis
Poster presentation
Presenter: Eyal Shteyer

2408

Reactive cholangiocyte-derived orosomucoid-2 (ORM2) drives a pathogenic modulation of the injured biliary niche through macrophage reprogramming
Poster presentation
Presenter: Adrien Guillot

2417

Dnmt1 deletion impairs liver regeneration and stem cell activation during cholestatic liver disease
Poster presentation
Presenter: Juliana Marques Affonso

2420

Pharmacological modulation of hepatocyte glucocorticoid receptor alpha can toggle enclysis, the deletion of regulatory T cells by hepatocytes
Poster presentation
Presenter: Yiyu Fan

2446

IL-27 drives activation of tissue-destructive CD8+ T cells and is functionally indispensable in immune checkpoint inhibitor-induced hepatitis
Poster presentation
Presenter: Cathrin Gudd

2465

A combined immunotherapy that maintains the balance and stability of intrahepatic regulatory T cells to enhance biliary regeneration

Poster presentation
Presenter: Man Chun Wong

2467
Bile and plasma metabolome reveals association of TMA-TMAO pathway metabolites with gallstone disease progression
Poster presentation
Presenter: Vipin Yadav

2709
Protectin DX improves the efficiency of low dose obeticholic acid to reduce hepatic bile acids and mitigate inflammation, ER stress and fibrosis in liver cells
Poster presentation
Presenter: Audrey-Anne Lavoie

2866
Immune profiling in autoimmune hepatitis identifies distinct patterns autoreactivity
Poster presentation
Presenter: Arielle Klepper

2903
Mitochondrial dynamics and auto(mito)phagy are altered in experimental models of primary biliary cholangitis, contributing to disease pathogenesis
Poster presentation
Presenter: Irune Lasa-Elosegi

2955
Spatial transcriptomic analysis of archived primary sclerosing cholangitis livers reveals distinct molecular signatures
Poster presentation
Presenter: Sayed Aseem

Liver development and regeneration

593
Harnessing antioxidant nano-chimeras for combining targeted transforming growth factor β receptor I degradation and transforming growth factor β reduction to attenuate liver fibrosis
Poster presentation
Presenter: Hanshu Liu

835
3D assembloid model as a useful in vitro tool to study acute and chronic liver diseases
Poster presentation
Presenter: Riccardo Perriera

921
Mucosal-associated invariant T cells promote liver regeneration
Oral presentation
Presenter: Charles Caer

937
A comprehensive study on acute and chronic liver injury response in *Acomys* (Spiny mice): insights into the role of p21 in liver regeneration
Poster presentation

Presenter: Karen Ching

1401

Impact of NEDDylation on aging and liver senescence: key insights

Poster presentation

Presenter: Leidy Estefanía Zapata-Pavas

1446

Time-restricted feeding modulates genes involved in liver regeneration and damage regression processes in a rat model treated with diethylnitrosamine

Poster presentation

Presenter: Christian Molina-Aguilar

1478

A 3D human liver organoid model to study the impact of ischemia-reperfusion injury on liver regeneration during transplantation

Poster presentation

Presenter: Maura Cimino

1543

Extracellular matrix protein 1 (ECM1) as a dual regulator of liver regeneration via HGF/c-MET and TGF- β signaling pathways

Poster presentation

Presenter: Ye Yao

1643

Generation and functional profiling of injury-resistant ductal organoids with biliary tree networks optimized by genipin

Poster presentation

Presenter: Shiwen Ma

1785

Echinococcus multilocularis infection induces pathological angiogenesis in mouse liver via PDGFR/PI3K/AKT/FAK signaling pathway

Poster presentation

Presenter: Xiaojuan Bi

2177

Knockout of DDX3X promotes liver regeneration through CD36-mediated hepatic lipid accumulation

Poster presentation

Presenter: Ling Xu

2225

The reelin signaling pathway in lymphatic endothelial cells is a key driver of ductular reaction during liver injury

Poster presentation

Presenter: Aarti Sharma

2270

Cathepsin L inhibitor enhances liver regeneration in fibrotic liver

Poster presentation

Presenter: Shunhei Yamashina

2276

Extending the lifespan of human chemically derived hepatic progenitors by treating with Drug A

Poster presentation

Presenter: Seunghee Kim

2563

Regulation of interleukin-6- and epidermal growth factor receptor-dependent pathways by augmenter of liver regeneration is mediated by activation of ADAM17

Poster presentation

Presenter: Christoph Voigt

2663

Room for improvement in female authorships across leading medical journals

Poster presentation

Presenter: Sara Hauskov

2901

Engineered extracellular vesicles derived from mesenchymal stem cell carrying insulin-like growth factor I to promote liver regeneration after partial hepatectomy

Poster presentation

Presenter: Mailín Casadei

3028

MAIT cells mediate liver tissue repair via VEGF and VIM secretion

Poster presentation

Presenter: Katia Sayaf

Liver immunology

140

Single nucleotide polymorphisms of the vitamin D receptor and their impact on vitamin D- and Interleukin-6 levels in liver cirrhosis and acute-on-chronic-liver failure

Poster presentation

Presenter: Alina Bauschen

533

Non-neuronal role of immune cells in liver regeneration

Poster presentation

Presenter: nastaran fazel modares

680

Lnk/Sh2b3 regulates the development of hepatic memory CD8+ T cells via IL-15 signaling and suppresses the pathogenesis of MASLD

Poster presentation

Presenter: Taizo Mori

749

The tumor suppressor miR-122 regulates liver cancer stem cells immune evasion and proliferation through CD24

Poster presentation

Presenter: Nofar Rosenberg

882

MicroRNA-122 functions as a rheostat regulating liver tolerance, inflammation and fibrosis

Poster presentation

Presenter: Maytal Gefen

1021

Safety and efficacy of everolimus in autoimmune hepatitis – a single center retrospective analysis

Poster presentation

Presenter: Florian Seltsam

1072

CD155 blockade modulates monocyte responses in acute-on-chronic liver failure

Poster presentation

Presenter: Joseph Delo

1251

A human cirrhosis single-cell atlas identifies a pro-inflammatory subpopulation of scar-associated macrophages as a therapeutic target for liver fibrosis

Oral presentation

Presenter: Kexin Kong

1484

Integrated single-cell transcriptome and protein analysis unveils long-lasting liver NK cell dysfunction in NUC-treated chronic HBV

Poster presentation

Presenter: Boris Beudeker

1554

Transcriptional and functional profiling of HBV-specific CD8 T cells in chronic HBV infection for the design of novel targeted T cell correction strategies for HBV cure

Poster presentation

Presenter: Carolina Boni

1563

Intrahepatic TCF-1+ T cells reside with myeloid cells in peribiliary lymphoid follicles, respond to the autoantigen pyruvate dehydrogenase complex E2 and T cell receptor stimulation

Poster presentation

Presenter: Rémi Fiancette

1567

Influence of T cell exhaustion versus senescence in the development of spontaneous operational tolerance following liver transplantation

Poster presentation

Presenter: Jorge Torres

1584

Establishing an optimised method for single-cell RNA-seq based immunophenotyping from cryopreserved human liver needle biopsies

Poster presentation

Presenter: Juliet Luft

1609

miRNA/mRNA signature of mouse Kupffer cells during the progression of chronic liver disease from fibrosis to hepatocellular carcinoma

Poster presentation

Presenter: Ananya Ajith

1618

The role of T-cell immunoglobulin and mucin domain 3 (TIM-3) in immune dysregulation and infection in patients with decompensated cirrhosis and liver failure syndromes

Poster presentation

Presenter: Roosey Sheth

1622

Inhibition of the lysophatidylcholine-autotaxin-lysophosphatidic acid axis restores monocytic pro-inflammatory cytokine production in patients with acute-on-chronic liver failure

Poster presentation

Presenter: Joseph Wilson

1663

Defining the role of tissue-resident Kupffer cells in the pathogenesis of chronic liver disease

Poster presentation

Presenter: Fabio Colella

1672

The role of FOXP3+ regulatory T (Treg) cells in mouse models of liver disease

Poster presentation

Presenter: Caitlin Abbott

1682

In vivo stimulation of 4-1BB signaling enhances the efficacy of therapeutic vaccination in high-titer hepatitis B virus carrier mice

Oral presentation

Presenter: Edanur Ates-Öz

1783

Inflammation-educated macrophages drive exacerbated re-injury patterns via innate immune memory

Poster presentation

Presenter: Yuting Wang

1820

Enhancing restorative macrophage functions through genetic modification improves liver fibrosis in MASH models

Poster presentation

Presenter: Christopher Sloas

1822

Circulating CD8 T cells are sentinels for intrahepatic T cell responses during HBV infection

Oral presentation

Presenter: Hannah Wintersteller

1861

Differential granzyme-mediated immune responses in CXCR6+PD-1+ CD8 T cells in acute versus chronic ALT flares

Poster presentation

Presenter: Roni Souleiman

1862

TIGIT blockade on CD8+T cells induces hepatocyte apoptosis

Poster presentation

Presenter: Amber Bozward

1920

Crohn's associated invariant T (CAIT) cell subphenotype analysis for inflammatory bowel disease and primary sclerosing cholangitis

Poster presentation

Presenter: Aya Mahdy

1958

Time-resolved liver fibrosis regression at single-cell resolution in a murine CCl₄-cessation model

Poster presentation

Presenter: Katharina Bonitz

1980

Trained human bone marrow mesenchymal stem cells enhance immunoregulatory responses and alleviate ConA-induced acute liver failure

Poster presentation

Presenter: Bingqi Li

1986

Scar-associated macrophages demonstrate phenotypic plasticity during the progression and regression of liver fibrosis

Poster presentation

Presenter: Ravi Parhar

2089

Human cirrhotic ascites contains myeloid reprogrammed T-cells capable of enhancing peritoneal immune surveillance

Poster presentation

Presenter: Erich Freyer

2249

Glucocorticoid receptor inhibits Th2 immune responses by down-regulating Pparg and Gata3 in schistosomiasis

Poster presentation

Presenter: Guodong LYU

2375

Mucosal-associated invariant T (MAIT) cells possess direct cytotoxic potential against HCC, but are rendered dysfunctional within the tumour microenvironment

Poster presentation

Presenter: Junika Pohl-Topcu

2430

Single-cell profiling of hepatic dendritic cells in metabolic-associated steatotic liver disease

Poster presentation

Presenter: Camilla Klaimi

2449

Hepatic stellate cells orchestrate the retention and functional impairment of tissue-resident CD8⁺ T-cells in the fibrotic human liver

Poster presentation

Presenter: George Finney

2486

Investigating macrophage- phenotype and organ injury in acute-on-chronic liver failure

Poster presentation

Presenter: Juan Wang

2492

Dynamic adaptations of CD8⁺γδ T cells in acute and chronic hepatitis E virus infection

Poster presentation

Presenter: Erich Freyer

2568

T-cell receptor analysis of circulating T cells reveals non-epitope-driven clonal expansion in metabolic-associated steatotic liver disease

Poster presentation

Presenter: Xinlei Zhao

2619

CD4+T cells license Kupffer cells to produce IL-27 and reverse the CD8+T cell dysfunction induced by hepatocellular priming

Oral presentation

Presenter: Valentina Venzin

2630

p120 catenin expression by CD8+ T cells correlates with their frequency of invasion into cholangiocytes in autoimmune liver disease

Poster presentation

Presenter: Scott Davies

2674

Fine needle aspiration reveals immunotherapy biomarkers and targets compartmentalised within hepatocellular carcinoma

Poster presentation

Presenter: Gloryanne Aidoo-Micah

2748

Exploiting the ChIP-Seq to validate the role of histone modifiers KDM and HDAC in seroconversion of hepatitis B reactivation patients

Poster presentation

Presenter: Nirupma Trehanpati

2807

Low-dose lipopolysaccharide administration improves the survival rate of septic shock by enhancing the bactericidal activity of Kupffer cells and reducing hepatic infiltration of pro-inflammatory monocyte-derived macrophages in mice

Poster presentation

Presenter: Hiroyuki Nakashima

2848

Identification and characterization of tumor-reactive CD8 and CD4 T cells in hepatocellular carcinoma

Poster presentation

Presenter: Luc Magré

3038

Unraveling the liver immune rheostat: How contact-dependent regulation causes dysfunction of antigen-specific CD8 T cells over the course of chronic hepatitis B

Poster presentation

Presenter: Anna Fürst

3047

Understanding the impact of the liver microenvironment on regulatory T cells

Poster presentation

Presenter: Maegen Fleming

Liver transplantation and hepatobiliary surgery - Basic

1129

Extracellular nicotinamide adenine dinucleotide as an independent prognostic marker for long-term survival after liver transplantation

Poster presentation

Presenter: Can Kamali

1185

Affinity-tuning chimeric antigen receptors could improve the therapeutic efficacy of regulatory t cells in liver transplantation

Poster presentation

Presenter: Ada Sera Kurt

1245

Effective in vivo transplantation of revascularized porcine liver scaffolds in pigs for extended function over one month

Poster presentation

Presenter: Sandra Melitón Barbancho

1535

Kallikrein-Kinin system activation in hepatic ischemia/Reperfusion injury: a key driver of Edema and thrombosis

Poster presentation

Presenter: Rajni Yadav

1718

HepatoPredict has a good prognostic value in patients with hepatocellular carcinoma independently of biopsied nodule

Poster presentation

Presenter: Joana Cardoso

1801

Reconstruction of native biliary networks in decellularized rat liver scaffolds with human intrahepatic cholangiocyte organoids

Poster presentation

Presenter: Álvaro Blanes-Rodríguez

1819

3D engineered endothelial cell implants protect liver explant viability ex vivo and reduce liver inflammation

Poster presentation

Presenter: Mireia Medrano-Bosch

1943

The recovery failure of fecal microbiota diversity in patients after liver transplant is associated with a complicated postoperative course

Poster presentation

Presenter: Maike Rebecca Pollmanns

2057

"The feasibility of cell-free DNA for monitoring liver graft rejection: a pilot study perspective"

Poster presentation

Presenter: Joanna Raszeja-Wyszomirska

2658

Three-dimensional cell cultures for biliary disease therapies
Poster presentation
Presenter: Mattia Pasqua

2782
Integrated spatial transcriptomics and multi-omics analysis of sequential extrahepatic bile duct biopsies reveal key mechanisms of ischemic biliary injury during liver transplantation
Poster presentation
Presenter: Shaojun Shi

Liver transplantation and hepatobiliary surgery - Clinical

199
Association between pre-transplant body mass index and survival after liver transplantation in an adult recipient cohort from Johannesburg, South Africa
Poster presentation
Presenter: Preyanka Pillay

341
Reintegration into working life for liver transplant recipients: cross-disciplinary evaluation of risk factors for unemployment
Poster presentation
Presenter: Margherita Saracco

419
Hypothermic oxygenated machine perfusion (HOPE) treatment prior to organ transplant alters key immune modulators in patients receiving liver transplantation
Poster presentation
Presenter: Maike Rebecca Pollmanns

492
Coronary angiography in the preoperative work-up for liver transplantation (LT): a multicenter italian cohort study
Poster presentation
Presenter: Margherita Saracco

578
Impact of donor-recipient age disparity on survival and recurrence in liver transplantation for hepatocellular carcinoma
Poster presentation
Presenter: Nada El-domiaty

581
Recurrence of primary sclerosing cholangitis after liver transplantation: a single centre experience
Poster presentation
Presenter: Emil Bik

606
Factors associated with retransplantation-free survival in patients receiving TIPS after liver transplantation : results of a french multicenter retrospective study
Poster presentation
Presenter: Delphine Weil-Verhoeven

658

TAVI in liver transplant candidates: a retrospective analysis from a high-volume transplant center
Poster presentation
Presenter: Marta Sánchez-Ric

735
Hepatic artery atherosclerosis is a risk factor for biliary strictures after liver transplantation
Poster presentation
Presenter: Paloma Elma Alañón-Martínez

777
Sexual health after liver transplantation is significantly impacted and varies by gender
Poster presentation
Presenter: Chantattha Thimphitthaya

791
Current status of endoscopic treatment for anastomotic biliary stricture after living donor liver transplantation at our institution
Poster presentation
Presenter: Elsuke Ozawa

802
AI-generated high-fidelity synthetic data enables privacy-preserving liver transplant research across liver disease subtypes: a study of the united network for organ sharing (UNOS) database
Oral presentation
Presenter: Joseph Ahn

847
Prognostic impact of multi-resistant bacteria gut colonization in patients undergoing liver transplantation
Poster presentation
Presenter: Marina Orti-Cuerva

939
NT-proBNP predicts the development of acute-on-chronic liver failure and mortality in patients with cirrhosis listed for liver transplantation
Poster presentation
Presenter: Juan Manuel Diaz

1009
The transcriptomic profile of antibody-mediated rejection is independent from the presence of donor specific antibodies
Oral presentation
Presenter: Bastian Engel

1079
An audit to assess adherence to local guidelines for prophylaxis and monitoring of herpes simplex virus (HSV) in patients following orthotopic liver transplant in a tertiary transplant centre
Poster presentation
Presenter: Rachel McGaw

1088
Nephrocheck as a predictive tool for post-operative acute kidney injury following liver transplant for chronic liver disease
Poster presentation
Presenter: Rosemary Worrall

1096

Rising global burden of liver transplants attributable to metabolic-associated steatotic hepatitis: trends from 68 countries (2009–2023)

Poster presentation

Presenter: Zobair Younossi

1114

The impact of donor and recipient HSD17B13, PNPLA3 and TM6SF2 genotype on post-transplant fibrosis, steatosis and survival in liver transplant recipients

Poster presentation

Presenter: Maria Rosina Troppmair

1141

Torque Teno virus as a biomarker of immune status and attenuated immune response to vaccination in liver transplant recipients

Poster presentation

Presenter: Ezequiel Mauro

1228

Conversion from standard-release to prolonged-release tacrolimus mitigates calcineurin-induced nephrotoxicity in patients after liver transplantation

Poster presentation

Presenter: Maximilian Joseph Brol

1317

Outcome and predictors of major adverse cardiovascular events after liver transplantation: a single center experience

Poster presentation

Presenter: Eugenia Vittoria Pesatori

1340

Development of an explainable machine learning model for predicting waitlist mortality in liver transplant candidates

Poster presentation

Presenter: Ilias Kounis

1347

Pre-transplant hepatorenal syndrome as a predictor of recurrent post-transplant cirrhosis and portal hypertension-related complications

Poster presentation

Presenter: Abhinav Rao

1350

Changes in sarcopenia and adipose tissue alterations do not predict post-transplant outcomes in patients with cirrhosis and hepatocellular carcinoma undergoing liver transplantation

Poster presentation

Presenter: Francesca D'Arcangelo

1387

QEL-001 LIBERATE study expansion cohort, CAR (Chimeric Antigen Receptor) T regulatory (Treg) cells engraftment and expansion following rATG (rabbit anti-thymocyte globulin) conditioning in post liver transplantation

Poster presentation

Presenter: Alberto Sanchez-Fueyo

1477

Machine learning in predicting 3-month mortality for liver transplant candidates with HCC: a paradigm shift

Poster presentation
Presenter: Ilias Kounis

1487

Coronary atherosclerosis progression in patients with cirrhosis: effect of liver transplantation and association with early post-LT kidney dysfunction

Poster presentation
Presenter: Giulia Pagano

1592

Liver resection versus systemic therapy in patients with hepatocellular carcinoma and vascular invasion in the "Immunotherapy Era". On behalf of HE.RC.O.LE.S. and ITA.LI.CA study groups

Poster presentation
Presenter: Alessandro Vitale

1597

Clinical factors associated with non-tumoral portal vein thrombosis in liver transplant candidates and its impact on pre-transplant outcomes

Poster presentation
Presenter: Simona Parrisè

1610

Dynamic changes of spleen stiffness in liver transplanted patients: preliminary findings from a single-center study

Poster presentation
Presenter: SOFIA RIDOLFO

1654

Impact of pre-transplant infection and multi-drug resistant organisms colonization on in-hospital post-transplant survival in subjects with pre-transplant liver failure

Poster presentation
Presenter: Alice Mulè

1731

Derivation and validation of a new donor risk score incorporating graft steatosis and donor diabetes mellitus

Poster presentation
Presenter: Milan J. Sonneveld

1771

Impact of comorbidities on liver transplant outcomes: assessing sex-specific differences by using machine learning analysis

Poster presentation
Presenter: Trinidad Serrano

1786

Evolving trends and the role of mitigating performance status decline on the liver transplant waitlist

Poster presentation
Presenter: Tomohiro Tanaka

1799

Depression is highly prevalent amongst patients listed for liver transplant and unrelated to liver disease severity

Poster presentation
Presenter: Victoria Kronsten

1845

Effect of donor and recipient CYP3A5 genotypes on the pharmacokinetics of tacrolimus after liver transplantation

Poster presentation

Presenter: Ana Pascual-Dapena

1857

Assessing the safety and efficacy of advanced therapies to treat inflammatory bowel disease in patients with a liver transplant

Poster presentation

Presenter: Samantha Campbell

1925

Benefits of calcineurin inhibitor sparing regimen in a biopsy-guided personalized immunosuppression program after liver transplantation

Poster presentation

Presenter: Alisa Kielkowski

2034

Concomitant sarcopenia and myosteatorsis in patients with cirrhosis is associated with longer recovery and mortality after liver transplantation

Poster presentation

Presenter: Ellina Lytvyak

2069

Retrospective study on simultaneous liver kidney transplantation: renal outcome and prevalence of acute cellular rejection

Poster presentation

Presenter: Dorien Pint

2087

Artificial versus human intelligence: Lessons from machine learning models to predict liver transplant waitlist death

Poster presentation

Presenter: Vivek Charu

2101

Extensive portal vein thrombosis in patients with cirrhosis undergoing liver transplantation : results of a national multicenter retrospective study

Poster presentation

Presenter: Romain Barousseau

2107

The effect of dual hypothermic oxygenated machine perfusion on the incidence of post-transplant diabetes mellitus in recipients of livers donated after circulatory death

Poster presentation

Presenter: Efrayim H. Küçükerbil

2117

Quantifying liver function by cholate clearance in extracorporeal circuits with a genetically modified porcine liver and brain-dead human decedent

Poster presentation

Presenter: Greg Everson

2124

Acute pancreatitis in emergency liver transplantation for acute liver failure: prevalence, predictors and consequences

Poster presentation

Presenter: Samuel Tribich

2142

Donor derived cell free DNA can be used to tailor immunosuppression in liver transplant recipients - results of largest single center experience in the US

Oral presentation

Presenter: Kinnari Modi

2153

Outcomes of ABO-incompatible deceased donor liver transplantation in adults with acute liver failure: a study from a Costa Rican hospital

Poster presentation

Presenter: Maria Lynch-Mejia

2321

Treatment of grafts not meeting criteria for transplantation with nor-ursodeoxycholic acid during normothermic machine perfusion reduces apoptosis and biliary injury markers

Poster presentation

Presenter: Jule Dingfelder

2337

Comparison of the effects of tenofovir alafenamide and entecavir on renal function and serum lipids in liver transplant recipients: a retrospective observational study

Poster presentation

Presenter: Hüseyin Döngelli

2413

The post-operative recurrence rate is significantly higher in patients with HBV-HCC compared to those with HCV-HCC

Poster presentation

Presenter: Tsung-Han Wu

2441

Adherence to the mediterranean diet and physical activity levels among liver transplant recipients in Greece: relationship to the metabolic syndrome

Poster presentation

Presenter: Kleoniki Chatzistavridou

2463

Effects of sodium-linked glucose transporter 2 inhibitors in liver transplant recipients with impaired renal function

Poster presentation

Presenter: Christiana Graf

2482

How immunosuppression influences cancer survival in liver transplant recipients: insights from a tertiary care center

Poster presentation

Presenter: Carmen Alonso Martin

2496

Steatotic liver disease is associated with frailty, but this does not influence transplant listing outcomes: a retrospective study

Poster presentation
Presenter: Niall Burke

2576

AI-driven prediction of fibrosis progression in liver transplant recipients using a temporal deep learning framework

Poster presentation

Presenter: Xiang Xuan Eunice Tan

2598

Chronic rejection outcomes in pediatric post liver transplantation-single center experience-King Faisal specialist hospital & research center,Riyadh, Saudi Arabia

Poster presentation

Presenter: Dalal Albogami

2660

Graft rejection and biliary complications affect liver stiffness measurements in the first year after liver transplantation

Poster presentation

Presenter: Michele Sagasta

2680

A cfChIP-seq liquid biopsy for the diagnosis of acute cellular rejection following liver transplantation

Oral presentation

Presenter: Achraf Imam

2744

Outcomes for patients listed for liver transplantation with low MELD-Na scores: high frequency of MELD-Na score increases, liver transplantation, death and removal from waitlist

Poster presentation

Presenter: Emaraee Cobb

2781

Incidence and risk factors for incisional hernias following liver transplantation: a retrospective single-centre european study

Poster presentation

Presenter: Callum Riley

2928

Feasibility and effectiveness of liver transplantation following immunotherapy in patients with hepatocellular carcinoma

Poster presentation

Presenter: Giuliana Amaddeo

2960

Inequalities in liver transplantation: data from the EPA-RITY study

Oral presentation

Presenter: Eloisa Franchi

3025

Sodium and lactate levels during hypothermic oxygenated machine perfusion as predictive biomarkers for early allograft dysfunction in liver transplantation

Poster presentation

Presenter: David Pereyra

Liver tumours: Clinical aspects except therapy

58

Improvement in the very poor mortality rate of hepatocellular carcinoma during two decades of collaborative preventive therapy by different specialties in a region with a limited number of hepatologists

Poster presentation

Presenter: Kenji Hirai

132

The Liver Frailty Index predicts survival in hepatocellular carcinoma: an Australian multicentre prospective cohort study (APriCa study)

Poster presentation

Presenter: Leo Ye

133

Delta hepatitis versus HBV mono-infection associated hepatocellular carcinoma: spot the difference

Poster presentation

Presenter: Razvan Cerban

168

Tumor burden score as a surrogate prediction marker in patients with hepatocellular carcinoma: prognostic role of performance status

Poster presentation

Presenter: Hung-Ting Tseng

179

National burden of MASH-related liver cancer in the United States 1990 – 2021: a systematic analysis for trends and patterns of geographic variations of the global burden of disease study

Poster presentation

Presenter: Seung Up Kim

260

Breaking barriers: intensive care admission in patients with advanced HCC on immunotherapy

Poster presentation

Presenter: Marta Fortuny

272

HCC detection using LI-RADS ultrasound surveillance algorithms: a comparative analysis of v2024 and v2017

Poster presentation

Presenter: Subin Heo

288

Development and external validation of preoperative prediction model for early recurrence of intrahepatic cholangiocarcinoma

Poster presentation

Presenter: Sang Hyun Choi

366

Challenges and adherence to hepatocellular carcinoma screening program in patients with advanced chronic liver disease

Poster presentation

Presenter: José Presa

387

Targeted immunotherapy combined with TACE for conversion therapy of unresectable hepatocellular carcinoma: metabolomic biomarker insights

Poster presentation

Presenter: Yuhai Hu

436

Prevalence and impact of clinically significant portal hypertension (CSPH) in patients with hepatocellular carcinoma (HCC): a multicenter cohort study on the ITA.LI.CA database

Poster presentation

Presenter: Rusi Chen

444

Surrogate survival endpoint in hepatocellular carcinoma patients on first-line Atezolizumab-Bevacizumab: RECIST 1.1 vs modified RECIST

Poster presentation

Presenter: Hyo Jung Park

451

Morphomolecular proliferative disease and microvascular invasion characterize PET-CT positive hepatocellular carcinoma cases: a single-center pilot study

Poster presentation

Presenter: Spyridon Pantzios

524

Differential gene expression in hepatocellular carcinoma: a bioinformatic approach to correlate with HIF1A

Poster presentation

Presenter: Jennifer Martínez-Geijo

554

Somatic copy number alterations in circulating cell-free DNA as a predictive biomarker for hepatocellular carcinoma: insights from a proof-of-concept study

Poster presentation

Presenter: Elisa Pinto

571

Impact of metformin on the prevention of hepatocarcinoma in chronic hepatitis C with advanced fibrosis after sustained virologic response

Poster presentation

Presenter: Henar Calvo Sánchez

589

Impact of antibiotic therapy in patients with cholangiocarcinoma treated with chemoimmunotherapy

Poster presentation

Presenter: Francesco Vitiello

629

Diagnostic accuracy of novel serum biomarkers in predicting recurrence of hepatocellular carcinoma: a systematic review and diagnostic test accuracy meta-analysis

Poster presentation

Presenter: Sean Loke

662

Prognostic significance of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in hepatocellular carcinoma: a retrospective multicentre study on overall survival following hepatectomy or orthotopic liver transplantation

Poster presentation
Presenter: Konstantinos Arvanitakis

668
The mind and monitoring: The psychological impact of hepatocellular carcinoma surveillance
Poster presentation
Presenter: Azzra Maricar

724
Clinical evaluation of multimarker algorithmic scores for detection of early stage hepatocellular carcinoma in high-risk liver patients
Poster presentation
Presenter: Aliya Sarmanova

896
Digital risk stratification management platform improves the early diagnosis and surveillance of liver cancer in china: a real-world study in Zhuhai people's hospital
Oral presentation
Presenter: Yong Li

897
Evaluating the performance of large language models at hepatobiliary tumor boards: a prospective study
Poster presentation
Presenter: Robert Oehring

997
Bone mineral density predicts survival in patients with hepatocellular carcinoma and portal vein tumor thrombosis
Poster presentation
Presenter: Aline Mähringer-Kunz

1076
Integrating gut microbiota composition and machine learning to predict therapeutic response in hepatocellular carcinoma treated with Atezolizumab and Bevacizumab: exploratory analysis from the phase 3b AMETHISTA study
Oral presentation
Presenter: Fabio Piscaglia

1142
Cost-effectiveness of ultrasound plus alpha-fetoprotein and biomarker-based strategies for hepatocellular carcinoma surveillance in patients with chronic hepatitis B
Poster presentation
Presenter: Tanat Saeoui

1182
Low FIB-4 in multinational hepatocellular carcinoma cohort
Poster presentation
Presenter: Margaret Teng

1187
Insights into the GALAD Score: a new optimal cut-off for hepatocellular carcinoma
Poster presentation
Presenter: Endrit Shahini

1191
An artificial intelligence-based risk prediction model for early-onset hepatocellular carcinoma

Poster presentation
Presenter: Won Kim

1263
Machine learning approaches for hepatocellular carcinoma risk stratification across various aetiologies
Poster presentation
Presenter: Pierre Nahon

1286
Impact of hepatocellular carcinoma surveillance on survival in a contemporary international cohort
Poster presentation
Presenter: Ryan YanZhe Lim

1293
Machine learning-based survival analysis and risk stratification for patients with cholangiocarcinoma
Poster presentation
Presenter: Chun-Ting Ho

1306
Ki-67 and CK19 as predictors of hepatocellular carcinoma recurrence after liver transplantation
Poster presentation
Presenter: Saur Hajiev

1471
Evaluation of elevated tumor markers in the absence of detectable hepatocellular carcinoma during post-curative ablation follow-up
Poster presentation
Presenter: Makoto Moriyama

1492
Prognosis after resection or ablation of hepatocellular carcinoma: a danish population-based multi-state cohort study
Poster presentation
Presenter: Andreas Halgreen Eiset

1555
Artificial intelligence foundation models for histological diagnosis of hepatocellular carcinoma based on 121,344 digitalized whole slide image patches
Poster presentation
Presenter: Yan Miao

1607
A patient charter for hepatocellular carcinoma: a co-created community call for action on equitable access to early diagnosis and multidisciplinary care
Poster presentation
Presenter: Pharm Hassan

1670
Machine learning-based decision tree model for predicting survival in patients with single-large hepatocellular carcinoma
Poster presentation
Presenter: Yi-Chen Lin

1671
Metabolic response to locoregional treatment for hepatocellular carcinoma measured by 18F-FDGal PET/CT

Poster presentation
Presenter: Mona Kristiansen

1686
Use of a cGPT 4.0, a large language model in grading the Barcelona clinic liver cancer (BCLC) prognosis for patients referred for hepatocellular carcinoma management
Poster presentation
Presenter: Jonas Ho

1710
Validation of hepatocellular carcinoma risk scoring tools in patients with chronic hepatitis B virus and hepatitis C virus infection– results from a large multicentre cohort study
Poster presentation
Presenter: Yun Jung Kim

1761
Serologic and immunologic biomarkers for the identification of patients with hepatocellular carcinoma with high tumour burden and poor survival
Poster presentation
Presenter: Marta Guariglia

1764
Shifting etiologies and emerging metabolic factors of hepatocellular carcinoma from 2005 to 2020: a german nationwide population-based study
Poster presentation
Presenter: Josune Cabello Calleja

1851
Identification of diagnostic markers based on spectral infrared fingerprints of bile samples from endoscopic drainage of patients with biliary stenosis due to extrahepatic cholangiocarcinoma or pancreatic adenocarcinoma
Poster presentation
Presenter: Elia Gigante

1852
Comparison of clinical characteristics, risk factors and prognosis of HCC patients with lean and non-lean MASLD undergoing surgical resection
Poster presentation
Presenter: Chun-Ting Ho

1867
Development and validation of PSU's AI-assisted ultrasound (AI-US) algorithm for focal liver lesion detection
Poster presentation
Presenter: Apichat Kaewdech

1911
Role of Child-Turcotte-Pugh and ALBI scores in patients with non-cirrhotic hepatocellular carcinoma
Poster presentation
Presenter: Abelina Kreuter

1937
Predictive microRNA panel of hepatocellular carcinoma occurrence in patients with chronic hepatitis C achieving sustained virological response after direct-acting antiviral therapy
Poster presentation
Presenter: Emanuela De Santis

1941

Lower allele frequency of the TERT-rs2242652 in sub-saharan african than american populations and hepatocellular carcinoma risk

Poster presentation

Presenter: Perapa Chotiprasidhi

1982

Reevaluating alpha-fetoprotein in hepatocellular carcinoma: low levels across stages and cirrhosis, and the role of ALT and AFP-L3 as better markers

Poster presentation

Presenter: Hariti Shah

2050

Liver function and tumor stage determines adherence to tumor board recommendation in HCC

Poster presentation

Presenter: Robert Oehring

2055

MicroRNA profiling of hepatocellular carcinoma can improve the prediction of tumor recurrence after liver resection

Poster presentation

Presenter: Robin Zenlander

2076

Added-value of PET imaging to AFP score in predicting HCC recurrence after liver transplantation

Poster presentation

Presenter: Alina Pascale

2090

Statin and its effects on hepatocellular carcinoma risk and liver fibrosis in chronic liver disease

Poster presentation

Presenter: Jonggi Choi

2191

Hepatocellular carcinoma after liver transplantation: development of a machine learning-based risk score for safely ruling out recurrence

Poster presentation

Presenter: Pedro Passos

2231

Age differences in the association between alcohol consumption and risk of hepatocellular carcinoma: a nationwide cohort study

Poster presentation

Presenter: Mi Na Kim

2428

Development and external validation of a weakly supervised deep learning algorithm for the diagnosis of focal liver lesions on contrast-enhanced ultrasound

Poster presentation

Presenter: Tobias Paul Seraphin

2489

A machine learning model to predict the treatment response of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma incorporating computed tomogram-derived imaging biomarkers

Poster presentation

Presenter: Moon Haeng Hur

2535

Prognostic influence of clinically significant portal hypertension in patients with compensated cirrhosis and hepatocellular carcinoma receiving systemic therapy: The HIPERIA study

Poster presentation

Presenter: Antonio Guerrero

2541

Clinicopathological features of liver tumors in Guilin: a region with significant Aflatoxin contamination in food crops in China

Poster presentation

Presenter: Wenhua Shao

2615

Prognostic significance of tumor-associated endothelial B7-H3 expression in hepatocellular carcinoma

Poster presentation

Presenter: Yunmi Ko

2685

Prognostic value of a composite biomarker score for predicting overall survival in HCC patients

Poster presentation

Presenter: Francesco Damone

2706

Increasing prevalence of hepatocellular carcinoma in the Netherlands: changing etiologies, tumor characteristics and survival rates

Poster presentation

Presenter: Koen van Son

2754

Novel "3-in-1" blood metabolomic test for the early diagnosis and risk stratification of primary sclerosing cholangitis and cholangiocarcinoma

Oral presentation

Presenter: Ainhoa Lapitz

2812

Proton-pump inhibitors and gut microbiome are associated with survival in patients with hepatocellular carcinoma under immunotherapy

Poster presentation

Presenter: Marco Sanduzzi Zamparelli

2842

Impact of statin therapy on survival in hepatocellular carcinoma: a single-center study

Poster presentation

Presenter: Konstantinos Papantoniou

2915

Outcome in patients with liver cirrhosis and hepatocellular carcinoma : comparing MRI and ultrasound for HCC surveillance

Poster presentation

Presenter: Jasper van Leengoed

2931

Hepatocellular carcinoma in the MENA region differs in presentation and outcomes: an analysis of 2736 patients from Saudi Arabia, Oman, Egypt and Turkiye

Poster presentation
Presenter: Faisal M Sanai

3043

Treatment of hepatocellular carcinoma according to multiparametric therapeutic hierarchy approach: a prospective multicenter validation study

Poster presentation
Presenter: Lorenzo Canova

Liver tumours: Experimental and pathophysiology

47

A naturally derived monoterpene potentiates sorafenib's anticancer efficacy in drug-induced-hepatocellular carcinoma animal model

Poster presentation
Presenter: Amr Amin

138

Perineural invasion drives hilar cholangiocarcinoma progression via epithelial-mesenchymal transition augmented by cancer-associated Schwann cell-derived nerve growth factor inducible (VGF)

Poster presentation
Presenter: Honghua Zhang

195

Protein kinase R-like endoplasmic reticulum kinase in hepatic stellate cells promotes hepatocellular carcinoma progression via the p38delta mitogen-activated protein kinase/interleukin-1beta axis

Poster presentation
Presenter: Makoto Morita

234

The liver artificial intelligence (lai) consortium: a benchmark dataset and optimised machine learning methods for MRI-based diagnosis of solid-appearing liver lesions

Poster presentation
Presenter: Ruben Niemantsverdriet

262

Selective targeting of class I histone deacetylases with new derivatives of ursodeoxycholic acid as a novel treatment strategy for bile duct cancer

Poster presentation
Presenter: Francisco Javier Caballero-Camino

317

MicroRNA-372-3p impairs fatty acid metabolism in hepatocellular carcinoma cells by targeting CPT1A and ACSL4

Poster presentation
Presenter: Chaiyaboot Ariyachet

333

Harnessing human immune system mouse models to validate NADPH oxidase 1 inhibition as a treatment for hepatocellular carcinoma

Poster presentation
Presenter: Zenzi De Vos

405

Targeting UBE2I-mediated protein hyper-SUMOylation halts cholangiocarcinoma progression and rewires the tumor-stroma crosstalk
Poster presentation
Presenter: Irene Olaizola

407
Novel chemotherapy selectively induces double-strand DNA breaks and death in naïve and Cisplatin-resistant cholangiocarcinoma tumours
Poster presentation
Presenter: Irene Olaizola

432
Artificial intelligence-driven prediction of biology-related poor outcome and presence of vascular invasion in hepatocellular carcinoma
Poster presentation
Presenter: Agavni Mesropian

446
Efficacy of WNTinib, a novel selective therapeutic for CTNNB1-mutant tumors, in preclinical models of hepatoblastoma
Poster presentation
Presenter: Ugne Balaseviciute

523
Role of hypoxia on the progression and survival of hepatocellular carcinoma in hypoxia-inducible factor 1 alpha knockout bi- and tri-dimensional in vitro models
Poster presentation
Presenter: Tania Payo-Serafin

559
Cryptochrome proteins as key regulators in circadian rhythm-enhanced photodynamic therapy for cholangiocarcinoma
Poster presentation
Presenter: Tianxiao Huang

560
A novel panel of Methylated DNA markers for hepatocellular carcinoma
Poster presentation
Presenter: William Chung

569
Single-cell spatial proteomic landscape of intrahepatic cholangiocarcinoma immune microenvironment reveals immune evasion via FSTL1negative macrophage
Poster presentation
Presenter: Yongquan Chi

638
Clinical potential and non-canonical roles of the cytosolic aspartyl-tRNA synthetase (DARS1) in hepatocellular carcinoma
Poster presentation
Presenter: Natalia Hermán-Sánchez

641
Liver-derived mesenchymal stem cells promote epithelial-mesenchymal transition in a hepatocellular carcinoma spheroid coculture model
Poster presentation

Presenter: Grégory de Bodt

672

Infiltration of CD69- T cells in tumor tissue reflects longer recurrence-free survival in surgically resected hepatocellular carcinoma

Poster presentation

Presenter: Pil Soo Sung

704

Brown adipose tissue activation: a novel strategy to prevent/treat the hepatocarcinogenesis promoted by metabolic lipotoxicity

Poster presentation

Presenter: Marion Peyrou

764

Crosstalk between senescent cancer cells and the TME reveals myeloid cell centric therapeutic targets in HCC

Oral presentation

Presenter: Efi Tsouri

778

HDAC7 drives malignancy by preventing FBXW7-mediated ubiquitination degradation of YAP1 in hepatocellular carcinoma

Poster presentation

Presenter: Penghong Song

787

Association of T cell epitope spreading with the clinical efficacy of HBV-TCR T cell therapy for HBV-related HCC

Poster presentation

Presenter: Anthony Tan

794

High-resolution quantitative reconstruction of microvascular architectures in mouse hepatocellular carcinoma models

Poster presentation

Presenter: Yan Zhao

855

Microenvironment-responsive bispecific T-cell receptor-engineered T cells against hepatocellular carcinoma

Oral presentation

Presenter: Xinyu Lu

925

miR-30e-3p/CXCL3 axis predicts early tumor escape in hepatocellular carcinoma patients undergoing sorafenib treatment

Poster presentation

Presenter: Elisa Monti

950

Therapeutic potential of Human antigen R inhibition in chronic liver disease and hepatocellular carcinoma

Poster presentation

Presenter: Mickaël Jouve

956

E2F1-driven metabolic dysregulation is involved in hippo pathway-driven cholangiocarcinoma progression
Oral presentation
Presenter: Kendall Alfaro-Jiménez

982
GPC3-based mRNA cancer vaccine for hepatocellular carcinoma immunotherapy
Poster presentation
Presenter: Yifan Jiang

983
The metabolic heterogeneity induced by different genetic mutations in hepatocellular carcinoma leads to a particular response to feeding a lipid-enriched diet
Poster presentation
Presenter: Natalia Sainz-Ramirez

994
Comprehensive characterization of the peripheral immune landscape through single-cell transcriptomics in hepatocellular carcinoma patients undergoing immunotherapy
Poster presentation
Presenter: Beatriz Minguez

1003
FSP1 inhibitor icFSP1 enhances lenvatinib sensitivity for hepatocellular carcinoma treatment by promoting ferroptosis through the FSP1/MIR4435-2HG pathway
Poster presentation
Presenter: Congyue Zhang

1049
Targeting Annexin A1 improves immunotherapy efficacy by remodeling the macrophage-related immunosuppression for hepatocellular carcinoma
Poster presentation
Presenter: Zhenghui Song

1054
Integrated multi-omics profiling of pan heat shock proteins in hepatocellular carcinoma identifies CCT3 and CCT7 as druggable oncogenes in hepatocytes
Poster presentation
Presenter: Manju Nidagodu Jayakumar

1063
SMG7 as a potential driver of chronic liver disease progression to hepatocellular carcinoma
Poster presentation
Presenter: Betsaida Ojeda-Perez

1104
Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Poster presentation
Presenter: Takahiro Kodama

1105
3,4-dihydroxyphenylpropionic acid deficiency in chronic hepatitis B promotes hepatocellular carcinoma
Poster presentation
Presenter: Zhixian Lan

1125

A large-scale genetic analysis of hepatocellular carcinoma reveals novel mutational patterns and ancestry-linked mutations
Poster presentation
Presenter: Christoph Gerdes

1130
Oleic acid-PPARgamma-FATP1 loop fuels cholangiocarcinoma colonization in lymph node metastases through lipid metabolic reprogramming
Oral presentation
Presenter: Xiuxian Li

1156
The role of CNNM4 in the progression of cholangiocarcinoma: implications for ferroptosis and therapeutic potential
Poster presentation
Presenter: Naroa Goikoetxea-Usandizaga

1174
Microscale detection of selenium in liver tissue using laser ablation-inductively coupled plasma time-of-flight mass spectrometry
Poster presentation
Presenter: Nataliya Rohr-Udilova

1189
So hot, yet so cold: bacterial lipopolysaccharides hinder tumor adaptive immunity by producing inflammatory and suppressive innate immunity in non- or poorly-infiltrated hepatocellular carcinoma
Poster presentation
Presenter: Lugien AL ASADI

1239
Expression and role of trefoil factor 3 (TFF3) in hepatoblastoma
Poster presentation
Presenter: Matías A Avila

1259
mRNA-based vaccination for tumor neoantigens to induce a therapeutic T cell response in HCC
Poster presentation
Presenter: Paul Schneider

1272
Tumour-infiltrating regulatory T cells engage Nrf2 signalling to support their metabolic adaptation in hepatocellular carcinoma
Poster presentation
Presenter: Niloufar Safinia

1281
MFAP-5 siRNA nanohydrogels for antiangiogenic stromal-targeting HCC therapy
Poster presentation
Presenter: Paul Schneider

1316
Macrophage-targeted biodegradable polymer nanocarriers loaded with a cytokine pathway activator effectively suppress orthotopic HCC growth in immune-competent mice

Poster presentation
Presenter: Hicham El Mard

1392

Tumor microenvironment differences in liver cancer are lineage-dependent when controlled for oncogenic pathway activation

Poster presentation

Presenter: Chun-Shan Liu

1448

Multiomic insights into bile acid dysregulation, microbiome dysbiosis, and epigenetic modifications in metabolically associated non-B, non-C hepatocellular carcinoma: findings from multi-cohort studies and implications for early detection and therapeutic

Poster presentation

Presenter: Royston Liew

1485

YAP activity in cancer-associated fibroblasts is relevant for immune escape in cholangiocarcinoma

Poster presentation

Presenter: Kieu Trinh Dinh

1498

Glutaminolysis-driven iron accumulation in the liver: a mechanism for aging through Lysosomal dysfunction

Poster presentation

Presenter: Claudia M. Rejano-Gordillo

1500

Tumor size-dependent endothelial switch modulates CD8⁺ T cell immune surveillance in liver cancer

Oral presentation

Presenter: Carlotta Tacconi

1575

E7386 enhances lenvatinib's antitumor efficacy and upregulates ATF4 signalling in preclinical models and human hepatocellular carcinoma

Poster presentation

Presenter: Agavni Mesropian

1594

Using patient-led genetics to identify new therapeutic targets in metastatic cholangiocarcinoma

Poster presentation

Presenter: Paula Olaizola

1598

A syngeneic and orthotopic HCC mouse model demonstrating the high efficacy of combination therapies targeting the ECM and immune microenvironment

Poster presentation

Presenter: Emma Eichler

1645

Translational approaches to evaluating novel antifibrotic and anticancer drugs for hepatocellular carcinoma: strategies for prevention and treatment

Poster presentation

Presenter: Caecilia Sukowati

1688

Engineered oncolytic vesicular stomatitis virus expressing HBsAg and IL-15 enhances immune activation and tumor killing in hepatitis B-positive hepatocellular carcinoma

Poster presentation
Presenter: Yuchen Xia

1689
Functional properties of unannotated, small RNA clusters during hepatocarcinogenesis
Poster presentation
Presenter: Francesca Pagani

1722
Targeting CDC7 enhances anti-PD-1 immunotherapy in hepatocellular carcinoma
Poster presentation
Presenter: LIANG ZHANG

1727
CD40–Integrin $\alpha 5\beta 1$ and CD27-CD70 axes: novel mechanisms driving HCC progression in chronic hepatitis C
Poster presentation
Presenter: Le Thi Thanh Thuy

1790
Development and performance of AI in supporting the diagnosis of liver tumors using B-mode ultrasound
Poster presentation
Presenter: Naoshi Nishida

1802
The genetic alterations in circulating tumor cells correlate with the clinical outcomes of hepatocellular carcinoma by large-scale whole-genome sequencing
Poster presentation
Presenter: Zhihang Zhou

1856
Reduction in lipid accumulation, inflammation and hepatocellular carcinoma development after protease-activated receptor 2 inhibition through 1-Piperidinepropionic acid
Poster presentation
Presenter: Pietro Guerra

1879
Longitudinal analyses of Innate Lymphoid Cells in patients with HCC identifies patterns associated with disease stage and response to therapy with atezolizumab and bevacizumab
Poster presentation
Presenter: Tijana Ristic

1890
Can fractal descriptors distinguish vascular organization within the tumor microenvironment?
Poster presentation
Presenter: Jake Penney

1891
Treatment of cholangiocarcinoma with Claudin-1 antibodies reprograms the tumor microenvironment to improve survival in an orthotopic mouse model
Poster presentation
Presenter: Romain Desert

1926
Metabolic and functional characterization of CD8+ T-cell subpopulations in hepatocellular carcinoma: implications of tumor microenvironment on T-cell dysfunction

Poster presentation
Presenter: Gabriele Missale

1952
Claudin-1 modulates cell plasticity, carcinogenic signaling and proliferation in patient-derived cholangiocarcinoma organoids in vivo
Poster presentation
Presenter: Jade Brochon

2009
Modulation of the tumor microenvironment: targeted silencing of AATF suppresses TGF- β signaling via lncRNA MIR100HG in hepatocellular carcinoma
Poster presentation
Presenter: Divya Kumar

2083
Primary cilia loss promotes neoplastic outgrowth in intrahepatic cholangiocarcinoma through suppression of neutrophilic immune surveillance
Poster presentation
Presenter: Sara Teles

2121
Distinct roles of SOS1 and SOS2 in lipid metabolism and tumorigenesis: implications for therapeutic targeting in cancer and metabolic disorders
Poster presentation
Presenter: Andrea Olarte

2277
MiR-485-3p as a predictor of therapeutic response and its role of the PIAS3/STAT3/VEGF signal in Atezolizumab plus Bevacizumab therapy for hepatocellular carcinoma
Poster presentation
Presenter: Kyoko Oura

2315
Single-cell transcriptomics reveal DDX1 as a driver of cancer stemness and tumorigenesis in hepatocellular carcinoma
Poster presentation
Presenter: Yao Yang

2396
Impact of environmental pollution and the aryl hydrocarbon receptor signaling pathway on hepatic carcinogenesis
Poster presentation
Presenter: Sri-Kamini SOOCHETA

2442
A druggable RuvBL1-HSF1 axis in hepatocellular carcinoma stress response
Poster presentation
Presenter: Dimitri Papini

2453
Proteomic profiling of advanced hepatocellular carcinoma identifies predictive signatures of response to treatments
Poster presentation
Presenter: Frederic Saltel

2493

The liver microenvironment of MASH and MetALD HCCs: a spatial transcriptomics analysis

Poster presentation

Presenter: Yasmina Chouik

2503

Impact of PNPLA3 and TM6SF2 single nucleotide polymorphisms in metabolic dysfunction-associated steatohepatitis-linked hepatocellular carcinoma development in 3D extracellular matrix models

Poster presentation

Presenter: Giulia Lupo

2513

The role of Activating Factor 4 (ATF4) in the immunosuppressive phenotype of beta-catenin mutant hepatocellular carcinoma

Poster presentation

Presenter: Stefany Infante

2534

Selective targeting of integrin $\alpha v\beta 8$ effectively suppresses tumor growth in the new PSC-associated cholangiocarcinoma model (SB CCA.Mdr2^{-/-} mouse)

Poster presentation

Presenter: Pinzhu Huang

2554

Proinflammatory cytokines drive peripheral Foxp3^{high} Tregs into tumor sites: a reliable and accessible prognostic biomarker for HCC patients

Poster presentation

Presenter: Chien-Hao Huang

2591

Engineering NK cell immunotherapy to optimise liver tumour homing and block PD-L1-mediated inhibition of T cells

Poster presentation

Presenter: Mariana Diniz

2605

The NLRP3 inflammasome and its downstream target IL1R, but not IL18R drive hepatocarcinogenesis

Poster presentation

Presenter: Mona Peltzer

2617

Atorvastatin and gene expression signatures in hepatocarcinogenesis

Poster presentation

Presenter: Ezequiel Ridruejo

2652

Activation of coagulation system and platelet aggregation in patients with primary sclerosing cholangitis and cholangiocarcinoma

Poster presentation

Presenter: Luca Fabris

2666

TIGAR SUMOylation: a key modulator of metabolic balance in hepatocellular carcinoma

Poster presentation

Presenter: Carolina Conter

2671

Spatio-genomic characterization of malignant transformation in dysplastic nodules

Poster presentation

Presenter: Jihyun An

2679

Platelet-derived extracellular vesicles (PEVs) in hepatocellular carcinoma. Emerging diagnostic biomarkers

Poster presentation

Presenter: Ángela Rojas

2684

OGT and c-Myc promote non-canonical activation of gene expression by EZH2 in hepatocellular carcinoma

Poster presentation

Presenter: Mirjam Zeisel

2696

Modulation of mitotic stress-induced activation of the cGAS/STING signaling pathway by DNA demethylation

Poster presentation

Presenter: Umar Mukhamedaliev

2771

The intratumoral microbiome in HCC and its impact on treatment response

Poster presentation

Presenter: Ugne Balaseviciute

2796

Liposomal doxorubicin and atezolizumab promote EMT regression by acting on the tumor microenvironment: preclinical in vitro and in vivo studies

Poster presentation

Presenter: Ilaria Zanotto

2924

Immunoregulation and T cell paralysis mediated by MDSC induction in hepatocellular carcinoma following rVSV-NDV therapy

Poster presentation

Presenter: Mirta Jimenez

2951

Prediction of hepatocellular carcinoma using AI-driven MRI radiomics: development of the AI-HCC prediction model

Poster presentation

Presenter: Maureen Guichelaar

3003

Beta klotho as a regulator of liver cancer cell proliferation and liver cancer development

Poster presentation

Presenter: Alexandra Aaldijk

3024

RIPK3 is a metabolic regulator impacting mitochondrial dysfunction, endoplasmic reticulum stress and tumour development during murine chemical-induced hepatocarcinogenesis

Poster presentation

Presenter: André F. L. Cardador

3046

Defective liver endothelial autophagy occurring in metabolic dysfunction-associated steatotic liver disease promotes hepatocellular carcinoma

Poster presentation

Presenter: Samira Laouirem

Liver tumours: Therapy

50

Multi-omics analyses identify a novel HCC subtype with better response to immune checkpoint inhibitor therapies

Poster presentation

Presenter: Junjie Xu

280

TACE combined with ICIs plus MTT after 125I irradiation stent placement in patients with hepatocellular carcinoma and main portal vein tumor thrombosis (PATENCY II)

Poster presentation

Presenter: Junhao Mei

293

Microwave ablation versus liver resection for patients with hepatocellular carcinomas

Poster presentation

Presenter: Hyundam Gu

349

Transcatheter arterial chemoembolization combined with immune checkpoint inhibitors plus molecular targeted therapy after 125I irradiation stent placement in patients with hepatocellular carcinoma and main portal vein tumor thrombosis (PATENCY II)

Poster presentation

Presenter: Junhao Mei

364

Local control and survival after stereotactic body radiotherapy for hepatocellular carcinoma without macrovascular invasion

Poster presentation

Presenter: Jose Paul

379

Viral etiology of hepatocellular carcinoma as an independent determinant of survival for patients receiving tyrosine kinase inhibitor treatment

Poster presentation

Presenter: Lu Li

400

Clinical outcomes of stereotactic body radiotherapy for hepatocellular carcinoma with macrovascular invasion in a predominantly non-viral cohort

Poster presentation

Presenter: Jose Paul

505

Liver resection versus trans-arterial chemoembolization for huge hepatocellular carcinoma (>10cm): a nationwide propensity score adjusted analysis

Poster presentation
Presenter: Jai Young Cho

512

Impact of radiation dose on treatment response and survival outcomes in solitary hepatocellular carcinoma treated with Y90 selective internal radiation therapy: a retrospective single-center study

Poster presentation

Presenter: Lu Yang

537

Outcomes by liver function in patients with unresectable hepatocellular carcinoma treated with nivolumab plus ipilimumab vs lenvatinib or sorafenib in the CheckMate 9DW trial

Oral presentation

Presenter: Bruno Sangro

608

Improving outcomes in unresectable hepatocellular carcinoma through proactive adverse event management with Atezolizumab-Bevacizumab therapy

Poster presentation

Presenter: Jeayeon Park

788

Sorafenib plus transarterial chemoembolization versus sorafenib alone in advanced hepatocellular carcinoma (SELECT): a multicenter, phase 3, randomized, controlled trial

Poster presentation

Presenter: Guohong Han

849

Histologic predictors of response to atezolizumab and bevacizumab in hepatocellular carcinoma biopsies

Poster presentation

Presenter: Alexandre Sayadi

870

Prognosis of patients undergoing curative surgery for combined hepatocellular-cholangiocarcinoma

Poster presentation

Presenter: Eung-Ho Cho

890

Microwave ablation versus single-needle radiofrequency ablation for the treatment of HCC up to 4 cm: a randomized control trial

Poster presentation

Presenter: SHUNSUKE NAKAMURA

899

Real-world treatment patterns and survival outcomes in patients with unresectable hepatocellular carcinoma (uHCC): the OREIOS - Middle East and North Africa (MENA) cohort

Poster presentation

Presenter: Imam Waked

915

The "A-B-C" cluster-based classification reveals distinct outcome trajectories in patients with hepatocellular carcinoma under atezolizumab/bevacizumab

Poster presentation

Presenter: Claudia Campani

981

Incidence of radiation pneumonitis following resin-based yttrium-90 selective internal radiation therapy
Poster presentation
Presenter: Kaina Chen

1083

Integrating quality of life and overall survival to quantify benefit from frontline systemic therapy options in unresectable/advanced hepatocellular carcinoma: a network meta-analysis
Poster presentation
Presenter: Ciro Celsa

1092

Real-world treatment patterns and outcomes among patients with hepatocellular carcinoma managed at a single centre in Switzerland
Poster presentation
Presenter: Pompilia Radu

1109

Sub-symptomatic Child-Pugh score 7 shows comparable survival outcomes to Child-Pugh score 6 in hepatocellular carcinoma patients treated with Atezolizumab and Bevacizumab
Poster presentation
Presenter: Jaejun Lee

1160

Statins in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab/bevacizumab: a propensity score-matched cohort analysis from ARTE an italian prospective multicentric dataset
Poster presentation
Presenter: Marco Vicardi

1162

Impact of sarcopenia on medium-long-term survival of patients with hepatocellular carcinoma treated with lenvatinib
Poster presentation
Presenter: Lorenzo Lani

1270

Immunoprofiling-based machine learning model predicts outcomes to pembrolizumab plus lenvatinib in patients with unresectable hepatocellular carcinoma
Poster presentation
Presenter: Pei-Chang Lee

1808

Deep learning derived radiomics with advanced machine learning outperforms clinical biomarkers in predicting outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma
Poster presentation
Presenter: Mathew Vithayathil

1868

Recompensation before first-line systemic therapy for hepatocellular carcinoma yields comparable survival to compensated cirrhosis
Poster presentation
Presenter: Manuel Mendizabal

1894

Long-term survival outcomes in patients receiving atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma: an update of the AB-real study

Poster presentation
Presenter: Bernardo Stefanini

1977

Conversion ability of systemic therapy in patients with hepatocellular carcinoma: a multicenter international study. On behalf of the converse survey collaborative study group

Poster presentation
Presenter: Alessandro Vitale

1991

Systematic review of stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma with tumor thrombus extension to the inferior vena cava or right atrium

Poster presentation
Presenter: Divya Khosla

2108

Phase III trials in hepatocellular carcinoma: IMbrave 050 and strategies to address non-proportional hazards

Oral presentation
Presenter: Ezequiel Mauro

2151

Radiofrequency ablation is safe in patients with hepatocellular carcinoma and thrombocytopenia

Poster presentation
Presenter: Songchi Xiao

2166

Exosomal miR-30a-5p: a promising biomarker for predicting response to Atezolizumab-Bevacizumab therapy in advanced hepatocellular carcinoma

Poster presentation
Presenter: Eunho Choi

2179

Immune cell profiling predicts response to Atezolizumab-Bevacizumab in advanced hepatocellular carcinoma

Poster presentation
Presenter: Eunho Choi

2204

Pre-treatment serum IgG levels predict immune-related adverse events in HCC patients treated with atezolizumab plus bevacizumab

Poster presentation
Presenter: Yutaka Yasui

2248

Bridging and long-term impact of pre-orthotopic liver transplant transjugular intrahepatic portosystemic shunt (TIPS) creation: a propensity-matched analysis using the united network for organ sharing (UNOS) database

Poster presentation
Presenter: Nariman Nezami

2283

Evolutionary learning-derived multimodal models integrating comprehensive imaging features to predict early recurrence of hepatocellular carcinoma after curative resection

Poster presentation
Presenter: I-Cheng Lee

2318

Prognostic value of early change in neutrophil to lymphocyte ratio after atezolizumab plus bevacizumab treatment for hepatocellular carcinoma

Poster presentation

Presenter: Young Mi Hong

2329

Updated network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma: consistent role of TACE

Poster presentation

Presenter: Jihyun An

2333

Patterns and outcomes of recurrence after thermal ablation for hepatocellular carcinoma

Poster presentation

Presenter: CHI-PING TAN

2376

Selective internal radiation therapy (SIRT) for HCC: real-world experience from a tertiary care center

Poster presentation

Presenter: Ilkay Ergenc

2444

The role of immune cell composition potentially predicts response to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma

Poster presentation

Presenter: Jana Knorr-Klocke

2659

Hepatic artery infusion chemotherapy(HAIC) combined with Lenvatinib and Camrelizumab for hepatocellular carcinoma(HCC) with portal vein tumor thrombus(PVTT): a prospective longitudinal real-world study

Poster presentation

Presenter: Qingxian Cai

2713

Nodule US-elastography: enhancing diagnostic and monitoring toolkits for predicting treatment response and prognosis in hepatocellular carcinoma post-TACE

Poster presentation

Presenter: Teodor-Marcel Puiu

2716

A holistic approach of systematic tumor and non-tumor biopsy during percutaneous radiofrequency ablation for hepatocellular carcinoma: diagnostic, prognostic and therapeutic impact

Oral presentation

Presenter: Lorraine Blaise

2735

The changing epidemiology of patients with HCC receiving a first-line systemic therapy: insights from ARPES and ARTE databases (2008-2024)

Poster presentation

Presenter: Lorenzo Lani

2745

Predictors for postembolization syndrome in a cohort of patients with hepatocellular carcinoma

Poster presentation
Presenter: Razvan Rababoc

2869
The dose of radiation absorbed by the tumor and the non-tumoral compartments does not impact peripheral immune markers after SIRT
Poster presentation
Presenter: Elisa Pinto

2948
Real world treatment patterns and outcomes for hepatocellular carcinoma (HCC) patients receiving transarterial chemoembolization (TACE) or transarterial radioembolization (TARE) in the TARGET-HCC registry
Poster presentation
Presenter: Amit Singal

2949
Effects of pre-transplant locoregional therapies on dropout rates and survival outcomes in patients with hepatocellular carcinoma: a propensity-matched analysis of the United Network for Organ Sharing (UNOS) database
Poster presentation
Presenter: Nariman Nezami

2972
Evaluation of the intratumoral immune microenvironment in hepatocellular carcinoma treated with liver surgery after selective internal radiation therapy
Poster presentation
Presenter: Maria Stella Franzè

3011
Non-selective beta blockers: mitigating hepatocellular carcinoma progression and enhancing sorafenib efficacy through Wnt/beta-catenin pathway modulation
Poster presentation
Presenter: Tasnim Mahmoud

3031
Impact of hepatocellular carcinoma multidisciplinary team on treatment outcomes: an analysis from the Middle East and North Africa region
Poster presentation
Presenter: Al Naamani Khalid

3071
Laparoscopic liver resection as a treatment for early-stage hepatocellular carcinoma in patients with and without portal hypertension: a case-control study
Poster presentation
Presenter: Alvaro Urzúa

MASLD: Clinical aspects except therapy

153
The severity of MASLD is associated with chronic kidney disease in patients with type 2 diabetes and/or obesity
Poster presentation
Presenter: Cyrielle Caussy

170

The paradox of low hepatic fat content in steatotic liver disease: insights from an MRI-PDFF study

Poster presentation

Presenter: ATSUSHI NAKAMURA

220

Endothelial dysfunction and metabolic dysfunction-associated steatotic liver disease: is there a relationship?

Poster presentation

Presenter: Kateryna Pivtorak

248

Type 2 diabetes increases the risk of progression to metabolic dysfunction-associated steatohepatitis-related cirrhosis in a real world setting

Poster presentation

Presenter: Sabine Kahl

319

Hepatic mitochondrial reductive stress predicts major adverse liver-related outcomes and is modifiable by common medications and diet

Poster presentation

Presenter: Juho V. Asteljoki

325

Liver-related events are uncommon in patients meeting AASLD criteria for Resmetirom and are not seen in those with a liver stiffness measurement < 10 kPa

Poster presentation

Presenter: Hua Xuan Yeow

429

Altered C-fiber function and neuropathic changes in metabolic syndrome and MASLD indicate early peripheral nerve dysfunction

Poster presentation

Presenter: Miriam M. Düll

455

Risk stratification of liver-related complications through unsupervised partitioning clustering of alanine aminotransferase (ALT) levels and trajectories in patients with type 2 diabetes (T2D)

Poster presentation

Presenter: Nana Peng

513

Patient preferences for metabolic-dysfunction associated steatotic liver disease: moving towards patient centred care

Poster presentation

Presenter: Katie Williams

572

Ongoing fibrosis quantification in paired liver biopsy samples from MASLD patients using AI-based digital pathology: an international multicenter study

Poster presentation

Presenter: Ming-Hua Zheng

577

Early-onset cancer risk in young adults with metabolic dysfunction-associated steatotic liver disease

Poster presentation
Presenter: Eun Ju Cho

663
Clinical and genetic predictors of steatotic liver disease in lean individuals: a cohort study of risk factors and fibrosis prediction
Poster presentation
Presenter: Angela Sato Espinoza

684
Impact of metabolic dysfunction-associated steatotic liver disease on post-surgical outcomes in HBV-related hepatocellular carcinoma
Poster presentation
Presenter: Younghyeon Ahn

697
All-cause and disease-specific mortality in young adults with metabolic dysfunction-associated steatotic liver disease: a nationwide cohort study
Poster presentation
Presenter: Jeayeon Park

816
Life-style factors of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) – data from the german SLD-registry
Poster presentation
Presenter: Andreas Geier

839
Bariatric surgery identifies a protective amino acid in metabolic dysfunction-associated steatotic liver disease
Oral presentation
Presenter: Laura Granö

844
Disease state transitions across the spectrum of steatotic liver disease significantly affect long-term incidence of cirrhosis among a national cohort of veterans in the United States
Poster presentation
Presenter: Mai Sedki

888
Informing management of patients at increased risk of hepatic decompensation by two-step non-invasive assessment - a multicentre cohort study of 12,950 patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
Oral presentation
Presenter: Terry Cheuk-Fung Yip

917
Differences in quality of life and coping strategies between patients with metabolic dysfunction-associated steatotic liver disease and liver transplant recipients. A comparison with the general spanish population
Poster presentation
Presenter: Jesús Funuyet-Salas

948
Evaluation of liver steatosis and advanced fibrosis assessed by transient elastography in general population: a prospective study from north-eastern Romania
Poster presentation

Presenter: Robert Nastasa

985

Subgroup definition and monitoring of liver fibrosis evolution in patients with MASH bridging fibrosis based on objective measurements of septa parameters using digital pathology with artificial intelligence analyses

Poster presentation

Presenter: Nikolai Naoumov

1028

Intravenous infusions of fatty acids and ethanol induce hepatic mitochondrial reductive stress in humans

Poster presentation

Presenter: Riikka M. Sane

1048

Coagulation imbalance is associated with hepatic and vascular complications in patients with MASLD and diabetes: key role of factor VIII

Poster presentation

Presenter: Rosa Lombardi

1056

Carriage of rare pathogenic APOB variants predispose to severe metabolic-associated steatotic liver disease and hepatocellular carcinoma

Poster presentation

Presenter: Giulia Periti

1089

Serum bile acid is associated with clinically significant pruritus in patients with metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Zobair Younossi

1095

Rising trends in preventable premature MASLD-related deaths: disparities across urban and rural U.S. counties (2011–2021)

Poster presentation

Presenter: Zobair Younossi

1099

Metabolic dysfunction-associated steatotic liver disease (MASLD) screening according to EASL guideline is cost-effective

Poster presentation

Presenter: Zobair Younossi

1103

Impact of a multidisciplinary clinic for metabolic dysfunction-associated steatotic liver disease on cardiovascular risk and liver health

Poster presentation

Presenter: Mirko Zoncapè

1111

Development of a machine learning model for predicting cardiovascular disease in metabolic dysfunction-associated steatotic liver disease: a prospective cohort study from UK Biobank

Poster presentation

Presenter: Tae Seop Lim

1124

Liver disease severity and cardiovascular risk in steatotic liver disease with different alcohol exposure - a nationwide study in Taiwan

Poster presentation

Presenter: Ming-Lung Yu

1157

Steatosis in cirrhosis: a prognostic marker for liver related outcomes in metabolic-dysfunction associated steatotic liver disease

Poster presentation

Presenter: Yiying Pei

1175

Food insecurity is associated with poorer metabolic health in adults with MASLD but is not mediated by overall diet quality or total energy intake

Poster presentation

Presenter: Ani Kardashian

1186

Long-term mortality in steatotic liver disease is greatest in those with a combination of metabolic dysfunction and excessive alcohol consumption

Poster presentation

Presenter: Zobair Younossi

1200

When is a liver biopsy necessary? Predictive factors of autoimmune hepatitis in patients with metabolic dysfunction-associated steatotic liver disease and positive autoantibodies

Poster presentation

Presenter: Leire Sancho

1203

Association between polycystic ovary syndrome, steatotic liver disease in pregnancy, and adverse pregnancy outcomes: results from the prospective fatty liver in pregnancy cohort

Poster presentation

Presenter: Cecilia Katzenstein

1308

Clinically meaningful fatigue is associated with the presence of systemic inflammation, lower erythrocyte count and haemoglobin level, and decreased muscle strength in patients with metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Ekaterina Lusina

1400

Both high intensity and moderate intensity exercise interventions improve steatotic liver disease: a prospective randomized trial

Poster presentation

Presenter: Chun-Jen Liu

1402

The effect of a fast-food meal on endothelial function in people with metabolic dysfunction-associated steatotic fatty liver disease

Poster presentation

Presenter: James O'Beirne

1440

Influence of cardiometabolic risk factors on HCC risk in patients with metabolic dysfunction-associated steatotic liver disease
Poster presentation
Presenter: Ho Soo Chun

1452
Characterization and validation of regional variation in fibrosis within traditional fibrosis stages
Poster presentation
Presenter: Elaine Chng

1493
The impact of cardiopulmonary fitness on metabolic dysfunction-associated steatotic liver disease in a combined lifestyle intervention for adolescents with obesity
Poster presentation
Presenter: Maarten Buytaert

1520
The impact of chronic hepatitis B on fibrosis progression in metabolic dysfunction-associated steatotic liver disease
Poster presentation
Presenter: Fajuan Rui

1542
Weight loss was associated with risk reduction of MASLD, at-risk MASH and fibrosis with ongoing effects beyond the current recommendations
Poster presentation
Presenter: Laurens A. van Kleef

1571
Volatile organic compound metabolites in urine are associated with MASLD and fibrosis: an environmental health study
Poster presentation
Presenter: Laurens A. van Kleef

1574
Multimorbidity, disease clusters and all-cause mortality in people with metabolic dysfunction association steatotic liver disease in UK Biobank
Poster presentation
Presenter: Qi Feng

1587
Causal analysis of steatotic liver disease based on linear mixed causal model using a cohort with comprehensive medical dataset
Poster presentation
Presenter: Yoshito Itoh

1659
Genetic risk score correlates with Cytokine expression and risk of HCC and cirrhosis in MASLD patients from Latin America
Poster presentation
Presenter: Siyu Fu

1661
Genome-wide association study of noninvasive scores of fibrotic MASLD in an Italian population
Poster presentation
Presenter: Francesco Malvestiti

1698

Comparison of clinical characteristics and outcome of HCC patients with and without MASLD underwent surgical resection – experience from an asian tertiary center

Poster presentation

Presenter: Chia Jung Ho

1738

Assessing muscle function in non-cirrhotic patients with steatotic liver disease : a cross-sectional study

Poster presentation

Presenter: Guillaume HENIN

1816

Impact of metabolic dysfunction-associated steatotic liver disease on fatigue and pruritus in primary sclerosing cholangitis: a U.S. single-center cross-sectional study

Poster presentation

Presenter: Natalia Rojas-Amaris

1824

The impact of first and further decompensation in patients with metabolic-dysfunction associated compensated advanced chronic liver disease

Poster presentation

Presenter: Grazia Pennisi

1825

Metabolic-dysfunction associated steatotic liver disease in inflammatory bowel disease: prevalence and progression

Poster presentation

Presenter: Grazia Pennisi

1837

Real-world assessment of clinical burden and healthcare resource utilisation among patients with metabolic dysfunction-associated steatohepatitis with additional cardiovascular, renal and metabolic comorbidities in France, Italy, Germany and Canada

Poster presentation

Presenter: Riku Ota

1838

Adverse outcomes and HBsAg seroclearance of chronic hepatitis B complicated with metabolic dysfunction-associated steatotic liver disease: a cohort study

Poster presentation

Presenter: Jialan Wang

1880

10 year progression of metabolic risk factors - correlation with steatosis and fibrosis degree in a general population cohort

Poster presentation

Presenter: Joana Estrabocha

1899

10 years progression of metabolic risk factors, diet quality and degree of steatosis and fibrosis in a general population cohort - ECOR liver study

Poster presentation

Presenter: Joana Estrabocha

2022

The relationship between insulin resistance, thyroid gland dysfunction and bacterial overgrowth syndrome in the development of vascular complications in patients with metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Kateryna Pivtorak

2065

Analysis of body composition in patients with metabolic dysfunction-associated steatotic liver disease and its relationship with liver fibrosis

Poster presentation

Presenter: Claudia Alexandra Pontes Ivantes

2095

Metabolic dysfunction-associated steatotic liver disease (MASLD) in Italian women: is liver fibrosis independent from menopause?

Poster presentation

Presenter: Agnese Salamone

2172

Hypertension combined with hyperlipidemia increased the risk of extrahepatic malignancy in the MASLD population

Poster presentation

Presenter: Xinyue Zhao

2187

Cryptogenic cirrhosis in Brazil: much beyond burned-out metabolic associated steatohepatitis

Poster presentation

Presenter: Paulo Bittencourt

2206

Histologic severity on liver biopsy is identical between normal weight and overweight adults with metabolic dysfunction associated steatotic liver disease: is it time to revise the definition of lean MASLD?

Poster presentation

Presenter: Kaela Miller

2226

Association of alpha-1 antitrypsin Pi*Z allele and disease severity in metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Kaela Miller

2233

Long-term clinical outcomes across biopsy-confirmed steatotic liver disease categories: a multicenter prospective cohort study using merged data

Poster presentation

Presenter: Won Kim

2236

Changes in liver stiffness and controlled attenuation parameters of transient elastography according to weight change in metabolic dysfunction-associated liver disease

Poster presentation

Presenter: Seong Kyun Na

2252

Influence of cardiometabolic risk factors and alcohol consumption on liver stiffness in MASLD patients: a multicenter study in Colombia

Poster presentation
Presenter: Ismael de Jesus Yepes Barreto

2260
Risk assessment for carotid atherosclerosis in asymptomatic patients with metabolic dysfunction-associated steatotic liver disease
Poster presentation
Presenter: Hana Park

2312
A systematic review and meta-analysis - does metabolic dysfunction-associated steatotic liver disease increase the risk of cardiovascular disease above and beyond shared risk factors?
Poster presentation
Presenter: Alexander Hung

2335
Long term outcomes of liver transplantation for patients with metabolic dysfunction and alcohol associated/related liver disease (MetALD) versus alcohol associated liver disease (ALD)
Poster presentation
Presenter: Swapnil Dhampalwar

2507
Liver phenotypes in a multicentric PCOS cohort: prospective analysis including steatotic liver disease-associated genetic variants
Poster presentation
Presenter: Marcin Krawczyk

2546
Muscle fat content quantified by L3-PDFFPsoas is strongly associated with fibrosis in patients with metabolic dysfunction-associated steatotic liver disease
Poster presentation
Presenter: Zi-Ming An

2549
Impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on serological milestones of chronic hepatitis B patients
Poster presentation
Presenter: Hui-Chun Yang

2657
Long-term outcomes of metabolic dysfunction associated steatotic liver disease (MASLD) patients in a prospective, german real-world cohort
Poster presentation
Presenter: Monika Rau

2723
Sarcopenia is an independent risk predictor for all-cause mortality in individuals with a body mass index less than 25
Poster presentation
Presenter: Wang Zilong

2760
MASLD and FIB4 are independent predictors of major adverse liver outcomes and cardiovascular events in type 2 diabetes: findings from a single-center cohort using AI-driven machine learning
Poster presentation
Presenter: Valentin Calvez

2804

The association of Ferritin with subclinical coronary artery calcification is an expression of underlying cardiometabolic risk

Poster presentation

Presenter: Sophie Gensluckner

2819

Exploring the interplay between sarcopenia, liver and cardiovascular damage in non-cirrhotic MASLD patients: a genetic perspective

Poster presentation

Presenter: Annalisa Cespiati

2836

Prevalence, clinical features and determinants of MASLD in Klinefelter syndrome: a cross-sectional study

Poster presentation

Presenter: Aldo Marrone

2856

Real-world practice using liver stiffness measurement through two-dimensional shear wave elastography (SuperSonic Imagine) as a predictive tool for hepatocellular carcinoma risk in non-cirrhotic MASLD patients

Poster presentation

Presenter: Federico Ravaioli

2895

Liver stiffness and MACE development: an intricate relationship

Poster presentation

Presenter: Ernestina Santangeli

2921

Impact of ultra processed foods on metabolic dysfunction-associated steatotic liver disease: limitations of the NOVA classification

Poster presentation

Presenter: Franziska Beck

2963

Cardiovascular risk screening in patients with metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Balint Dracz

2973

Longitudinal dynamics and predictors of hepatic fibrosis and steatosis in people living with HIV: an egyptian cohort study

Poster presentation

Presenter: Ahmed Cordie

2986

Rising prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD)-associated hepatocellular carcinoma: a comparative analysis of clinical features and outcomes

Poster presentation

Presenter: Gupse Adali

2997

Obesity-related cognitive problems are not related to liver disease severity and remain unchanged after metabolic restoration

Poster presentation
Presenter: Mette Lauridsen

3002
Impact of anthropometric and body composition on response to lifestyle intervention in patients living with MASLD
Poster presentation
Presenter: Paloma Carrillo

3004
Coexistence of fatty acid desaturase 2 (FADS2) and PNPLA3 risk alleles contributes to fibrosis progression in MASLD
Poster presentation
Presenter: Shunsuke Ikejima

3098
Genetic risk accentuates the impact of lifestyle on progression hepatic steatosis and fibrosis: insights from a population-based cohort
Poster presentation
Presenter: Yanhua Ding

MASLD: Diagnostics and non-invasive assessment

59
Evaluation of liver fibrosis by FIB4, liver stiffness (Fibroscan, ShearWave), LiverRisk score and EASL 2-step approach in a cohort of 1169 patients (STEATOLIB) followed for MASLD
Poster presentation
Presenter: Denis Ouzan

191
Potential issues with practical implementation of EASL-EASD-EASO clinical practice guidelines on management of metabolic-associated steatotic liver disease in a Swedish healthcare setting
Poster presentation
Presenter: Merle Roeren

196
Translating genetic information into clinical practice: Improved decision-making in advanced fibrosis assessment
Poster presentation
Presenter: Dong Yun Kim

238
A prospective comparison of two ultrasound attenuation imaging modes using different frequencies for assessing hepatic steatosis
Poster presentation
Presenter: Hyeon Ji Jang

241
Validating non-invasive tests for diagnostic prediction of fibrosis in patients with biopsy-proven MASLD: CORE, LiverRisk, and FIB-4
Poster presentation
Presenter: Rickard Strandberg

289

The "LITMUS metabolic-dysfunction associated steatotic liver disease intention-to-treat" (LiMITT) score: a machine learning proteomic tool to select patients for therapy

Poster presentation

Presenter: Anastasia Resteu

338

Development of novel supervised machine learning models to predict the population at risk of metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis in a spanish mediterranean population

Poster presentation

Presenter: Marta Cedenilla

347

US markers and necroinflammation, steatosis, and fibrosis in metabolic dysfunction-associated steatotic liver disease: the iLEAD study

Poster presentation

Presenter: Katsutoshi Sugimoto

368

The urine steroid metabolome combined with machine learning performs similarly to established non-invasive markers to risk stratify for the presence of advanced MASLD fibrosis

Poster presentation

Presenter: Hamish Miller

459

Misclassification in non-invasive tests for liver fibrosis is expected: an example predicting liver stiffness in an international cohort

Poster presentation

Presenter: Rickard Strandberg

462

Novel metabolomics-based non-invasive test for pediatric metabolic dysfunction-associated steatohepatitis using data from youth enrolled in NASH CRN studies

Poster presentation

Presenter: Helaina Huneault

477

Dynamics in lab-based non-invasive tests predict the development of liver-related outcomes in tertiary care

Poster presentation

Presenter: Georg Semmler

521

Artificial intelligence measurement of portal tracts enables quantification of portal, lobular and interface inflammation in metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction-associated steatohepatitis and autoimmune hepatitis

Poster presentation

Presenter: Caitlin Langford

530

Nuclear magnetic resonance metabolomics for non-invasive MASLD phenotyping

Poster presentation

Presenter: Christian Karger

532

Improved reader alignment in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis with the use of a study reading plan

Poster presentation

Presenter: Caitlin Langford

539

Longitudinal validation of the AGA, AASLD and EASL care pathways for metabolic dysfunction-associated steatotic liver disease (masld) in a prospective cohort of individuals with type 2 diabetes

Poster presentation

Presenter: Veeral Ajmera

570

Plasma FSTL-1 accurately assesses MASH-associated liver fibrosis stage

Poster presentation

Presenter: Jianhua Rao

646

Comparative analysis and cross-validation of artificial intelligence digital pathology (PathAI AIM-MASH and HistoIndex qFIBS) vs. expert hepatopathologist scoring in MASLD biopsies – results of the LITMUS study cohort

Oral presentation

Presenter: Alasdair Blain

655

Steatotic liver disease as a mortality risk enhancer in the presence of metabolic syndrome

Poster presentation

Presenter: Guyu Zeng

708

Fibroblast activity assessed by PRO-C3 is prognostic for fibrosis progression in MASH patients treated with insulin sensitizer MSDC-0602K during a phase IIb clinical trial

Poster presentation

Presenter: Alejandro Mayorca Guiliani

716

Prescreening with a novel machine learning model (LiverPRO) may improve trial enrollment efficiency in metabolic dysfunction-associated steatohepatitis (MASH): a retrospective analysis of the SYNERGY-NASH trial

Poster presentation

Presenter: Mark Hartman

729

Diagnostic performance of imaging and serum based MASLD biomarkers: robust validation in the prospective LITMUS imaging study

Oral presentation

Presenter: Michael Pavlides

812

The blood-based SteatoTest-2 score identifies a previously invisible early steatosis phenotype

Poster presentation

Presenter: Thierry Poynard

818

Personalised prediction of the individual risk of liver-related complications in MASLD using the dynamics of non-invasive tests of liver fibrosis

Oral presentation

Presenter: Jerome Boursier

845

Alpha-1 antitrypsin Pi*^{MZ} variant and risk of disease progression in MASLD and MASH

Poster presentation

Presenter: Bradley Jermy

904

Development and validation of two NIS2+@-based models for the detection of MASH resolution and fibrosis improvement

Poster presentation

Presenter: Yacine Hajji

907

ALT is an effective screening tool for advanced MASLD in children with obesity and overweight

Poster presentation

Presenter: Anne-Sophie Stroes

911

suPAR levels independently discriminate patients with at-risk MASLD

Poster presentation

Presenter: Julian Pohl

1093

A global analysis of patients with metabolic dysfunction associated steatotic liver disease with liver biopsy, non-invasive tests and mortality

Poster presentation

Presenter: Zobair Younossi

1101

Determinants of liver stiffness improvements and worsening in metabolic dysfunction associated steatotic liver disease: insights from two cohorts

Poster presentation

Presenter: Mirko Zoncapè

1102

One-year changes in ALT and LSM, not in CAP, predict long-term liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Grazia Pennisi

1108

Noninvasive fibrosis indices are less effective in predicting significant fibrosis in younger adults with metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Jaejun Lee

1158

Ultrasound-derived visceral adipose tissue: an easily obtainable adiposity index strongly associated with metabolic dysfunction-associated steatotic liver disease and metabolic parameters

Poster presentation

Presenter: Valentina Flagiello

1167

Thrombospondin-2, a direct serum marker of fibrogenesis, to assess treatment response in MASLD in a 6-month lifestyle intervention program

Poster presentation
Presenter: Angelo Armandi

1183

First construction and validation of new circulating markers (NITs) to assess the risk of early-fibrosis (eF) occurrence in outpatients with type-2 diabetes (T2D) and elevated transaminases

Poster presentation
Presenter: Thierry Poynard

1216

Intra-abdominal fat thickness measured by ultrasound correlates with CAP (Controlled Attenuation Parameter) measured by FibroScan® in a cohort of patients followed for MASLD/MASH at an urban liver centre: Impact of utilization in clinical practice

Poster presentation
Presenter: Magdy Elkhashab

1226

The diagnostic ability for hepatic steatosis by attenuation imaging using MRI-PDFF as reference standard ; a prospective multicenter study in Japan

Poster presentation
Presenter: Hiroko Iijima

1273

Liver fibrosis is a strong predictor of all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease independent from metabolic syndrome

Poster presentation
Presenter: Weiwei Xu

1282

Diagnostic and clinical implications of high spleen-to-liver stiffness ratio in MASLD – a prospective, comparative study

Poster presentation
Presenter: Christian Sebesta

1294

Identifying risk factors for “major liver-related outcomes” in patients with metabolic dysfunction-associated steatotic liver disease

Poster presentation
Presenter: Anastasia Raptis

1318

Three-tier testing pathways are required in metabolic dysfunction-associated steatotic liver disease for improved detection of advanced fibrosis

Poster presentation
Presenter: Mirko Zoncapè

1320

AI improves non-invasive diagnosis and screening of advanced MASLD

Poster presentation
Presenter: Paul Cales

1337

Good diagnostic performance of Hepatoscope™ in diabetology clinics for the screening of MASLD patients with high risk of advanced liver fibrosis

Poster presentation
Presenter: Cyrielle Caussy

1361

Relevant incidental histologic diagnoses in MASLD patients enrolled in the NASH CRN

Poster presentation

Presenter: Daniela Allende

1414

Does hyperferritinemia predict ferroptosis in metabolic dysfunction associated steatotic liver disease? A real-world experience

Poster presentation

Presenter: Ritu Singh

1445

Assessment of the metabolic dysfunction-associated steatohepatitis resolution index and component biomarkers in prediction of histology response to denifanstat in the FASCINATE-2 trial

Poster presentation

Presenter: Rohit Loomba

1470

Utilizing AI digital pathology for quantitative measurement, grading and differentiation of lobular and portal inflammation in MASH: preliminary analysis in liver histology

Poster presentation

Presenter: Kutbuddin Akbary

1489

Does measuring the components of the Fibrosis-4 index (FIB-4) separately on different days affect its diagnostic and prognostic performance in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)?

Poster presentation

Presenter: Sherlot Juan Song

1509

The ultrasound multiparametric method Steatoscore2.0 measures liver steatosis with high inter- and intra-operator reproducibility

Poster presentation

Presenter: Laura De Rosa

1512

LiverPRO to diagnose and monitor liver fibrosis in patients with MASLD and obesity

Poster presentation

Presenter: Charlotte Wernberg

1526

Noninvasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Jimmy Che-To Lai

1551

A comparison of the prognostic value of 12 body composition markers for MASLD, at-risk MASH and Increased liver stiffness in a general population setting

Poster presentation

Presenter: Laurens A. van Kleef

1559

Comparison of diagnostic accuracy and utility of 10 non-invasive tests for clinically significant liver disease among a general population with metabolic dysfunction
Oral presentation

Presenter: Laurens A. van Kleef

1576

Establishing a training protocol for liver stiffness measurement by transient elastography in metabolic dysfunction-associated steatotic liver disease screening

Poster presentation

Presenter: Faisal Abaalkhail

1578

Liver stiffness as a predictor of major adverse cardiac events in metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Nirbaanjot Walia

1580

Non-invasive markers to predict biopsy response in people with metabolic dysfunction-associated steatohepatitis and fibrosis: exploratory analysis of a phase 2 trial of glucagon receptor/glucagon-like peptide-1 receptor dual agonist, survodutide

Poster presentation

Presenter: Mazen Nouredin

1582

Systematic review of care pathways for metabolic dysfunction-associated steatotic liver disease (MASLD)

Poster presentation

Presenter: Kirsi van Eekhout

1621

Non-invasive identification of MASLD patients eligible for resmetirom treatment – data from a multicenter biopsy-proven MASLD cohort

Poster presentation

Presenter: Heike Bantel

1627

Serum biomolecules improve liver enzyme-based prediction scores of significant liver fibrosis and fibrotic metabolic dysfunction-associated steatohepatitis

Poster presentation

Presenter: Nateneal Beyene

1628

Vibration-controlled transient elastography scores to predict liver fibrosis in biopsy-proven metabolic dysfunction-associated steatotic liver disease patients with diabetes: a prospective, multicenter study

Poster presentation

Presenter: Xiaolong Qi

1639

Enhancing the non-invasive diagnosis of fibrosis in metabolic dysfunction-associated steatotic liver disease: the role of transient elastography and a two-stage machine learning diagnostic model

Poster presentation

Presenter: Zhengao Xu

1662

Multiparametric ultrasound-based algorithm SteatoScore 2.0 versus monoparametric controlled attenuation parameter in clinical practice: a comparison study in a monocentric MASLD cohort

Poster presentation
Presenter: Giovanni Petralli

1684

PRO-C4, a biomarker of perisinusoidal fibrosis, is related to cardiometabolic risk factors, steatosis, and liver stiffness

Poster presentation
Presenter: Diana Julie Leeming

1720

Fibroblast activity (PRO-C3) and liver stiffness correlate with spatial distribution of collagens in MASLD and ALD: insights from digital pathology

Poster presentation
Presenter: Diana Julie Leeming

1728

Advanced metabolic-dysfunction associated steatotic liver disease fibrosis: low number-needed-to screen in multiple lines of care

Poster presentation
Presenter: Stan Driessen

1750

Anthropometric measures and mortality risk in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD): a population-based cohort study

Poster presentation
Presenter: Yee Hui Yeo

1813

Hepatic collagen percent by morphometry correlates with non-invasive tests in metabolic dysfunction associated steatotic liver disease

Poster presentation
Presenter: Zobair Younossi

1859

Identifying risk factors linked to metabolic-associated steatotic hepatitis in people living with HIV in Newark, New Jersey

Poster presentation
Presenter: Jihad Slim

1864

Decoding fibrosis: transcriptomic and clinical insights via AI-derived collagen clusters in MASLD

Poster presentation
Presenter: Marta Wojciechowska

1905

Comparison of the pathophysiology of “metabolic” and “genetic” MASLD: a multiOmics cohort study

Poster presentation
Presenter: Mario Masarone

1913

The effect of obesity risk factors in steatotic liver disease: a genome-wide association study

Poster presentation
Presenter: Yu-Hsuan Chang

1914

A shallow-deep neural network approach combining non-invasive tests to enhance advanced fibrosis detection in metabolic dysfunction-associated steatotic liver disease patients

Poster presentation

Presenter: Athanasios Angelakis

1971

FICE-4C nomogram can help anticipating liver related complications in non-cirrhotic MASLD patients

Poster presentation

Presenter: Douglas Maya-Miles

1973

Risk factors for hepatic steatosis- a study of deceased liver donors

Poster presentation

Presenter: Jaimie Chang

1993

The association between non-invasive tests of liver fibrosis and early diastolic dysfunction in patients with metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Fabrizio Amato

2003

The use of controlled attenuation parameter for the assessment of treatment response in patients with metabolic dysfunction-associated steatotic liver disease undergoing a lifestyle intervention program

Poster presentation

Presenter: Lorenza Vaira

2029

Non-invasive assessment of fibrotic metabolic dysfunction-associated steatohepatitis by multisensorial electronic technologies

Poster presentation

Presenter: Francesca Terracciani

2049

Use of noninvasive tests (NITs) to diagnose and follow non-alcoholic steatohepatitis (NASH) with liver fibrosis patients treated with resmetirom

Poster presentation

Presenter: Jörn M. Schattenberg

2054

Bone fragility and fracture risk assessment in metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Clelia Asero

2072

Untargeted lipidomic profiling in pediatric metabolic dysfunction-associated steatohepatitis: insights from youth enrolled in NASH CRN studies

Poster presentation

Presenter: Helaina Huneault

2077

Development of a novel model using machine learning algorithms to predict absence of metabolic associated steatotic liver disease in healthy and patient trial volunteers. A population screening tool

Poster presentation

Presenter: James Rickard

2081

Prevalence and risk factors of steatotic liver disease in primary care in Slovakia

Poster presentation

Presenter: Beata Shiratori

2091

Low sensitivity of the 2024 EASL screening criteria for identifying MASLD fibrosis in the NHANES cohort

Poster presentation

Presenter: Nicolas Goossens

2147

Denifanstat-mediated reduction of plasma glycine- and taurine-conjugated bile acids correlates with histological improvements in denifanstat-treated metabolic dysfunction-associated steatohepatitis patients in phase 2b FASCINATE-2 study

Poster presentation

Presenter: Rohit Loomba

2150

Evaluating noninvasive diagnostic pathways for identifying MASH patients eligible for Resmetirom therapy: a real-world cohort analysis

Oral presentation

Presenter: Winston Dunn

2193

Clinical validation of MRI-PDFF super-response in identifying MASH resolution: data from a prospective cohort and validation in an RCT

Poster presentation

Presenter: Daniel Huang

2208

Evaluating noninvasive tests for significant fibrosis in a population-based MASLD cohort: insights from NHANES 2017–2020

Poster presentation

Presenter: Winston Dunn

2221

Fibroscan-based screening to determine the prevalence and severity of steatotic liver disease in type 1 diabetes – an Australian quaternary centre experience

Poster presentation

Presenter: Janakan Selvarajah

2222

Cost-effectiveness of hepatic fibrosis screening in suspected MASLD cases in primary care settings

Poster presentation

Presenter: Hyo Young Lee

2247

Three proteins in advanced liver fibrosis: a minimalistic shallow-deep neural network approach on metabolic dysfunction-associated steatotic liver disease patients using open data

Poster presentation

Presenter: Athanasios Angelakis

2294

Validation of proposed non-invasive criteria for resmetirom treatment in metabolic-associated liver disease in clinical practice

Poster presentation

Presenter: Javier Ampuero Herrojo

2298

Exploring the evolution of circulating protein biomarkers in liver transplantation setting for MASH, ALD, and MetALD

Poster presentation

Presenter: Laura Martínez-Arenas

2339

Best buys to diagnose and treat metabolic dysfunction-associated steatohepatitis among people living with diabetes type 2: a multi-country generalized cost-effectiveness analysis

Poster presentation

Presenter: Jeffrey Lazarus

2340

Comprehensive analysis of biomarker performance targeting “advanced fibrosis” and “at-risk” metabolic-dysfunction associated steatotic liver disease (MASH) – primary analysis of the LITMUS study cohort

Poster presentation

Presenter: Yasaman Vali

2367

Agreement between hepatic histology and non-invasive methods and their ability to detect MASLD/MASH among morbidly obese patients undergoing bariatric surgery: an egyptian cross-sectional study

Poster presentation

Presenter: Ahmed Cordie

2369

Novel multiparametric MRI imaging predicts histologic response in resmetirom versus placebo in the multicentre, international, Maestro NASH phase 3 trial

Poster presentation

Presenter: Rohit Loomba

2381

Optimizing non-invasive screening to reduce biopsy screen failure in clinical trials for metabolic dysfunction-associated steatotic liver disease

Oral presentation

Presenter: Yasaman Vali

2383

Change in cT1 following interventions in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis

Poster presentation

Presenter: Anneli Andersson

2427

Frequency and risk factors of fibrosis staging discrepancies between transient elastography and liver biopsy in patients with metabolic-associated steatotic liver disease: role of obesity and type 2 diabetes

Poster presentation

Presenter: Alba Jiménez-Masip

2462

Effect of liver damage on telomere length in people with diabetic kidney disease

Poster presentation

Presenter: Viktoriia Yerokhovych

2561

Comparison of FibroScan© and iLivTouch© for liver stiffness and steatosis assessment in patients with MASLD

Poster presentation

Presenter: Kamela Gjini

2571

Weight loss-related changes in MRI-derived measures of body composition and liver health: a large-scale analysis from the UK biobank

Poster presentation

Presenter: Tushy Kailayanathan

2608

Steatotic liver disease in patients with irritable bowel syndrome- a new category? Evidence based on response to therapy

Poster presentation

Presenter: Laura Iliescu

2682

Sampling variability of liver fibrosis assessed by digital pathology in pre-cirrhotic patients with MASH

Poster presentation

Presenter: Mathieu Petitjean

2703

Reliable quantitative multiparametric hepatic steatosis assessment by Steatoscore2.0 using routine liver ultrasound images

Poster presentation

Presenter: Laura De Rosa

2724

Can we use coronary-CT scan for screening of metabolic-associated steatotic liver disease?

Poster presentation

Presenter: Teodor-Marcel Puiu

2757

Are doppler alterations of the liver prognostic markers for MASLD Severity? How do doppler results correlate with transient elastography and anthropometric data?

Poster presentation

Presenter: Teodor-Marcel Puiu

2780

Similar prevalence of MASLD and liver fibrosis when screening high-risk patients identified in primary care versus outpatient clinics in secondary care

Poster presentation

Presenter: Vivian de Jong

2825

Liver stiffness measurement as a tool for identifying risk of hepatic-related hospitalizations: insights from a large real-world cohort

Poster presentation

Presenter: YAEL MILGROM

2855

Gaps in screening and management of metabolic dysfunction-associated steatotic liver disease: a retrospective audit of patients at cardiometabolic risk in a secondary care setting

Poster presentation

Presenter: Monica Cucco

2893

Comparative performance of controlled attenuation parameter and ultrasound-derived fat fraction in detecting hepatic steatosis in MASLD patients

Poster presentation

Presenter: Andrea Falcomata'

2904

Association of hepatic steatosis biomarkers with hepatic steatosis prevalence and risk of developing MASLD fibrosis in patients with type 2 diabetes mellitus in eastern Croatia: a pilot study

Poster presentation

Presenter: Martina Smolic

2979

Baseline liver elastography and its longitudinal changes predict liver-related outcomes in patients with metabolic dysfunction associated steatotic liver disease (MASLD)

Poster presentation

Presenter: Antonio Liguori

2990

Correlation between transient elastography, clinical scores and liver histology in patients with metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Diederick van Doorn

3008

Leveraging natural language processing (CogStack) to analyse FibroScan data: a seven-year exploration (2016–2023) of socioeconomic disparities, ethnic variations, and fibrosis trends

Poster presentation

Presenter: Saima Ajaz

3029

Referral algorithm from primary care based on the risk calculation for significant fibrosis

Poster presentation

Presenter: Marta Hernández Conde

3032

The utility of noninvasive tests - LIVERFAST, FIB4 and vibration-controlled transient elastography (VCTE, Fibroscan) - in the initiation and monitoring of the therapy with TNR-beta agonist (resmetirom) in MASH patients

Poster presentation

Presenter: Jeevin Sandhu

3052

The culprits behind methotrexate-proposed hepatotoxicity are modifiable risk factors

Poster presentation

Presenter: Sinan Sharba

3065

Metabolic associated steatotic liver disease- related significant and advanced fibrosis' prevalence in Brazil and the associated accuracy of FIB-4 and vibration-controlled elastography - a national register

Poster presentation

Presenter: Cristiane Villela-Nogueira

3072

Development of a deep learning-based model for predicting liver-related events in steatotic liver disease using specific health checkup data
Poster presentation
Presenter: Shun-ichi Wakabayashi

3073
Epigenetic biomarkers and methylome-wide association study (MWAS) for non-invasive diagnosis of at-risk MASH from plasma cell-free DNA
Poster presentation
Presenter: Manal F. Abdelmalek

3102
Novel point-of-care, rapid breath test to identify subjects with metabolic-dysfunction associated steatotic liver disease with advanced fibrosis - a pilot study
Poster presentation
Presenter: Orit Marom Albeck

MASLD: Experimental and pathophysiology

121
Disease-associated transcriptomic profiles of liver sinusoidal endothelial cells at single nucleus resolution in a non-human primate model of metabolic dysfunction-associated steatohepatitis
Poster presentation
Presenter: Joanne Hsieh

186
Fgl2-C3aR axis mediated NETs promote intravascular coagulation and liver fibrosis in MASLD progression
Poster presentation
Presenter: Xitang Li

219
Taurine reprograms hepatocyte metabolism and its plasma levels are inversely associated with the progression of MASLD
Poster presentation
Presenter: Pavitra Kumar

232
Low frequency, mild gradient intermittent hypoxia still induces liver fibrogenesis in mice fed a high-fed diet
Poster presentation
Presenter: Shogo Ohkoshi

251
Bispecific small interfering RNA targeting YAP1/WWTR1 as a novel therapeutic agent for metabolic dysfunction-associated steatohepatitis
Poster presentation
Presenter: Masayuki Sugimoto

258
Inhibition of hepatic bile salt uptake using the anti-HDV drug Bulevirtide attenuates inflammation in mouse models for colitis and diet-induced steatohepatitis
Poster presentation
Presenter: Thuc-Anh Nguyen

282

Liver disease activity measured with quantitative MRI is associated with major liver and cardiovascular events: a prospective cohort study

Poster presentation

Presenter: Edward Jackson

292

Spatial multiplex analysis reveals distinct senescence patterns and cellular interactions in mouse models of MASLD and MetALD

Poster presentation

Presenter: Charalampos Pavlidis

399

Leucine regulates mitochondrial function in an in vitro model of MASLD

Poster presentation

Presenter: Lizbeth Magnolia Aguilar

431

35 kilodalton specific-sized hyaluronan ameliorates high fat diet-induced liver injury in a murine model of moderate

Poster presentation

Presenter: Laura Nagy

471

Metabolic dysfunction-associated steatohepatitis (MASH) plays central role in western diet-induced cardiac dysfunction

Poster presentation

Presenter: Sandireddy Reddemma

472

Calciprotein crystallization assay as calcification biomarker in metabolic-dysfunction associated steatotic liver disease population

Poster presentation

Presenter: Joyce Xu

478

Tirzepatide reduces diet-induced senescence and NETosis-mediated liver fibrosis in mice

Poster presentation

Presenter: Feng Chen

488

Pharmacological decreases in reductive stress ameliorate lipotoxicity in hepatocytes

Poster presentation

Presenter: Mari J. Jokinen

531

Quantifying the periportal and lobular fat distribution in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis with artificial intelligence detection of portal tracts and macrovesicular steatosis

Poster presentation

Presenter: Caitlin Langford

590

Identification of differences in therapeutic mechanisms between Resmetirom and Semaglutide on metabolic dysfunction-associated steatohepatitis treatment in western diet-fed melanocortin 4 receptor knockout mice

Poster presentation
Presenter: Takumi Sugawara

599
Targeting activated fibroblasts in metabolic-associated steatotic liver disease with Nintedanib
Poster presentation
Presenter: Pil Soo Sung

656
Assessing perilipin-2 as a liver-specific biomarker: lack of correlation between cardiac damage and its levels in heart failure patients
Poster presentation
Presenter: Lucrezia Petrucci

669
Redundant yet distinct role of Vacuole membrane protein 1 and transmembrane protein 41B in regulating hepatic lipoprotein secretion and autophagy in metabolic dysfunction-associated steatohepatitis
Poster presentation
Presenter: Hongmin Ni

687
Bispecific small interfering RNA targeting YAP1/WWTR1 reduces low-density lipoprotein-cholesterol via proprotein convertase subtilisin/kexin type 9 transcriptional regulation in metabolic dysfunction-associated steatotic liver diseases
Poster presentation
Presenter: Yuki Yamada

758
Hepatic peroxisome proliferator-activated receptor gamma coactivator-1- alpha impacts the secretion of SerpinA3N in response to obesogenic diets in mice through induction of oxidative stress response in hepatocytes
Poster presentation
Presenter: James Eng

820
Anti-steatosis effect of telmisartan in a MASL-dietary rat model does not associates to changes in faecal bile acid metabolome
Poster presentation
Presenter: Roger Bentanachs

824
Sexual dimorphism of Sprague-Dawley rats in the liver inflammatory/fibrotic response to a high in sucrose and fat, choline-deficient, L-amino acid CDAA diet
Poster presentation
Presenter: Roger Bentanachs

825
MASH-in-a-dish: a multicellular pre-clinical model to identify targetable metabolite crosstalk in MASH
Poster presentation
Presenter: Jung-Chin Chang

829
Exploring the repurposing of Telmisartan for the treatment of MASLD: characterization of its antisteatotic mechanism of action
Poster presentation
Presenter: Roger Bentanachs

865

miRNA isoforms are differentially expressed with increasing disease activity and fibrosis in metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Arun J. Sanyal

885

Proteomics reveals the effect of liraglutide in enhancing fatty acid metabolism and reducing fibrosis in metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Yuxuan Chen

901

Paneth cells regulate intestinal lymphangiogenesis and lipid metabolism in metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Sheida Moghadamrad

975

SETDB2 promotes the progression of metabolic dysfunction-associated steatohepatitis by regulating liver macrophages polarization via MAPK signaling pathway

Poster presentation

Presenter: Baiyi Liu

1014

Integrated analysis of the liver tissue proteome and transcriptome in metabolic dysfunction-associated steatotic liver disease (MASLD) reveals an evolving pathophysiological milieu that may support identification of novel therapeutic targets

Poster presentation

Presenter: Georgia Graham

1041

The mGluR5 blockade by MPEP inhibits PKC and triggers AMPK activation reducing hepatic steatosis in vitro

Poster presentation

Presenter: Michelangelo Trucchi

1060

Spatial lipidomics applied to human liver across the spectrum of metabolic dysfunction-associated steatotic liver disease using mass spectrometry imaging

Poster presentation

Presenter: Monika Selvakumar

1066

Therapeutic potential of targeting processing-bodies in metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma

Poster presentation

Presenter: Noémie Gellée

1133

Comparative analysis of NAD⁺ boosters reveals the role of liver-nerve axis in metabolic health

Poster presentation

Presenter: Yasmine Liu

1152

Training non-experts to diagnose steatohepatitis on biopsy slides
Poster presentation
Presenter: Jennifer Cathcart

1161
Metabolomic profiling reveals early biomarkers of gestational diabetes mellitus with MASLD as a mediator
Poster presentation
Presenter: Won Kim

1180
Induction of liver injury in metabolic dysfunction-associated steatotic liver disease by microbial metabolite 3-4-Hydroxyphenyllactate through hepatic cellular senescence
Oral presentation
Presenter: Mijra Koning

1204
Liver sinusoidal endothelial cells affect lipid metabolism in hepatocytes and form lipid droplets under steatotic conditions
Poster presentation
Presenter: Ting Chen

1222
Preclinical studies of a novel hydrolysis-based prodrug for treating metabolic dysfunction associated steatohepatitis
Poster presentation
Presenter: Xiaowu Chen

1277
Metabolic molecular subtyping identifies actionable targets in MASLD and hepatocellular carcinoma: an integrative multi-omics and machine learning strategy for precise treatment
Oral presentation
Presenter: Xiqiao Zhou

1321
Genetic variation in GPAM and protection against histologic severity in metabolic dysfunction-associated steatotic liver disease
Poster presentation
Presenter: Aaron Hakim

1430
Transcriptomic analysis reveals alterations in mitochondrial energy metabolism and lipogenesis in GIPR/GLP-1R agonists treated metabolic dysfunction-associated steatohepatitis rodents
Poster presentation
Presenter: Hui Li

1436
Inhibition of the CCR9-CCL25 axis improves the visceral fat environment and ameliorates liver steatosis
Oral presentation
Presenter: Ryosuke Kasuga

1464
Investigating the pharmacological potential of a new investigational drug- AD64 for treating metabolic dysfunction-associated steatohepatitis induced by a hepatopathogenic diet in rats

Poster presentation
Presenter: Shiran Shetty

1494

Multimodal single-nuclei atlas of MASLD progression uncovers a link to type 2 diabetes

Oral presentation

Presenter: Laura Pikkupera

1503

Thrombospondin-2 reflects improved metabolism and attenuated liver fibrogenesis in severely obese patients undergoing an intensive weight-loss therapy

Poster presentation

Presenter: Rambabu Surabattula

1557

BTB and CNC homology 1 aggravates metabolic dysfunction-associated steatohepatitis by activating calreticulin

Poster presentation

Presenter: Zhiping Wan

1565

Increased nuclear localization of small heterodimer partner despite increased serum BA profile in patients with metabolic dysfunction-associated steatohepatitis

Poster presentation

Presenter: Shih-Chieh Chien

1581

Exercise protects against semaglutide-induced muscle loss in obese Ldlr-/-Leiden mice

Poster presentation

Presenter: Anita M. van den Hoek

1585

Effect of high-intensity interval, moderate continuous and voluntary training on body composition, hepatic steatosis and myosteatosis in a preclinical model of metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Camille Lannoy

1601

A dynamic human liver acinus-on-a-chip to model health-to-disease (MASLD-MASH) transitions

Poster presentation

Presenter: Debbie Neill

1636

Beneficial effects of milk-derived extracellular vesicles on liver fibrosis progression by restoring intestinal barrier integrity

Poster presentation

Presenter: Shinya Sato

1638

Sorafenib alleviates portal hypertension associated with metabolic dysfunction-associated liver disease by attenuating hepatic sinusoidal capillarization

Poster presentation

Presenter: Yingjie Ai

1675

Harnessing mouse genetic diversity to identify novel genetic determinants of MASLD to MASH transition

Poster presentation

Presenter: Giorgia Benegiamo

1702

Single-cell transcriptomics reveals THR- β agonist treatment increases macrophage proportion and inhibits complement pathway in mice with metabolic dysfunction-associated steatohepatitis

Poster presentation

Presenter: Feng Xue

1725

Differential fatty acid metabolism in the liver and adipose tissue in metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Saana Palomurto

1757

Impact of ageing on metabolic dysfunction-associated steatotic liver disease in a murine model: insights into progression, biomarkers, and therapeutic stratification

Poster presentation

Presenter: Lucia Lameroli Mauriz

1759

Lipidomics crosstalk with hepatic stellate cells and macrophages in people with metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Dan Wang

1780

Pathophysiological mechanisms involved in liver steatosis in metabolic dysfunction-associated steatohepatitis over time : a bulk RNAseq data analysis

Poster presentation

Presenter: Guillaume HENIN

1782

The role of extracellular ATP (ATPe) in the progression of metabolic dysfunction – associated steatotic liver disease (MASLD)

Poster presentation

Presenter: Vanessa García-Fernández

1795

HK3, a novel oral anti-obesity MASH drug with direct reduction of liver fibrosis

Poster presentation

Presenter: Juergen Eckel

1881

Sex-based differences in immune response and liver damage in MASLD-associated sepsis: role of neutrophil extracellular traps

Poster presentation

Presenter: Flavia Savino

1901

Caffeine ameliorates metabolic-associated steatohepatitis by rescuing hepatic Dusp9

Poster presentation

Presenter: Xin Xin

1903

Myostatin regulates the muscle-liver axis by inducing hepatocyte senescence via SLC7A11 ubiquitination in metabolic dysfunction-associated steatohepatitis

Poster presentation

Presenter: Jie Li

1999

HSD17B13 loss-of-function protects against steatosis-induced hepatic phosphatidylcholine depletion by promoting polyunsaturated fatty acid retention in humans in vivo and in experimental models

Oral presentation

Presenter: Sami F. Qadri

2001

ALG-055009, a potent and selective thyroid hormone receptor beta agonist for the treatment of metabolic dysfunction-associated steatohepatitis, induces pro-metabolic and anti-fibrotic gene expression in the liver of diet-induced obese mice

Poster presentation

Presenter: Xuan Luong

2010

NMR-based metabolic signature reveals the vicious circle between fasting and feeding in homozygous carriers of the PNPLA3 I148M variant in MASLD

Poster presentation

Presenter: Lina Jegodzinski

2058

NEDD4 regulates TGF-beta/SMAD signaling pathway through ubiquitinated decorin to ameliorate metabolic dysfunction-associated steatohepatitis

Poster presentation

Presenter: Jie Li

2122

Characterizing the response to high-dose gene therapy in non-human primates with a healthy or fibrotic liver at single nucleus resolution

Poster presentation

Presenter: Joanne Hsieh

2168

Qushi Huayu formula and some of its compounds directly promote the growth of Roseburia intestinalis to alleviate metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Yu Zhao

2176

The protective effect of dapagliflozin against kidney injuries by tubular mitochondrial preservation in metabolic dysfunction-associated steatohepatitis

Poster presentation

Presenter: Jee-Fu Huang

2182

Genipin 1-β-D-gentiobioside alleviates MASH by inhibiting hepatocyte PP2A enzymatic activity

Poster presentation

Presenter: Xin Xin

2186

Differential activation and clonal expansion of T cells by PNPLA3 I148 M genetic variant is associated with the progression of metabolic dysfunction-associated steatotic liver disease

Poster presentation
Presenter: Jaejun Lee

2228

High-throughput in vivo pooled screening can identify therapies applicable across the spectrum of metabolic dysfunction-associated steatohepatitis disease severity

Poster presentation
Presenter: Joanne Hsieh

2282

Anti-inflammatory effects of a chemokine receptor mimicking peptide in obesity-associated MASH and atherosclerosis in Ldlr^{-/-} Leiden mice

Poster presentation
Presenter: Eveline Gart

2290

Hepatic estrogen receptor alpha drives liver metabolic adaptation during pregnancy

Poster presentation
Presenter: Sara Della Torre

2327

The HSD17B13 rs72613567:A variant is associated with reduced hepatic glycolipid content in non-obese individuals

Poster presentation
Presenter: Nils Haep

2355

A 5-week treatment with the GLP-1/GIP/glucagon triple receptor agonist retatrutide demonstrates multiple metabolic benefits and strong reduction in liver steatosis in a diet-induced obese MASH mouse model

Poster presentation
Presenter: Francois Briand

2361

ETX-312, a GalOmic siRNA for the treatment of MASH, effectively improves the MASH phenotype of GAN DIO-MASH mice alone or in combination with emerging therapies

Poster presentation
Presenter: Alan Whitmore

2389

A novel GLP-1/GDF15 dual-agonist reduces hepatic inflammation and fibrosis in murine models of chemical-induced liver fibrosis and metabolic associated steatohepatitis (MASH)

Poster presentation
Presenter: Yuanping Shi

2409

The Nlrp3 inflammasome affects Kupffer cell phenotype, proliferation and triglyceride accumulation in the liver

Poster presentation
Presenter: Lukas Geisler

2412

CD8⁺ T cells are pro-inflammatory, cytotoxic, and clonally expanded in the early stages of fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH)

Poster presentation
Presenter: Raju Kumar

2424

Deep learning analysis reveals the impact of steatosis size and density on the progression of non-alcohol-related liver disease in severe obesity

Poster presentation

Presenter: Vicente Cambra-Cortes

2439

Oncostatin M contributes to liver steatosis in experimental metabolic dysfunction - associated steatotic liver disease

Poster presentation

Presenter: Jessica Nurcis

2455

Identifying health-to-disease transitional biomarkers in 3D human organotypic models of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH)

Poster presentation

Presenter: Anabel Martinez Lyons

2472

A quantitative systems pharmacology model identifies mechanisms attenuated by knockdown of HSD17B13 expression and associated with a reduction in hepatocellular ballooning

Poster presentation

Presenter: Mario Giorgi

2495

Hepatoprotective effects of efruxifermin treatment in GAN diet-induced obese and biopsy-confirmed mouse model of MASH

Poster presentation

Presenter: Henrik B. Hansen

2504

Hepatoprotective effects of fatty acid synthase inhibitor TVB-3664 in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH

Poster presentation

Presenter: Michael Feigh

2514

Comparative anti-fibrotic action of resmetirom, semaglutide, tirzepatide and efruxifermin in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH

Poster presentation

Presenter: Jacob Nøhr-Meldgaard

2520

Adding the serotonergic agonist psilocybin to semaglutide as a novel combination therapy to cure MASLD

Poster presentation

Presenter: Martina Colognesi

2528

Reproducible hepatoprotective effects and clinical translatability of long-term semaglutide treatment in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH

Poster presentation

Presenter: Michael Feigh

2566

Generation of patient-derived liver organoids from needle biopsies for precision disease modeling of metabolic-associated steatotic liver disease

Poster presentation

Presenter: Raquel Ferrer-Lorente

2585

Role of TOX3 in regulating the progression of metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Shaoping She

2612

Shallow-deep neural networks reveal extracellular vesicles as robust biomarkers for liver steatosis stages S0 vs. S1-S3 in metabolic dysfunction-associated steatotic liver disease patients

Poster presentation

Presenter: Eleni-Myrto Trifylli

2668

DR10624, a novel FGF21R, GCGR, and GLP-1R tri-agonist, demonstrated extraordinary efficacy in B6-Alms1-del mice, a spontaneous MASH model of mice with obesity, hyperglycemia, and dyslipidemia phenotype

Poster presentation

Presenter: Yongliang Fang

2669

Impaired hepatocyte autophagy and bile dysregulation as a novel histological and genetic signature in metabolic dysfunction-associated steatotic liver disease patients with early fibrosis

Poster presentation

Presenter: Lorenzo Nevi

2721

Preclinical characterization of BJT-188, a liver-targeted fatty acid synthase inhibitor for the treatment of MASH

Poster presentation

Presenter: Jerome Deval

2749

Therapeutic potential of a GHRH analog in experimental MASLD

Poster presentation

Presenter: Antonio Gil-Gómez

2759

Patatin-like phosphatase domain-containing 3 (PNPLA3) genotype and dietary fat modify the liver adiposity

Poster presentation

Presenter: Milla-Maria Tauriainen

2775

Serum lipidome heterogeneity in MASH patients identifies DNA damage as predominant hit in one subtype

Poster presentation

Presenter: Idoia Fernández-Puertas

2803

Adaptative immune activation as a biomarker of Metabolic dysfunction- associated steatotic liver disease severity

Poster presentation

Presenter: Adriana Martínez-Cuazitl

2829

Quantitative digital pathology and AI to characterize histological phenotypes of regression in a robust mouse model of human MASH

Poster presentation

Presenter: Li Chen

2834

Somatic mutation in early stage metabolic-dysfunction associated steatotic liver disease (MASLD)

Poster presentation

Presenter: Georgeina L Jarman

2927

Genetic predisposition for hepatic fat accumulation impacts the uptake of fatty acids through fatty acid translocase in a human stem cell-based in vitro model

Poster presentation

Presenter: Alexandra Gatzios

2937

Lysine-specific demethylase 1 modulates hepatic lipid metabolism in metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Hardik Makwana

2941

Brain dysfunction is ameliorated by alpha 2A adrenergic receptor antagonism in experimental metabolic dysfunction-associated steatotic liver disease through vasodilatory and anti-inflammatory effects

Poster presentation

Presenter: Anne Catrine Daugaard Mikkelsen

2958

MASLD-associated changes across the gut-liver-brain axis are not ameliorated by a low-fat diet intervention in an aged mouse model

Poster presentation

Presenter: Matthew Siddle

2992

Histological phenotypes of regression in advanced liver fibrosis using quantitative digital pathology in a rodent model of cirrhotic human NASH with HCC

Poster presentation

Presenter: Li Chen

3013

Plasma proteomics identifies pathways to target in metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Niharika Jakhar

MASLD: Therapy

Multidisciplinary management combining hepatologist counseling, cognitive/behavioral therapy, and nutritional support (the "CoCoNut" protocol) significantly improves metabolic and clinical outcomes of MASLD patients

Poster presentation

Presenter: Mario Romeo

178

MASH resolution index, a novel, highly sensitive non-invasive measure of histologic improvement, predicts high rates of MASH resolution with pemvidutide treatment of metabolic dysfunction-associated steatohepatitis (MASH)

Poster presentation

Presenter: Shaheen Tomah

184

Effect of hepatic impairment on the pharmacokinetics of Miricorilant: results from a phase 1, open-label, adaptive-design study

Poster presentation

Presenter: Joseph M. Custodio

302

ALG-055009, a novel thyroid hormone receptor beta agonist, demonstrated significant reductions in atherogenic lipids/lipoproteins, including lipoprotein (a), in patients with presumed metabolic dysfunction-associated steatohepatitis in the Phase 2a HERALD

Poster presentation

Presenter: Rohit Loomba

305

A 10-week, randomized, double blind, placebo-controlled exploratory proof of concept study of Ureglutide (GL0034) in individuals with overweight and obesity

Poster presentation

Presenter: Rajamannar Thennati

582

Denifanstat improves multiple qFibrosis-based collagen features linked to major adverse liver outcomes in patients with metabolic dysfunction-associated steatohepatitis patients and high polygenic risk

Poster presentation

Presenter: Mary E. Rinella

665

GLP1 agonist and metabolic dysfunction-associated steatohepatitis (MASH): systematic review and meta-analysis

Poster presentation

Presenter: Ryan YanZhe Lim

763

Effects of Berberine Ursodeoxcholate (HTD1801) in patients with at-risk MASH and T2DM

Poster presentation

Presenter: Nadege Gunn

765

Effects of Berberine Ursodeoxcholate (HTD1801) in chinese patients with T2DM and presumed MASLD

Poster presentation

Presenter: Jianhua Ma

786

The impact of SGLT-2i and GLP-1RA on liver-related events in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and network meta-analysis

Poster presentation

Presenter: Lu Li

805

First-in-human single and multiple ascending dose study of AZD2389, a potent inhibitor of fibroblast activation protein, in healthy participants to evaluate safety, tolerability, pharmacokinetics and target engagement

Poster presentation

Presenter: Vian Azzu

819

Indication of resmetirom in patients with metabolic dysfunction associated steatohepatitis in the real-world setting - data from the german SLD-registry

Poster presentation

Presenter: Eva Messer

947

Therapeutic Effects of GLP-1 agonist versus SGLT2-i on patients with T2D and MASLD

Poster presentation

Presenter: Ermina Stratina

972

The synergistic effects of 4 weeks of resistance exercise and whey protein supplementation on liver health in individuals with metabolic dysfunction-associated liver disease

Poster presentation

Presenter: Hong Soo Kim

1010

Efficacy of lower carbohydrate diets for reducing liver fat and improving metabolic dysfunction: a systematic review and meta-analysis

Poster presentation

Presenter: Aslihan Ozdemir

1064

Assessing early changes and responses to resmetirom therapy using real world single center data

Poster presentation

Presenter: Allysa Saggese

1221

General characteristics of the patients prescribed Resmetirom: data derived from six tertiary care centers in the United States

Poster presentation

Presenter: Naim Alkhouri

1271

The impact of metabolic surgery on metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Hiromasa Namba

1344

Natural explant with dihydromircetin in metabolic associated steatotic liver disease (MASLD): a double-blind, placebo controlled, randomized clinical trial

Poster presentation

Presenter: George Papatheodoridis

1384

Can non-diabetic patients with metabolic dysfunction associated steatotic liver disease benefit from glucagon-like peptide-1 analogs? A multicenter cohort study

Poster presentation

Presenter: Ritu Singh

1388

Are glucagon-like peptide-1 analogs better answer for obese patients with metabolic dysfunction associated steatotic liver disease than bariatric surgery? Real-world evidence

Poster presentation

Presenter: Ritu Singh

1421

Effectiveness of a smartphone app in promoting weight loss in patients with metabolic dysfunction-associated steatotic liver disease: a pilot randomized controlled trial

Poster presentation

Presenter: Lung Yi Loey Mak

1431

Survodutide, a glucagon/GLP-1 receptor dual agonist, in people with MASH with moderate-to-advanced liver fibrosis (stage F2-F3): rationale and design of an event-driven, multinational, randomised, placebo-controlled, phase 3 trial (LIVERAGETM)

Poster presentation

Presenter: Jörn M. Schattenberg

1465

Comprehensive intensive lifestyle intervention to reverse significant liver fibrosis in overweight and obese patients with metabolic dysfunction-associated steatotic liver disease: data from a multicenter randomized controlled trial

Poster presentation

Presenter: Xiaolong Qi

1619

Sustained improvements in non-invasive biomarkers with the novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide: longitudinal analysis from a phase 2 trial in people with metabolic dysfunction-associated steatohepatitis and fi

Poster presentation

Presenter: Mazen Nouredin

1650

Direct effects of survodutide on liver endpoints beyond weight loss: insights from a phase 2 trial of the glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide in people with metabolic dysfunction-associated steatohepatitis and fibro

Oral presentation

Presenter: Mazen Nouredin

1665

Evaluating the efficacy of a carnitine orotate and biphenyl dimethyl dicarboxylate complex in the pathogenetic treatment of metabolic-associated fatty liver disease: midterm data

Poster presentation

Presenter: Aliya Kaisina

1678

Efficacy of Imeglimin in MASLD with type 2 diabetes: a multicenter study

Poster presentation

Presenter: Asahiro Morishita

1695

A comparative analysis of metabolic dysfunction-associated steatotic liver disease and Mediterranean diet across different races

Poster presentation

Presenter: Meng-Lun Hsieh

1751

The early impact of bariatric surgery on liver fibrosis and steatosis in MASLD patients

Poster presentation

Presenter: Valentina Cossiga

2017

qFibrosis enables earlier detection of fibrosis response in Efruxifermin-treated patients with F2-F3 MASH in 96-week HARMONY study

Poster presentation

Presenter: Jörn M. Schattenberg

2048

Baseline characteristics in well-compensated NASH cirrhosis patients diagnosed with or without a liver biopsy in MAESTRO-NASH-OUTCOMES, a clinical outcome phase 3 study assessing the effect of resmetirom in well compensated NASH cirrhosis

Poster presentation

Presenter: Jörn M. Schattenberg

2102

Alignment of response assessed by non-invasive fibrosis biomarkers and HistoIndex AI-based qFibrosis histology in metabolic dysfunction associated steatohepatitis (MASH) clinical trials: a new roadmap for robust drug efficacy assessment demonstrated in th

Oral presentation

Presenter: Quentin M. Anstee

2146

Role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in mortality reduction among patients with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis: a global retrospective analysis

Poster presentation

Presenter: Varun Aitharaju

2152

Population pharmacokinetic/pharmacodynamic modelling of novel thyroid hormone receptor beta agonist ALG-055009 reveals statistically significant correlation between exposure and key efficacy endpoints

Poster presentation

Presenter: Kha Le

2185

ALG-055009, a novel thyroid hormone receptor beta (THR-beta) agonist, demonstrated robust reductions in liver fat at Week 12 across subgroups including glucagon-like peptide-1 (GLP-1) receptor agonist users in non-cirrhotic MASH patients in the Phase 2a H

Poster presentation

Presenter: Rohit Loomba

2303

The reversal of MASH cirrhosis. Pooled analysis from RCTs

Poster presentation

Presenter: Henrik Hee Seung Yang

2434

Saroglitazar vs. vitamin E in metabolic-dysfunction associated fatty liver disease related compensated chronic liver disease- a cohort study

Poster presentation

Presenter: Rakhi Maiwall

2499

Statin, but not aspirin use, is inversely associated with steatotic liver disease and liver fibrosis: results from two large population based studies

Poster presentation

Presenter: Jesse Pustjens

2538

Sex disparities in response to low-carb, high-fat diet in MASLD

Poster presentation

Presenter: Ellen Elise Petersen

2560

A postbiotics and metabiotics reduces the hepatic steatosis indices and aminotransferase activity in MASLD patients: a randomized clinical trial (DELI_MASLD study)

Poster presentation

Presenter: Yeva Ilkiv

2565

Efimosfermin alfa once monthly treatment improves collagen biomarker profiles and rapidly induces histological fibrosis regression in subjects with MASH stage F2-F3 fibrosis in a 24-week phase 2 trial

Oral presentation

Presenter: Rohit Loomba

2609

Effectiveness of bariatric surgery versus glucagon-like peptide-1 receptor agonists for prevention of adverse cardiovascular outcomes among patients with metabolic dysfunction-associated steatotic liver disease, diabetes, and obesity

Poster presentation

Presenter: Arunkumar Krishnan

2634

Cardiovascular disease risk, liver outcomes, and statin use among adults with metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Arunkumar Krishnan

2643

A single centre, comparative study of Saroglitazar combined with vitamin E versus Saroglitazar alone in managing steatotic liver disease and/or metabolic dysfunction among liver transplant recipients

Poster presentation

Presenter: Swapnil Dhampalwar

2656

Current evidence on dietary interventions in people with metabolic-dysfunction associated fatty liver disease and MetALD – a systematic review and meta-analysis of randomized controlled trials

Poster presentation

Presenter: Ute Stern

2681

Efficacy of pharmacotherapy in improvement of liver fibrosis and steatohepatitis in patients with metabolic dysfunction associated steatotic liver disease (MASLD): a network meta-analysis

Poster presentation

Presenter: Shubham Mehta

2738

Survodutide activates cAMP signaling and reduces steatosis and fibrosis through its glucagon component in human liver spheroids

Poster presentation

Presenter: Philip Vonschallen

2740

Lifestyle intervention with a mediterranean diet and structured exercise promotes improved liver steatosis, steatohepatitis, and fibrosis, and allows for patient stratification. EHmet+DIA study

Poster presentation

Presenter: Carmen Lara-Romero

Non-invasive assesment of liver disease except MASLD

538

Decoding the dynamics: minimal detectable difference in non-invasive tests may exceed proposed thresholds for meaningful changes

Poster presentation

Presenter: Georg Semmler

551

Evaluation of a non-invasive pathway for advanced fibrosis detection and liver-related outcomes prognosis in the general population from China, United Kingdom, and United States

Poster presentation

Presenter: Xiaolong Qi

584

Prediction of esophageal varices in fontan associated liver disease (FALD)

Poster presentation

Presenter: Victoria Kuszto

867

Repeated transient elastography measurements for the assessment of liver fibrosis

Poster presentation

Presenter: Helena Katchman

872

Role of liver and spleen stiffness in predicting hepatic decompensation following transarterial chemoembolization in patients with hepatocellular carcinoma

Poster presentation

Presenter: Kessarini Thanapirom

905

FIB-4 for identifying chronic liver disease patients requiring HCC surveillance

Poster presentation

Presenter: Jan Embacher

1207

Liver stiffness measurement by acoustic radiation force impulse predicts further decompensation and death after index decompensation: The LSM-ART study

Poster presentation

Presenter: Akash Roy

1369

Evaluation of novel point-of-care ultrasound for hepatitis "PUSH" for healthcare workers managing hepatitis B infection in Zambia

Poster presentation

Presenter: Costanza Bertoni

1714

Bile acids drive fibroblast activation, fibrogenesis, interstitial matrix fibrosis and outcomes in PSC

Poster presentation

Presenter: Morten Karsdal

1830

Comparing ultrasound and magnetic resonance imaging for hepatocellular carcinoma screening in high-risk populations: a systematic review and meta-analysis of prospective cohorts

Poster presentation

Presenter: Pedro Passos

1992

Validation of Baveno VII criteria for non-invasive diagnosis of clinically significant portal hypertension: systematic review and individual patient data meta-analysis

Poster presentation

Presenter: Juan Bañares

2359

Validation of small transient elastography device for liver fibrosis and steatosis detection in a population-based study

Poster presentation

Presenter: Anna Soria

2416

Phase angle by BIA is useful for screening for malnutrition in patients with cirrhosis

Poster presentation

Presenter: Masafumi Haraguchi

2505

Clinical decision tree for non-invasive diagnosis of graft steatosis in liver transplant patients

Poster presentation

Presenter: Dominik Lüttgen

2519

Prognostication of liver disease patients via ARFI-based liver stiffness measurement using the WFUMB "Rule-of-4" algorithm

Poster presentation

Presenter: Christian Sebesta

2595

Weight dependent, weight independent and non-pharmacological effects on fibroblast activity in metabolic dysfunction associated steatotic liver disease (MASLD)

Poster presentation

Presenter: Morten Karsdal

2854

Prognostic utility of serum ammonia in cirrhosis: a systematic review and meta-analysis

Poster presentation

Presenter: Yevedzo Ntuli

2868

Patient-reported experience measures of EUS-guided and percutaneous liver biopsy. A prospective observational study

Poster presentation

Presenter: Dina Khalil

2922

Multi-omic machine learning for risk prediction of cholangiocarcinoma in population-based cohorts

Poster presentation

Presenter: Felix Van Haag

Nurses and Allied Health Professional

109

iCARE: Insights on competency advancement and recommendations for nurses managing HBV/HDV with bulevirtide – findings from a european advisory board

Poster presentation

Presenter: Patrizia Künzler-Heule

228

The challenge of adherence in Wilson disease: a prospective study

Poster presentation

Presenter: Anna Miralpeix

409

Nurse-led clinic for patients with decompensated liver cirrhosis

Poster presentation

Presenter: Palle Bager

410

Patient-perceived quality of care – effectiveness of the quality liver nursing care model

Poster presentation

Presenter: Maria Hjorth

627

A palliative care approach for cirrhosis patient: feasibility and preliminary results from a prospective Danish multi-center study

Oral presentation

Presenter: Birgitte Jacobsen

648

Evaluation of the utility of the Nora-hepatitis B mobile application: a comparative study between chronic infection and HBeAg-negative chronic hepatitis

Poster presentation

Presenter: Judit Romero-Vico

657

Impact of hepatitis delta infection on quality of life: results from the Nora-hepatitis B study

Poster presentation

Presenter: Judit Romero-Vico

711

Health-related quality of life, events of decompensation and mortality – effectiveness of the quality liver nursing care model

Poster presentation

Presenter: Maria Hjorth

789

Health-related quality of life in patients with chronic hepatitis D receiving bulevirtide and pegylated interferon: interim results from the SEE-D clinical trial

Poster presentation

Presenter: Annika Olsson

919

Allied health professionals are essential for facilitating initial evaluation and optimisation of patients for liver transplantation

Poster presentation

Presenter: Abigail Greenwell

942

Long-term real-world outcomes of obeticholic acid treatment for primary biliary cholangitis: insights from a pharmacy-led single-centre study

Poster presentation

Presenter: Kate Greener

1001

Negative consequences of screening for steatotic liver disease

Poster presentation

Presenter: Helle Lindholm Schnefeld

1004

Identifying training needs to improve detection and management of metabolic dysfunction-associated steatotic liver disease in primary care settings: a qualitative interview study with healthcare professionals

Oral presentation

Presenter: Hollie Smith

1070

Demonstration of the success of a nurse led service surveying for hepatocellular carcinoma and other cirrhosis associated complications

Poster presentation

Presenter: Amy Thatcher

1197

Improving the outcomes of patients with cirrhosis in a community clinic through the utilization of advanced practice providers and standardized tailored management protocol

Poster presentation

Presenter: Tarek Hassanein

1382

Impact of consensus guidelines on hepatitis B reactivation risk assessment and management in immunosuppressive therapy

Poster presentation

Presenter: Naz Kanani Alviri

1418

Internal consistency and diagnostic validity of SARC-F questionnaire in chronic liver disease patients with sarcopenia on liver transplant wait list

Poster presentation

Presenter: Ganesh Sankarrajan

1613

Development and implementation of an innovative allied health professional (AHP)-led group education programme for patients with metabolic dysfunction-associated steatotic liver disease (MASLD)

Oral presentation

Presenter: Kate Hallsworth

1646

Community liver health checks are a valuable tool to support early diagnosis of liver disease

Poster presentation

Presenter: Bethia Featherstone

1809

Should all patients referred for liver transplantation undergo a review in a dedicated multidisciplinary assessment clinic prior to formal liver transplant work up?

Poster presentation

Presenter: Katie McCollum

2163

A quality improvement project: multidisciplinary nutrition approach to improve the nutritional and functional status of pre-liver transplant patients

Oral presentation

Presenter: Valerie Goh

2695

Prescribing for pain and symptom management in hospital patients with advanced liver disease: a single centre, retrospective clinical audit

Poster presentation

Presenter: Sarah Phillips

2832

Improving clinical efficiency of Hepatology clinics by optimising patient adherence with blood test monitoring

Poster presentation

Presenter: Jennifer Finn

2839

Multi-disciplinary team initiation of GLP-1/GIP agonist Tirzepatide in patients with metabolic-dysfunction associated steatotic liver disease (MASLD): single-centre UK study

Poster presentation

Presenter: Rachel Halley

2851

Non-weight-based ribavirin dosing for hepatitis E in immunosuppressed patients: a single-centre experience

Poster presentation

Presenter: Fatema Jessa

3068

Malnutrition, sarcopenia and inadequate dietary intake before liver transplant: a time for action

Poster presentation

Presenter: Brooke Chapman

Public Health: Except Viral Hepatitis

49

Impact of COVID-19 pandemic on racial/ethnic disparities in liver transplant waitlist outcomes among U.S. adults with end-stage liver disease

Poster presentation

Presenter: Shyam Patel

67

The placebo project - comprehensive analysis of 134 commonly prescribed homeopathic remedies in India uncovers potential for severe hepatotoxicity

Poster presentation

Presenter: Arif Theruvath

68

Bridging the gap between primary care physicians and hepatology with electronic consultations

Poster presentation

Presenter: Aviel Hankin

80

The "Traffic Light System" – a radiology-led pathway for hepatocellular carcinoma surveillance in patients with liver cirrhosis

Poster presentation

Presenter: Lusyan Dayalan

159

Unveiling the burden of cirrhosis among Ontario, Canada's refugee population

Poster presentation

Presenter: Saloni Aggarwal

239

Angiotensin receptor blockers and drug-induced liver injury: a cohort study using electronic-health records-based common data model database

Poster presentation

Presenter: Jun Kyu Lee

355

The largest, exhaustive in-depth analysis and concerning report on 386 complementary and alternative medicinal products belonging to the Indian-systems of medicine (AYUSH) retrieved from patients that caused liver-related harm at the consumer level

Poster presentation

Presenter: Cyriac Philips

415

Impact of an abnormal liver function test pathway with reflex fibrosis screening on national incidence rates of liver disease diagnoses

Poster presentation

Presenter: Tom Pembroke

575

Smoking and risk of steatotic liver disease: a meta-analysis of cohort studies

Poster presentation

Presenter: Hyun Phil Shin

667

Hospital-based and individual disparities in liver transplantation access in France: a national health data system analysis

Poster presentation

Presenter: José Ursic Bedoya

811

Assessing awareness of fatty liver disease among people in Scotland: a cross-sectional survey study (ADIPOSE)

Poster presentation

Presenter: Damien Leith

840

Cirrhosis death rates are increasing rapidly among young Americans – analysis of national death certificate data

Oral presentation

Presenter: Andrew Moon

886

Metabolic dysfunction-associated steatohepatitis (MASH) prevalence in Germany – results from a claims analysis

Poster presentation

Presenter: Yestle Kim

933

Advanced care planning (ACP) for liver cirrhosis patients in Singapore: barriers to ACP and influence of hepatocellular carcinoma diagnosis on ACP preferences

Poster presentation

Presenter: Danelle Lai

1013

Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) in four cities in the United States, including among people with diabetes and primary care providers

Poster presentation

Presenter: Jeffrey Lazarus

1020

Risk factor awareness for liver disease in four United States cities

Poster presentation

Presenter: Jeffrey Lazarus

1057

What is known about the relationship between food insecurity and metabolic dysfunction-associated steatotic liver disease? A systematic review

Poster presentation

Presenter: Patricia Treseder-Griffin

1069

Gaps in palliative care for liver cirrhosis in Singapore: an analysis on disease burden, timing and utilization of palliative services

Poster presentation

Presenter: Charlene Yeo Li Xin

1087

In patients with metabolic dysfunction-associated steatotic liver disease, sleep disturbance is highly prevalent and associated with a profound impairment of health-related quality of life
Poster presentation
Presenter: Zobair Younossi

1091
Impact of weekend warrior physical activity on all-cause mortality in metabolic dysfunction-associated steatotic liver disease
Oral presentation
Presenter: Zobair Younossi

1106
Changing prevalence and risk factors of metabolic dysfunction associated steatotic liver disease in Taiwan
Poster presentation
Presenter: Ming-Lun Yeh

1206
Ultra-processed foods significantly increase liver and metabolic injury among younger adults, lessons from the liver screening program SIRIUS
Poster presentation
Presenter: Tomas Koller

1389
First nations australians with cirrhosis have higher and premature mortality and multiple cofactors
Poster presentation
Presenter: Catherine Brown (First Nation Australian)

1394
One-stop shop: a bespoke single-point-of-referral clinic enhances linkage to care for ultrasound surveillance of hepatoma in patients diagnosed with advanced fibrosis and cirrhosis via targeted community screening
Poster presentation
Presenter: Basil Ahmad

1398
Age-related trends in FIB-4 scores among MASLD risk groups: insights from primary care data
Poster presentation
Presenter: Hiroko Setoyama

1501
MASLD impacts quality of life and work productivity
Poster presentation
Presenter: Leen Heyens

1541
Real-world experience using serial transient elastography by FibroScan in a community outreach service for the earlier detection of liver disease
Poster presentation
Presenter: Ann Archer

1572
Examining the causal link between alcohol consumption and fatty liver disease using Mendelian randomization
Poster presentation
Presenter: Yun-Chen Wu

1595

Chronic liver diseases are often diagnosed at an advanced stage despite identification of risk factors: insights from a french national study

Poster presentation

Presenter: Charlotte Costentin

1631

Patient safety, cross-sectoral quality of care, cost efficiency, and interprofessional competence: a comparison of the interprofessional training wards A-STAR with conventional hepatology-focused wards at Regensburg university hospital

Poster presentation

Presenter: Schlosser Sophie

1674

Circulating metabolites, gallstones, and gallbladder cancer

Poster presentation

Presenter: Felix Boekstegers

1882

Performance of chronic liver disease questionnaire – metabolic dysfunction-associated steatohepatitis (CLDQ-MASH) against non-invasive tests

Poster presentation

Presenter: Zobair Younossi

1895

Prevalence of steatotic liver disease and steatohepatitis in a population of healthy workers

Poster presentation

Presenter: Pietro Guerra

1954

The global prevalence and mortality of metabolic dysfunction associated steatotic liver disease-related cirrhosis

Poster presentation

Presenter: Zobair Younossi

1969

Prevalence of the spectrum of steatotic liver disease and associated fibrosis and cirrhosis among adults in the United States

Poster presentation

Presenter: Zobair Younossi

2028

Metabolic dysfunction-associated steatohepatitis as a risk factor for hepatocellular carcinoma mortality

Poster presentation

Presenter: Yestle Kim

2078

Population study of hepatocellular carcinoma survival in northeast region of Spain

Poster presentation

Presenter: Isabel Serra

2099

Readily available indices of liver fibrosis and insulin resistance associated with cancer and cardiovascular disease outcomes

Poster presentation

Presenter: Xuehong Zhang

2111

Shortfalls and obstacles in sexual function assessment by healthcare providers in patients with liver disease and liver transplantation

Poster presentation

Presenter: Yooyun Chung

2119

Leave no one behind: an examination of how the hepatitis C elimination programme in England is reducing healthcare inequalities

Poster presentation

Presenter: Beatrice Emmanouil

2120

Living with liver disease: patient and carer experiences in the United Kingdom

Poster presentation

Presenter: Vanessa Hebditch

2140

Incidence-based mortality trends of primary liver cancer (hepatocellular carcinoma and intrahepatic cholangiocarcinoma) in Scotland between 2000 and 2021

Poster presentation

Presenter: Berkay Yanik

2314

Vibration-controlled transient elastography dynamics in the general population: longitudinal results from the LiverScreen consortium

Poster presentation

Presenter: Jesse Pustjens

2349

Hospital wide approach to limiting and treating alcohol use disorder

Poster presentation

Presenter: Janis Fernandes

2351

External validation of Dallas steatosis index (DSI) in the diagnosis of steatotic liver disease (SLD) in Thai population

Poster presentation

Presenter: Pimsiri Sripongpun

2364

Association between metabolic syndrome and hepatocellular carcinoma in Mongolia: Prevalence and risk factors across different populations

Poster presentation

Presenter: Munguntsetseg Batkhoo

2370

Long-term air-pollution exposure is associated with metabolic-dysfunction steatotic liver disease and liver fibrosis in the general population

Oral presentation

Presenter: Jesse Pustjens

2402

Prevalence of and outcomes related to metabolic dysfunction-associated steatotic liver disease (MASLD) in a nationwide cohort: insights from over 23 million individuals in Taiwan's national health insurance research database

Poster presentation

Presenter: Huei-Tyng Huang

2432

Trends in mortality due to liver neoplasms in Portugal (2013-2022): a decade of rising challenges

Poster presentation

Presenter: Mario Jorge Silva

2525

An algorithm based on the liver risk score to identify subjects at-risk for advanced liver disease in the general population

Poster presentation

Presenter: Patrick Ingiliz

2583

Health behaviors significantly modify the sex-specific alcohol-attributable liver-related mortality in the United States. A population-based study

Poster presentation

Presenter: Eduardo Vilar Gomez

2715

Reference blood-based biomarkers SteatoTest-2 (ST2) and NashTest-2 (NT2) permit assessment of the prevalence of steatosis and MASH in large general population of UK-Biobank (UKB), stratified by cardiometabolic risk factors (CRF) and alcohol consumption (A

Poster presentation

Presenter: Olivier Deckmyn

2792

Differential liver-related mortality among native hawaiian / pacific islander (NHPI) and asian subpopulations: a national cohort study

Poster presentation

Presenter: Tiange Zhang

2814

Metabolic dysfunction-associated steatotic liver disease as the leading cause of hepatocellular carcinoma in mexican cirrhotic patients: a perspective consistent with trends observed in europe

Poster presentation

Presenter: Nahum Méndez-Sánchez

2824

Economic evaluation of biomarker-base surveillance for hepatocellular carcinoma in thai patients with compensated liver cirrhosis

Poster presentation

Presenter: Pisit Tangkijvanich

2878

Global association between metabolic dysfunction policies and the burden of metabolic dysfunction-associated steatotic liver disease (MASLD)

Poster presentation

Presenter: Luis Antonio Diaz

2932

Gender biasing and disparities in living donor liver transplant setup from a tertiary care liver transplant centre
Poster presentation
Presenter: Arvind Tomar

2987
Prevalence of MASLD and its association with the consumption of sugar sweetened beverages among a non-communicable disease cohort in the rural district of Iringa, Tanzania
Poster presentation
Presenter: Valentin Calvez

Public Health: Viral Hepatitis

28
Delta in Denmark: prevalence of hepatitis delta virus infection
Poster presentation
Presenter: Hugh Watson

257
Emergency department opt out testing for HBV and HCV in London with integrated linkage to care: an effective initiative to diagnose hepatitis or work in progress?
Poster presentation
Presenter: Rachel Hill-Tout

350
Implementation of a multicenter reflex testing program for hepatitis D detection of and registration of positive cases in Catalonia
Poster presentation
Presenter: Adriana Palom

388
Changes in hepatitis C virus screening and treatment rates in pregnant individuals before and after implementation of universal screening guidelines compared to hepatitis B virus screening during the same time frame
Poster presentation
Presenter: Chandler Shapiro

416
A comparative study on liver disease severity and comorbidity profile in patients with chronic hepatitis B virus infection and hepatitis B virus/hepatitis D virus co-infection: a Korean nationwide study
Poster presentation
Presenter: Heejoon Jang

460
Risk of advanced liver disease among individuals with hepatitis B virus infection with low-level viremia compared to individuals with no evidence of hepatitis B virus infection
Poster presentation
Presenter: Laura Telep

489
From screening to treatment: the impact of opportunistic hepatitis screening in emergency departments on hepatitis C prevalence
Poster presentation
Presenter: Juan Carlos Ruiz-Cobo

500

Treatment persistence, discontinuation, and health care cost among chronic hepatitis B (CHB) patients initiating antiviral treatment

Poster presentation

Presenter: Dilip Makhija

607

Community-based screening of viral hepatitis infections among high risk migrant and refugee populations in Greece, Italy and Spain: 2-year results of the VH-COMSAVAC project

Poster presentation

Presenter: Camila Picchio

633

Survival and inactivation of hepatitis A virus on inanimate surfaces

Poster presentation

Presenter: Lilli Pottkämper

640

Patient-reported outcomes measuring an individual's overall self-rated health after long-term treatment with bulevirtide 2 mg for chronic hepatitis delta in the phase 3 MYR301 trial

Poster presentation

Presenter: Chong Kim

647

Knowledge of hepatitis D epidemiology and access to hepatitis D diagnostic testing among healthcare providers in Africa: a multi-country survey

Poster presentation

Presenter: Maria Buti

670

Therapy of HCV infections among patients of ukrainian origin during the influx of war refugees to Poland

Poster presentation

Presenter: Robert Flisiak

751

Disparities in hepatocellular carcinoma screening and in its detection rates in individuals with hepatitis B or C and cirrhosis in Canada

Poster presentation

Presenter: Jean Damascene Makuza

768

A large multicentre hepatitis B cohort study in the United Kingdom highlights high rates of comorbidity associated with liver disease outcomes

Oral presentation

Presenter: Tingyan Wang

841

Identifying people who are HBV positive but undiagnosed : a model-based approach informed by health administrative data

Poster presentation

Presenter: William WL Wong

880

Knowledge and perception of chronic hepatitis B infection and attitude towards point-of-care testing among the general population in primary care settings in Hong Kong

Poster presentation
Presenter: Marco Tsun Lee

1178
National hepatitis C virus (HCV) screening pilot using rapid HCV antibody tests in Kazakhstan
Poster presentation
Presenter: Kulpash Kaliaskarova

1184
The impact of COVID-19 outbreak from February to June 2022 on chronic hepatitis B patient management in Shanghai: a cross-sectional study
Poster presentation
Presenter: Simin Guo

1246
The impact of peers on sustaining hepatitis C elimination in people who inject drugs - a network based model
Poster presentation
Presenter: Ryan M Buchanan

1303
Setting the record straight: utility and outcomes in patients with HCV related HCC
Poster presentation
Presenter: Maria Guerra Veloz

1333
Physician perspectives on hepatitis C treatment for women of childbearing age and during pregnancy: results from a global multispecialty survey
Poster presentation
Presenter: Tatyana Kushner

1335
Hepatitis C knowledge and perceptions among Singapore's LGBTQ+ Individuals: barriers and opportunities for outreach
Poster presentation
Presenter: Garrett Kang

1346
A global survey of practice patterns in the management of hepatitis C virus (HCV)-related fibrosis
Poster presentation
Presenter: Ira Jacobson

1395
Results of the national program for the elimination of viral hepatitis in Uzbekistan
Poster presentation
Presenter: Shakhlo Sadirova

1453
Hepatitis B surface antigen clearance rate achieved with pegylated interferon-alpha therapy in different chronic hepatitis B virus infection populations: a systematic review and meta-analysis
Poster presentation
Presenter: Enqiang Chen

1468
Genetic determinants of hepatitis B surface antibody disappearance in Taiwan's vaccinated generations: a genome-wide association study

Poster presentation
Presenter: Chun-Yi Chang

1480

Hepatitis C incidence in Pakistan – large scale test and recall analysis shows that infection rates can be reduced by pro-active ‘find and treat’ programs

Poster presentation
Presenter: Saad Niaz

1488

Epidemiological, economic and budgetary implications of expanding screening strategies for hepatitis C virus in Brazil: a modelling study

Poster presentation
Presenter: Everton Macêdo

1508

Treatment for chronic hepatitis C infection in Pakistan – in a high prevalence country treatment initiation is sub-optimal and may impact elimination programs

Poster presentation
Presenter: Aliya Hasnain

1617

A comparative analysis of carbon footprints: nucleic acid test vs. rapid antigen test for preventing mother-to-child transmission of hepatitis B in the gambia

Poster presentation
Presenter: Alassane Ndiaye

1635

Peer-led mass testing in prisons to support hepatitis C elimination

Poster presentation
Presenter: Leila Reid

1700

Eliminating hepatitis C in Nouvelle Aquitaine, the largest region of France: the SCANVIR® project

Poster presentation
Presenter: Sandrine Francois

1726

Trends and cross-country inequalities in the global burden of acute hepatitis A, 1990–2021: a population-based study

Poster presentation
Presenter: Deliang Huang

1792

Initiation of direct acting viral therapy in prison is associated with a significant loss to follow-up: relevance to WHO elimination metrics?

Poster presentation
Presenter: Matthew Foxton

1796

Direct measurement of incidence and prevalence of Hepatitis C infection using the gold-standard of prospective HCV re-testing of people at risk. A national needs assessment of people who inject drugs and of all people who use addiction services in England

Poster presentation
Presenter: Beatrice Emmanouil

1810

Automated universal testing for hepatitis B in the emergency department improves screening and characterises the undiagnosed and untreated cohort in an Australian setting

Poster presentation

Presenter: Bonita Gu

1855

Population-based hepatitis C screening and elimination program in Lithuania: 26-month results

Poster presentation

Presenter: Limas Kupcinskas

1877

Trends in the effect of direct acting antivirals on mortality in people diagnosed with hepatitis C in England using routine surveillance data

Poster presentation

Presenter: David Etoori

1898

Evaluation of Belgium's progress towards HBV elimination: results from a national serosurvey

Poster presentation

Presenter: Arno Furquim d'Almeida

1902

The burden of HDV chronic infection and the gaps in HDV screening across Europe: an urgent need to strengthen diagnostic strategies at pan-European level

Oral presentation

Presenter: Romina Salpini

1906

Three-year evaluation of retention in specialist care among migrants and refugees living with HBV in Catalonia following a community-based intervention

Poster presentation

Presenter: Camila Picchio

1962

Development of a predictive model using artificial intelligence (AI) for the detection of hepatitis C based on real-world data from the population health database (BPS) of Andalusia, Spain

Poster presentation

Presenter: Carlos Loucera

2000

Screening for risk factors for hepatitis C infection with a large metropolitan primary care population - The size of the problem

Poster presentation

Presenter: Matthew Foxton

2019

Evaluating and aiding hepatitis C elimination efforts through natural language processing (Cogstack): analysis of electronic health records including diagnosis, demographics and outcomes

Poster presentation

Presenter: Mahd Siddiqi

2046

Early diagnosis of HCV in people who inject drugs in the Czech Republic: preliminary results of a pilot project

Poster presentation

Presenter: Soňa Fraňková

2047

Micro-elimination of hepatitis C utilizing hepatitis C virus self-testing in a district prison of northern India: a demonstration project

Poster presentation

Presenter: Ajeet Bhadoria

2073

Mind the gap - addressing inequitable hepatitis D testing in Wales

Poster presentation

Presenter: Bazga Ali

2110

Treatment of Hepatitis C in the over-80s in the direct anti-viral therapy era: age is no barrier!

Poster presentation

Presenter: Matthew Foxton

2128

Semi-qualitative feedback from individuals living with HBV newly diagnosed in the emergency department ED opt-out testing program – high acceptability but better platforms of advocacy and support required

Poster presentation

Presenter: Mia Olsen

2133

Prevalence of HBV and HCV among migrants in EU-27: the impact of the ukrainian refugee crisis

Poster presentation

Presenter: Devin Razavi-Shearer

2135

Emergency department blood-borne virus screening and the revealed burden of hepatitis B-driven liver disease

Poster presentation

Presenter: Kartikeya Khanna

2139

Emergency department screening and linkage to care for undiagnosed hepatitis C infection: an effective initiative to reach elimination targets

Poster presentation

Presenter: Bo Wang

2167

The cost of HCV elimination in Kazakhstan based on the current disease burden

Poster presentation

Presenter: Samantha Hall

2198

One-pot assay based on CRISPR/Cas13a technology for HEV RNA point-of-care testing

Poster presentation

Presenter: Ling Xu

2217

The impact of cardio-metabolic risk factors on liver-related diseases and mortality after hepatitis C virus eradication: insights from a multi-center taiwanese cohort

Poster presentation

Presenter: Ming-Lung Yu

2259

Atherosclerotic cardiovascular disease risk in chronic hepatitis C patients with metabolic dysfunction-associated steatotic liver disease after viral eradication: a multi-center cohort study

Poster presentation

Presenter: Wan-Long Chuang

2263

The clinical characteristics and antiviral treatment status among chronic HBV mono and HDV co-infected patients

Poster presentation

Presenter: Tuvshinjargal Ulziibadrakh

2353

Emergency department opt-out testing for hepatitis B: a 2-year multicentre study of outcomes across 7 sites

Poster presentation

Presenter: Jennifer Plunkett

2502

Current hepatitis D virus infection prevalence in persons with human immunodeficiency virus and hepatitis B virus across Europe

Poster presentation

Presenter: Anders Boyd

2511

Liver stiffness and AST-to-platelet ratio index (APRI) predict all-cause mortality in untreated people living with hepatitis B across Africa: a multi-centre cohort analysis in the hepatitis B in Africa collaborative network (HEPSANET)

Poster presentation

Presenter: Alexander Stockdale

2572

Clearing the road for viral hepatitis microelimination in croatian prisons: the Hepatos project

Poster presentation

Presenter: Anna Mrzljak

2581

Global burden of liver cancer related to viral hepatitis attributable to high body mass index from 1990 to 2021

Poster presentation

Presenter: Sitao Ye

2714

A National web self-testing portal for hepatitis C: an empowering solution with good uptake and linkage to care - preliminary data

Poster presentation

Presenter: Ewan Glassey

2845

Revisiting hepatitis B and delta viral infections in the brazilian Amazon: current epidemiological, clinical and molecular characteristics

Poster presentation

Presenter: Wornei Braga

2870

Return to Care (R2C) - the missing link in hepatitis C elimination
Poster presentation
Presenter: Alistair Story

2887
Engaging hard-to-reach individuals through community-based holistic care health and wellness fairs linked to HCV testing and treatment in Alberta, Canada
Poster presentation
Presenter: Cari Egan

2902
Complex multiple morbidity and social vulnerability among hep C patients with delays accessing care
Poster presentation
Presenter: Alistair Story

2946
Linking community-based organizations and specialized prescribing pharmacist teams to improve testing and treatment in hard-to-reach hepatitis C-infected groups: the LiveRx experience in Alberta, Canada
Poster presentation
Presenter: Cari Egan

3006
Healthcare resource use (HCRU) and cost impact of potential drug-drug interactions (DDIs) among HCV patients receiving Direct-Acting Antivirals (DAAs) concomitantly with antipsychotic drugs in the US
Poster presentation
Presenter: Dilip Makhija

3060
Using community partnerships to achieve micro-elimination of HCV and HIV in inner-city Vancouver
Poster presentation
Presenter: Shana Yi

3085
Patient perspectives on barriers and enablers to a treatment for all approach for hepatitis B
Poster presentation
Presenter: Marvad Ahad

Rare liver diseases (including paediatric and genetic) - Basic

198
Patient-level analysis of intrahepatic z-alpha-1 antitrypsin burden in patients with alpha-1 antitrypsin deficiency-associated liver disease following fazirsiran treatment
Oral presentation
Presenter: Rohit Loomba

226
Artificial intelligence-driven qFibrosis® in alpha-1-antitrypsin deficiency-associated liver disease: correlation with METAVIR stage and other disease specific features
Poster presentation
Presenter: Kay Washington

315
Unique serum inflammatory protein signature correlates to blood CD8 Perforin expression in paediatric T-cell activated acute liver failure

Poster presentation
Presenter: Tamir Diamond

329
Disruption of primary cilia in hepatobiliary development: insights into biliary atresia pathogenesis
Poster presentation
Presenter: Prasanna Ramachandran

411
Fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease: long-term efficacy and safety results from a phase 2 extension study
Poster presentation
Presenter: Pavel Strnad

443
Matrix metalloproteinase-7 and osteopontin secretion are specifically upregulated in a novel human precision-cut liver slices model of biliary atresia-associated liver fibrosis
Poster presentation
Presenter: Jeske Fridrichs

563
Studying the enterohepatic circulation in progressive familial intrahepatic cholestasis type I
Poster presentation
Presenter: Georg-Friedrich Vogel

592
Prognostic factors and regulatory pathways in porto-sinusoidal vascular disorder: a longitudinal cohort and transcriptomic study
Poster presentation
Presenter: Won-Mook Choi

611
Missense mutation predominates in moldavian patients with Wilson's disease
Poster presentation
Presenter: Veronica Cumpata

726
Single-cell sequencing reveals heterogeneity differences in cholangiocyte organoids derived from biliary atresia patients compared to non-biliary atresia controls
Poster presentation
Presenter: Adi Har-Zahav

821
Recreating Wolman disease in human liver organoids: a new model for pathophysiology and therapeutic exploration
Poster presentation
Presenter: Davide Selvestrel

823
The metabolism of TH104; a new drug for the treatment of pruritus in primary biliary cholangitis
Poster presentation
Presenter: Nir Barak

866
The alpha-1 Pi*^{MZ} genotype is an independent risk factor for hepatocellular carcinoma development in patients with advanced chronic liver disease

Poster presentation
Presenter: Paul Thöne

1051

Rare but not forgotten - comprehensive molecular and histological analysis of the primary yolk sac tumor of the liver and corresponding patient-derived cell line

Poster presentation
Presenter: Darko Castven

1285

Human biliary atresia extra-hepatic cholangiocyte organoids: elevated ER and oxidative stress, altered drug metabolism, and modified cell-to-cell junction

Poster presentation
Presenter: Yara Hamody

1385

Integrated multiomic analysis of hepatoblastoma and patient-derived organoids

Poster presentation
Presenter: Darien Yeung

1513

A promising new treatment for Wilson disease: ^{64}Cu -Methanobactin (ARBM-101) pharmacokinetics examined in animal models by whole-body PET

Poster presentation
Presenter: Julie Loft Nagel

2032

Proteomic newborn screening for Wilson disease in Washington state

Oral presentation
Presenter: Sihoun Hahn

2045

Single-cell spatial transcriptomic map of biliary atresia

Oral presentation
Presenter: Jake Mann

2211

Ex vivo application of chemically derived hepatic progenitors for the treatment of maple syrup urine disease (MSUD)

Poster presentation
Presenter: Elsy Soraya Salas Silva

2297

Kinetics of copper uptake in liver cells using the novel ligand tracer method

Poster presentation
Presenter: Karina Rewitz

2331

A potent tool to study progressive familial intrahepatic cholestasis: urine – derived human induced – hepatocytes

Poster presentation
Presenter: Benedetta Blarasin

2360

Correction of the Wilson disease H1069Q point mutation by CRISPR/Cas9-mediated gene editing in induced pluripotent stem cells

Poster presentation
Presenter: Viktoria Iwan

2377

10 year short-term outcomes of a therapeutic stepwise approach involving low-dose systemic thrombolysis for managing acute portomesenteric thrombosis

Poster presentation
Presenter: Kohilan Gananandan

2653

Modeling rare genetic cholestasis using human hepatocyte organoids

Poster presentation
Presenter: Katarina Balazova

2739

The omega-3 fatty acids, eicosapentaenoic acid and docosahexaenoic acid, improve the response to fibrates in human liver cell models

Poster presentation
Presenter: Audrey-Anne Lavoie

Rare liver diseases (including paediatric and genetic) - Clinical

69

Liver disease and prevalence of liver transplantation in ZZ alpha-1 antitrypsin deficiency – a systematic review and meta-analysis

Poster presentation
Presenter: Dimitra Georgantaki

166

Relative exchangeable copper: an accurate biomarker for the diagnosis of Wilson disease

Poster presentation
Presenter: Karen Dons

212

Management of Wilson disease across Europe: an international physician-oriented survey by the ERN-RARE liver group

Poster presentation
Presenter: Frederik Kirk

308

Counselling young adults with liver disease on alcohol use: a survey of clinical practices across Europe

Poster presentation
Presenter: Janne Suykens

314

Liver disease progression in patients with alpha-1 antitrypsin deficiency and a Pi*ZZ genotype: a retrospective natural history study

Poster presentation
Presenter: Virginia C. Clark

381

Comparison of three methodologies to measure bioavailable copper in patients with Wilson disease

Poster presentation
Presenter: Peter Ott

382

Fontan-associated liver disease: clinical and epidemiological impact on a large cohort in the UK, a retrospective multicenter study

Oral presentation

Presenter: Eleonora Munaretto

401

Estimating the diagnosis rate of alpha-1 antitrypsin deficiency: insights from population-based cohorts in the USA

Poster presentation

Presenter: Virginia C. Clark

445

Disease penetrance and survival in HFE p.C282Y/p.H63D compound heterozygous and p.H63D homozygous individuals - a population-based cohort study

Poster presentation

Presenter: Lorenz Pammer

490

Rare variants in ABCB4 in intrahepatic cholestasis of pregnancy in the national genomic research library

Poster presentation

Presenter: Xi Yang

561

First-line therapy with Zinc salts for Wilson disease patients: descriptive analysis from the spanish AEEH Wilson registry

Poster presentation

Presenter: Anna Pocurull Aparicio

576

Long-term outcome of sinusoidal obstruction syndrome secondary to hematopoietic stem cell transplantation

Poster presentation

Presenter: Edilmar Alvarado-Tapias

601

Detection of rare mutations of Wilson's disease during family screening

Poster presentation

Presenter: Veronica Cumpata

614

Trajectories of serum bile acid levels and their determinants in progressive familial intrahepatic cholestasis: insights from the NAPPED consortium

Poster presentation

Presenter: Pauline Huisman

696

Can drug metabolites predict outcome of Wilson disease?

Poster presentation

Presenter: moinak sen sarma

732

Prognostic value of factor VIII, D-Dimer, and high mutation risk variants in re-thrombosis risk stratification for non-cirrhotic splanchnic vein thrombosis

Poster presentation

Presenter: Anna Baiges

772

The prevalence and risk factors of metabolic dysfunction - associated steatotic liver disease in patients with transfusion dependent thalassemia

Poster presentation

Presenter: Nikolaos Fragkou

784

Dynamics and prognostic implications of splanchnic volumetry in patients with portosinusoidal vascular liver disorder

Poster presentation

Presenter: José Ferrusquía-Acosta

858

Accuracy of non-invasive tools in excluding advanced fibrosis in Wilson disease: results from the Wilson disease registry and Barcelona cohorts

Poster presentation

Presenter: Zoe Mariño

883

Prevalence and characterization of hepatobiliary involvement in cystic fibrosis patients at a referral hospital

Poster presentation

Presenter: Carla de Sárraga

943

Standalone medical therapy versus early endovascular intervention as the first step in the management of patients with primary Budd-Chiari syndrome: a randomized controlled trial

Poster presentation

Presenter: Sagnik Biswas

951

Prevalence and prognostic impact of sarcopenia in porto-sinusoidal vascular disorder

Poster presentation

Presenter: José Ferrusquía-Acosta

1040

UNITED study: results of the up-titration phase of an open label, multicenter, prospective study to characterize the pharmacokinetics and pharmacodynamics of trientine dihydrochloride and to investigate the efficacy and safety in Wilson disease patients

Poster presentation

Presenter: Karl Heinz Weiss

1045

Screening, high risk symptomatology and outcomes of Wilson's disease in 56,606 new referrals in a large tertiary psychiatric population

Poster presentation

Presenter: James Liu Yin

1053

Population pharmacokinetic (PK) model describing the variability of trientine pharmacokinetics in Wilson disease patients in the UNITED study

Poster presentation

Presenter: Esmée Vendel

1059

Integrated PK-PD model relating serum copper concentrations, urinary copper clearance and trientine pharmacokinetics in Wilson disease: initial insights from the UNITED study

Poster presentation

Presenter: Peter Vis

1081

Liver and spleen stiffness measure by transient elastography: a promising tool for the clinical management of patients after Fontan-type surgery circulation

Poster presentation

Presenter: Giovanni Petralli

1151

A 10-year review of obstetric admissions to a quaternary liver intensive care unit: learning from morbidity and mortality

Poster presentation

Presenter: Charlotte Sewell

1192

Liver disease is highly prevalent in patients with hereditary transthyretin-related amyloidosis

Poster presentation

Presenter: Concetta Pitrone

1211

Epidemiology, clinical presentation and management of Wilson's disease in Portugal – data from a national registry

Poster presentation

Presenter: Maria Inês Canha

1274

Health related quality of life in patients with porto-sinusoidal vascular disorder

Poster presentation

Presenter: Marina Torrao Gomes

1324

Non-invasive stratification of portal hypertension in patients with BCR::ABL1-negative myeloproliferative neoplasms

Poster presentation

Presenter: Can Hopp

1359

Profiling patients with Wilson's disease using a behavioral diagnostic tool (Observia SPUR™): insights into adherence challenges and personalized care strategies

Poster presentation

Presenter: Rodolphe Sobesky

1479

Quality of life of patients living with vascular LIVER diseaseS: Results of the LIVES european project

Poster presentation

Presenter: Aurélie Plessier

1496

Understanding treatment efficacies of progressive familial intrahepatic cholestasis via a prospective world-wide registry, TreatFIC

Poster presentation

Presenter: Alida D.E. de Groot

1506

Isolated metabolic syndrome is a risk factor for splanchnic venous thrombosis and recurrence of vascular event

Poster presentation

Presenter: H el ene Larrue

1514

Elexacaftor-Tezacaftor-Ivacaftor Era and cystic fibrosis liver disease progression: a 10-year national study

Oral presentation

Presenter: Charlotte Mouliade

1532

Spleen stiffness in porto-sinusoidal vascular disorder: link to portal hypertension and varices

Poster presentation

Presenter: Lydie Ponselet

1677

Switching from zinc salts to Trientine Tetrahydrochloride in Wilson disease: the ZICUP study

Poster presentation

Presenter: Rodolphe Sobesky

1687

Comparison of pyogenic liver abscess of biliary and non-biliary origin

Poster presentation

Presenter: Cheuk Ming Chan

1713

Development of portal hypertension after non-cirrhotic non-tumoral recent portal vein thrombosis (RPVT).

A long-term follow-up study

Oral presentation

Presenter: Berta Bartrol  Alabau

1900

The Alpha-1 foundation research registry: liver disease among alpha-1 antitrypsin deficiency patients in a United States cohort

Poster presentation

Presenter: Nadine Nuchovich

1908

Children and adults with severe alpha-1 antitrypsin deficiency present a unique histological liver phenotype (Pi*ZZ genotype)

Poster presentation

Presenter: Malin Fromme

1936

Long-term clinical outcomes, efficacy, and safety of transjugular intrahepatic portosystemic shunt in Budd Chiari syndrome

Poster presentation

Presenter: Shekhar Swaroop

1942

Rapid liver disease progression after first hepatic decompensation in individuals with severe alpha-1 antitrypsin deficiency (Pi*ZZ genotype)

Poster presentation

Presenter: Malin Fromme

1984

Outcomes in Navajo neurohepatopathy patients who have undergone liver transplant

Poster presentation

Presenter: Katie Cox

1985

Effectiveness of cystic fibrosis transmembrane conductance regulator modulator triple therapy in patients with advanced cystic fibrosis related liver disease

Poster presentation

Presenter: Julian Yeh

2004

Antinuclear antibodies target unknown autoantigens in porto-sinusoidal vascular disorder without portal hypertension

Poster presentation

Presenter: Nicola Pugliese

2006

Porto-sinusoidal vascular disease: epidemiology, clinical features and treatments

Poster presentation

Presenter: Hamza Benazzouz

2092

Etiological reclassification of cryptogenic cirrhosis after liver transplantation : insights and impact on outcomes

Poster presentation

Presenter: Hèdi ARAR

2093

Quantitative biliary metrics may add to predictive ability of liver stiffness in patients with primary sclerosing cholangitis

Poster presentation

Presenter: Aisha Alawi

2109

The role of metabolic factors in alpha-1 antitrypsin deficiency

Poster presentation

Presenter: Christina Schrader

2138

The HepQuant DuO test finds linkage between liver blood flow, portal-systemic shunting and cardiac hemodynamics in Fontan-associated liver disease

Poster presentation

Presenter: Greg Everson

2202

Genetic and epidemiological profile of a large brazilian cohort of acute hepatic porphyria

Poster presentation

Presenter: Cibebe Franz

2309

Fatigue is common in adults with PBC and PSC: prospective analysis of two cohorts encompassing 1267 patients

Poster presentation

Presenter: Beata Kruk

2328

Modified leipzig versus leipzig score: an agreement for diagnosis in wilson disease

Poster presentation

Presenter: anmol anmol

2357

Prevalence and risk factors of liver function test abnormalities in celiac disease patients: Insights from the Kashmir, Pakistan

Poster presentation

Presenter: Usman Ghani

2522

Wilson disease: presentation, clinical course and complications in a large cohort of patients attending San Paolo hospital of Milan

Poster presentation

Presenter: Federica Samartin

2639

Genetic variant analysis in low phospholipid-associated cholelithiasis patients of the HiChol registry

Poster presentation

Presenter: Carola Dröge

2753

HLA associations with specific anti-nuclear antibody reactivity in people living with primary biliary cholangitis

Poster presentation

Presenter: Aisha Alawi

2762

Combination of pharmacological and surgical interruption of the enterohepatic circulation can treat cholestasis and pruritus in patients with progressive familial intrahepatic cholestasis types 1 and 2 who proved unresponsive to either treatment alone

Poster presentation

Presenter: Willem Lexmond

2808

Automated reflex testing for AAT deficiency in liver dysfunction: is it worth it?

Poster presentation

Presenter: Sava Handjiev

2853

Liver disease in adults with fontan circulation: a cross-sectional study from a tertiary center in western Sweden

Poster presentation

Presenter: Elin Hultgren

2865

Propranolol for primary prophylaxis for variceal bleed in infants and children with biliary atresia – results of a single blind placebo controlled randomized controlled trial (BABB-Trial)

Poster presentation

Presenter: anmol anmol

2867

Biochemical and immunological markers show limited accuracy in predicting histological remission in paediatric autoimmune hepatitis: results from a multicenter study

Poster presentation
Presenter: Francesca Trevisan

2923
Advanced phenotyping of hepatic involvement in AL Amyloidosis: the D-Amy-LIPHE study
Poster presentation
Presenter: Anna Sessa

2980
Frequency of ATP7B gene variants in brazilian patients with Wilson's disease
Poster presentation
Presenter: Maria Chiara Chindamo

2981
Comparison of disease presentation features, morbidity and mortality rates of screening or index cases in patients with Wilson's disease
Poster presentation
Presenter: Aslı Çıfcıbaşı Örmeci

2985
Prognostic role of endoscopic ultrasound guided direct portal pressure gradient measurement in porto-sinusoidal vascular disorder
Poster presentation
Presenter: Lucia Giuli

Viral hepatitis A/E: Clinical aspects

268
Prolonged cholestasis following hepatitis A : what lies beneath
Poster presentation
Presenter: Souveek Mitra

2425
Plasma exchange to treat hepatitis A related acute liver failure – a retrospective multicentre cohort study
Poster presentation
Presenter: Asisha Janeela.M

2831
Hepatitis E virus persistence in cerebrospinal fluid: a rare phenomenon observed in immunosuppressed patients beyond 18 months post-viremia clearance under Ribavirin therapy
Poster presentation
Presenter: Swetha Chalissery

2838
Cross-sectional study on clinico-pathological profile and outcomes of severe hepatitis A outbreak in India
Poster presentation
Presenter: Arun Valsan

Viral hepatitis B and D: Clinical aspects

HBV RNA ultra-deep sequencing as a tool for HBV genotyping and resistance monitoring in virologically-suppressed individuals with chronic hepatitis B infection

Poster presentation

Presenter: Rémi Kazma

233

End of treatment anti-HBc IgG and HBcrAg predict severe flares after nucleos(t)ide analogue withdrawal in CHB – interim analysis from the multicenter prospective COIN-B trial

Poster presentation

Presenter: Arno Furquim d'Almeida

423

Clinical utility of novel HBV serological marker HBcrAg and immunological markers in the second trimester of pregnancy for predicting post-delivery ALT flares

Poster presentation

Presenter: Ivana Carey

498

Healthcare resource utilisation and costs associated with hepatitis delta virus infection compared with hepatitis B virus mono-infection prior to death among adults in Spain

Poster presentation

Presenter: Chong Kim

519

Combination therapy of entecavir, peginterferon alpha and granulocyte-macrophage colony stimulating factor enhanced HBsAg loss and HBsAb response

Poster presentation

Presenter: Di Wu

567

Likelihood level of a functional HBV-specific CD8 cell response upon discontinuation of eAg(-) chronic hepatitis B treatment correlates with long-term clinical outcome

Poster presentation

Presenter: Henar Calvo Sánchez

745

Transition of immune tolerant to immune active chronic hepatitis B and potential implications for monitoring and treatment

Poster presentation

Presenter: Lisa M. van Velsen

932

Transient liver stiffening and mechanosignaling activation promote IFN-mediated anti-HBV response

Poster presentation

Presenter: Fahong Li

955

Performance of the PAGE-B score for the prediction of hepatocellular carcinoma in chronic hepatitis B patients with metabolic dysfunction

Poster presentation

Presenter: Lesley Patmore

973

Accelerated HBsAg reduction rate and increased proportion of HBsAg <100 IU/mL through repeated finite Nuc therapy in HBeAg-negative chronic hepatitis B patients

Poster presentation

Presenter: Rachel Wen-Juei Jeng

993

Performance evaluation of the Elecsys anti-HBc II quant assay

Poster presentation

Presenter: Christian Voitenleitner

1033

New strategies to enhance molecular diagnosis of hepatitis Delta

Poster presentation

Presenter: Federico García

1138

Enhancing hepatitis delta virus detection in Spain with the Delta Double Reflex (DDR) study

Poster presentation

Presenter: Federico García

1145

Scaling up treatment of chronic hepatitis B in Africa: 1-year results from a simplified public-sector treatment program in Ethiopia

Poster presentation

Presenter: Lasse Rossvoll

1179

High FIB-4 index predicts liver decompensation in chronic hepatitis B patients who develop clinical relapse after antiviral therapy cessation

Poster presentation

Presenter: Chun-Hsun Liao

1213

Molecular epidemiology of hepatitis delta virus in Spain using whole-genome sequencing

Poster presentation

Presenter: Federico García

1219

Functional cure of chronic HBV: natural history, determinants, and outcomes: a real-world experience from a tertiary liver center

Poster presentation

Presenter: Mai Kilany

1227

The correlation of P62 expression in predicting outcomes of HBV-related HCC after surgical resection

Poster presentation

Presenter: Chien-Wei Su

1229

Enhanced 2- and 3-Year recurrence-free survival rates with switching from Entecavir to Tenofovir post-radiofrequency ablation treatment in HBV-HCC patients

Poster presentation

Presenter: Jing Liang

1233

Prevention of HBV mother to child transmission using HBV three dose and selective use of HBV BD and treatment of high viral load pregnant women in Uganda

Poster presentation

Presenter: Ponsiano Ocama

1269

Accurate prediction of long-term hepatitis B surface antigen seroclearance with machine learning: prognostic and management implications

Poster presentation

Presenter: Rex Wan-Hin Hui

1336

The effect of antiviral therapy on the outcomes of baseline grey-zone (GZ) patients with HBeAg-negative chronic hepatitis B virus infection (CHBVe-)

Poster presentation

Presenter: Margarita Papatheodoridi

1348

Immune profiling of peripheral and intrahepatic B cells in chronic hepatitis B

Poster presentation

Presenter: Anna Pocurull Aparicio

1372

Metabolic comorbidities are risk factors for adverse liver-related events in individuals with HIV-HBV on tenofovir-based antiretroviral therapy

Poster presentation

Presenter: Lesley Patmore

1416

Establishment and application of a new method for dual detection of HDV RNA and HBV DNA based on CRISPR technology

Poster presentation

Presenter: Feng Ren

1426

Mitigation of immune dysfunction in patients with sustained suppression of hepatitis B surface antigen after siRNA treatment

Oral presentation

Presenter: Lung Yi Loey Mak

1456

The impact of HBV genotypic diversity and temporal variations on hepatocellular carcinoma risk in chronic HBV infected patients

Poster presentation

Presenter: Ding-Lian Wang

1527

Role of HBV RNA in predicting nucleos(t)ide analogues initiation and risk of relapse after cessation

Poster presentation

Presenter: Chen-Ta Chi

1591

High GALAD scores predict hepatocellular carcinoma in hepatitis B-related cirrhosis patients who received antiviral therapy

Poster presentation

Presenter: Tung-Hung Su

1658

Risk of hepatocellular carcinoma and other liver-related events in chronic hepatitis B patients with or without hepatitis D virus co-infection

Poster presentation
Presenter: Lesley Patmore

1699

Treatment duration, adherence and persistence in patients with chronic hepatitis B virus infection treated with long-term nucleos(t)ide analogues in Germany

Poster presentation
Presenter: Afisi Ismaila

1773

Impact of HDV RNA levels on the risk of liver-related outcomes in patients with CHD: a european multicenter validation cohort study

Poster presentation
Presenter: Adriana Palom

1789

Hepatitis B surface antigen loss after nucleot(s)ide analogue cessation in patients living with chronic hepatitis B: a model-based meta-analysis of published studies

Poster presentation
Presenter: Myriam Drysdale

1798

Predictive performances of PAGED-B and reREACH-B models in non-cirrhotic, treatment-naive patients with chronic hepatitis B

Poster presentation
Presenter: Ho Soo Chun

1800

Burden of hepatitis D virus infection in Italy: results from the HDV describe study

Poster presentation
Presenter: Gian Paolo Caviglia

1892

HBV integration can sustain HDV persistence especially in the setting of an absent HBV reservoir and can be a biomarker of response to bulevirtide

Oral presentation
Presenter: Stefano D'Anna

1934

Immunological correlates of rapid HBsAg decline in chronic HBV hepatitis patients undergoing Tenofovir Amibufenamide treatment

Poster presentation
Presenter: Shu Xiong

1995

A marker of cccDNA transcription - hepatitis B core-related antigen (HBcrAg) - mimics HBV RNA decline during antiviral therapy with bulevirtide in chronic hepatitis delta (HDV) patients

Poster presentation
Presenter: Ivana Carey

2035

Qualitative interviews to explore multicultural appropriateness and content validity of the hepatitis B quality of life (HBQOL) among highly impacted populations (chinese and vietnamese) with chronic hepatitis B (CHB) in the US

Poster presentation
Presenter: Marvin Rock

2112

Long-term outcomes of 'Grey Zone' (GZ) individuals living with HBeAg-negative chronic hepatitis B in a tertiary UK centre

Poster presentation

Presenter: Evangelos Chalatsis

2184

Long-term perspectives on treating or observing immune-tolerant chronic hepatitis B

Poster presentation

Presenter: Ahmed Elsheita

2200

Comparing Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in reducing hepatocellular carcinoma risk in chronic hepatitis B: a propensity score matching study

Poster presentation

Presenter: Hyung Joon Yim

2207

Efficacy and safety of Tenofovir Amibufenamide and Tenofovir Alafenamide in patients with hepatitis B cirrhosis: a retro-prospective observational study

Poster presentation

Presenter: Jun Chen

2210

Infants with chronic hepatitis B can achieve functional cure through a definite duration of antiviral treatment

Poster presentation

Presenter: Jing Li

2213

Characterizing serum HBcAg and phosphorylated HBcAg in the natural history of chronic hepatitis B infection

Poster presentation

Presenter: Lung Yi Loey Mak

2229

The multi-center study of functional cure for inactive hepatitis B surface antigen carriers in China: interim analysis of E-cure study

Oral presentation

Presenter: zhishuo mo

2304

In HDV sub-genotypes 1, the high degree of genetic variability can drive the selection of divergent genetic pathways modulating HDV replicative potential and cytolytic activity

Poster presentation

Presenter: Lorenzo Piermatteo

2325

Course and clinical outcomes of chronic hepatitis delta: a longitudinal analysis of 565 patients from the D-Solve consortium and HDV1000 database

Oral presentation

Presenter: Habiba Kamal

2330

Autoimmunity in chronic hepatitis D: results from the HDV describe study cohort

Poster presentation
Presenter: Eleonora Dileo

2378

Molecular epidemiology of chronic HDV infection in Italy: HDV genotypes and subgenotypes distribution in the HDV describe study cohort

Poster presentation
Presenter: Antonella Olivero

2454

Impact of drugs for hepatocellular carcinoma development in chronic hepatitis B patients who treated with entecavir and tenofovir disoproxil as initial therapy: population-based study

Poster presentation
Presenter: Hyung Joon Yim

2469

High rates of advanced chronic liver disease in patients with chronic hepatitis D virus infection in Uzbekistan

Poster presentation
Presenter: Malika Khodjaeva

2524

Analysis of liver pathological characteristics and influencing factors in patients with an inactive HBsAg carrier status

Poster presentation
Presenter: Shan Ren

2557

Treatment coverage of the WHO 2024 hepatitis B guidelines in patients with chronic hepatitis B

Poster presentation
Presenter: Shaoqiu Zhang

2562

HCC risk in intermediate PAGE-B patients: implications for surveillance strategies

Poster presentation
Presenter: Sara Battistella

2589

Investigation the persistent effects following HBsAg clearance in chronic hepatitis B patients treated with Interferon therapy

Poster presentation
Presenter: Huiling Xiang

2616

Sustained HBsAg loss in HIV/HBV-coinfected patients is not a rare event under HBV-active ART even if a residual risk of viral reactivation and liver disease progression still persists over time

Poster presentation
Presenter: Romina Salpini

2626

Characteristics and predictors for elevated alanine transferase in 3,399 treatment-naïve HBV/HDV co-infected patients, with comparison to propensity score-matched mono-HBV infected patients

Poster presentation
Presenter: Habiba Kamal

2641

The asymmetry of the liver and spleen stiffness measures between patients with chronic hepatitis B and D reflects clinic-pathologic differences

Poster presentation

Presenter: Francesco Damone

2726

Comprehensive analysis of the intrahepatic immune microenvironment and gene expression profiles in a large cohort of patients with untreated hepatitis B virus infection

Poster presentation

Presenter: Maria Stella Franzè

2769

Insufficient implementation of pretherapeutic hepatitis B and C screening guidelines in academic and general belgian hospitals

Poster presentation

Presenter: Marie Coessens

2776

Field evaluation of a novel hepatitis B core-related antigen rapid test (HBcrAg-RDT) for the identification of highly viremic pregnant women, the Gambia: preliminary results from a prospective diagnostic accuracy study

Poster presentation

Presenter: Erwan Vo Quang

2778

SE London emergency department (ED) testing for BBV demonstrates a high HBV prevalence: an effective public health intervention to address inequalities for people living with HBV

Poster presentation

Presenter: Kate Childs

2798

Assessment of hepatocarcinogenesis risk using CAMP-B and PAGE-B in patients with chronic hepatitis B

Poster presentation

Presenter: Masatsugu Ohara

2816

Distinct circulatory and intrahepatic mono-mac and CD8 T cell clusters associated with fibrosis in patients with low levels of hepatitis B surface antigen

Poster presentation

Presenter: Ravinder Singh

2881

Anti-HDV prevalence in HBsAg positive patients and virological characterization of HBV/HDV co-infected individuals at the diagnostic laboratory of the university medical center Hamburg-Eppendorf between 2008 and 2024

Poster presentation

Presenter: Marc Luetgehmman

2896

Nucleos(t)ide analogue cessation outcomes in non-cirrhotic patients with HBeAg-negative chronic hepatitis B

Poster presentation

Presenter: Zeynep Melekoğlu Ellik

2916

DM type 2 is a significant risk factor for HCC and decompensation of liver disease in HBV s Ag positive patients

Poster presentation

Presenter: Assaf Issachar

2918

Prevalence and burden of hepatitis delta virus infection in a large cohort of hepatitis B- infected individuals in the Brazilian Amazon

Poster presentation

Presenter: Maria Cassia Mendes-Correa

2938

Dynamics of HBsAg isoforms during up to 9 years in treated and untreated HBeAg-negative chronic hepatitis B patients

Poster presentation

Presenter: Maria Pfefferkorn

2968

Hepatitis B virus screening, antiviral prophylaxis, and reactivation in Rituximab-treated patients: insights from a large retrospective cohort study

Poster presentation

Presenter: Rawi Hazzan

3005

Should EASL expand its 2017 treatment criteria for chronic hepatitis B virus infection to ineligible people: analysis from a UK-based cohort

Poster presentation

Presenter: Monika Prabhaker-Kaushal

3020

Staging liver fibrosis using non-invasive tests in people with chronic hepatitis B (CHB) to inform WHO 2024 guidelines: a systematic review and meta-analysis

Poster presentation

Presenter: Antonio Liguori

Viral Hepatitis B and D: Current therapies

438

Effectiveness and renal safety following switching to tenofovir alafenamide in patients with chronic hepatitis B: Results from a five-year, multicenter cohort study

Poster presentation

Presenter: Eiichi Ogawa

470

Ethnicity and socioeconomic disparities in diagnostic and hepatic event incidences in patients with chronic viral hepatitis

Poster presentation

Presenter: Grace Lai-Hung Wong

504

Comparative renal safety of besifovir dipivoxil maleate and tenofovir disoproxil fumarate in chronic hepatitis B patients: insights from a nationwide cohort study

Poster presentation

Presenter: Hyun Bin Choi

557

Hepatocellular carcinoma risk in patients with chronic hepatitis B: Tenofovir Disoproxil Fumarate vs Tenofovir Alafenamide from a Korean nationwide study

Poster presentation

Presenter: Ji won Yang

568

HERACLIS_BLV_D: Increasing response rates during 2-year bulevirtide real-life therapy in chronic hepatitis D

Poster presentation

Presenter: Margarita Papatheodoridi

579

Atherosclerotic cardiovascular risk in patients with chronic hepatitis B: Tenofovir Disoproxil fumarate vs Tenofovir Alafenamide from a Korean nationwide study

Poster presentation

Presenter: Ji won Yang

630

Long term outcomes after nucleos(t)ide analogue cessation – an extended follow up study from the RETRACT-B cohort

Oral presentation

Presenter: Edo J. Dongelmans

631

HBsAg decline and clearance with peg-IFN add-on therapy – an individual participant data meta-analysis of prospective trials (PROSPER)

Poster presentation

Presenter: Edo J. Dongelmans

673

Paediatric pharmacokinetic-pharmacodynamic extrapolation to identify suitable bulevirtide doses for children and adolescents with chronic hepatitis delta

Poster presentation

Presenter: Parag Kumar

730

A mathematical viral load model characterises the exposure-response relationship between bulevirtide and hepatitis delta virus and identifies the minimum duration of on-treatment viral load monitoring required for accurate prediction of long-term virology

Poster presentation

Presenter: Parag Kumar

860

Good flare or bad flare? ALT variability predicts outcome after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B

Poster presentation

Presenter: Marte Holmberg

978

Ten-year follow-up after 96 weeks treatment with peginterferon plus tenofovir in hepatitis D (HIDIT-II)

Poster presentation

Presenter: Anika Wranke

1046

A cross-sectional, intrahepatic analysis of HBV and HDV markers in liver transplants of untreated and Bulevirtide-treated patients with chronic hepatitis Delta
Poster presentation
Presenter: Elisabetta Degasperi

1047
Real-world evidence shows comparable Bulevirtide effectiveness in hepatitis D patients with and without cirrhosis: results from the prospective nationwide D-Shield multicenter study
Poster presentation
Presenter: Maria Paola Anolli

1113
Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide and entecavir in the hepatitis B virus related acute-on-chronic liver failure patients: a single-centre retrospective study
Poster presentation
Presenter: Xiaochuan Diao

1117
Serum hepatitis B surface antigen decline combined with the quantification of hepatitis B virus antigen and hepatitis B surface antibody at the end of treatment of pegylated Interferon predict hepatitis B surface antigen loss at 96 weeks after withdrawal
Poster presentation
Presenter: Qianjun Wu

1121
High levels of hepatitis B virus deoxyribonucleic acid integration by high-throughput viral integration detection method predict non-responsiveness of antiviral treatment
Poster presentation
Presenter: Misi Gu

1208
Outcomes beyond 10 years in entecavir or tenofovir treated Caucasian chronic hepatitis B patients of the real-life PAGE-B cohort
Oral presentation
Presenter: George Papatheodoridis

1238
Comparative performance of highly sensitive HBcrAg and HBsAg assays in predicting clinical flares and HBsAg loss after nucleos(t)ide analogues withdrawal in patients with chronic hepatitis B
Poster presentation
Presenter: Yao-Chun (Holden) Hsu

1258
Concomitant diabetes mellitus in untreated chronic hepatitis B with low-level viremia is associated with increased risk of hepatocellular carcinoma: validating the world health organization 2024 recommendations
Oral presentation
Presenter: Rex Wan-Hin Hui

1276
Assessment of response and impact of safety treatment with bulevirtide in patients with chronic delta virus infection: an observational trial for evaluating long-term efficacy. The ARISTOTELE study
Poster presentation
Presenter: Luca Rinaldi

1367

HBV reactivation in HBV/HDV coinfecting patients during bulevirtide monotherapy
Poster presentation
Presenter: Alexander Killer

1667

Virological outcomes in patients with HDV-related compensated cirrhosis treated with Bulevirtide monotherapy for 144 weeks: a subanalysis of the retrospective multicenter european study (Save-D)
Poster presentation
Presenter: Elisabetta Degasperi

1716

Long risk of decompensation and HCC in patients with HDV-related compensated cirrhosis treated with Bulevirtide monotherapy for up to 144 weeks: the retrospective multicenter european study (Save-D)
Poster presentation
Presenter: Elisabetta Degasperi

1756

Predictors of undetectable hepatitis delta virus RNA at 48 weeks after end of treatment with bulevirtide monotherapy in the MYR 301 study
Oral presentation
Presenter: Soo Aleman

1828

Predictive value of baseline HBsAg, HBV RNA, and HBcrAg levels for HBsAg clearance in NAs-suppressed HBeAg-Negative chronic hepatitis B patients treated with pegylated interferon-alpha
Poster presentation
Presenter: Mengya Liu

1847

Impact of long-term oral antiviral treatment on hepatocellular carcinoma risk in patients with chronic hepatitis B who are hepatitis B e antigen positive using the PAGED-B score
Poster presentation
Presenter: Young-Suk Lim

1853

Quantification of plasma HDV RNA by three commercially available assays in untreated and Bulevirtide-treated real-life patients with CHD: Robogene 2.0 vs. Altostar vs. Eurobioplex EBX071
Poster presentation
Presenter: Maria Paola Anolli

1907

Treatment response to bulevirtide leads to improvement of portal hypertension in patients with chronic hepatitis D virus infection: results from the prospective IMPHROVE-D study
Poster presentation
Presenter: Lisa Sandmann

1989

Improvement in 3 noninvasive tests through 144 weeks of bulevirtide monotherapy in patients with chronic hepatitis delta with and without virologic response
Poster presentation
Presenter: Maurizia Brunetto

2023

Virological response and safety of combination treatment with bulevirtide and pegylated interferon in chronic hepatitis D patients with advanced fibrosis/cirrhosis: 48 weeks interim results from SEE-D trial
Poster presentation

Presenter: Karin Lindahl

2040

Pharmacokinetics, pharmacodynamics, and safety of bulevirtide 10 mg once daily for 6 days in participants with severe renal impairment and in matched control participants with normal renal function
Poster presentation

Presenter: Parag Kumar

2063

Pharmacokinetics, pharmacodynamics, and safety of bulevirtide 10 mg once daily for 6 days in participants with moderate hepatic impairment and in matched control participants with normal hepatic function
Poster presentation

Presenter: Parag Kumar

2085

Impact of long-term tenofovir-based treatment on hepatocellular carcinoma risk in patients with chronic hepatitis B using the reREACH-B score
Poster presentation

Presenter: Young-Suk Lim

Presenter: Young-Suk Lim

2096

Exploring predictive factors for treatment response to Bulevirtide in Delta-positive patients
Poster presentation

Presenter: Verdiana Zulian

Presenter: Verdiana Zulian

2144

Therapeutic options for persistent low-level viremia in patients with chronic hepatitis B: adding on peginterferon α -2b might be a better choice
Poster presentation

Presenter: Fengmin Lu

Presenter: Fengmin Lu

2223

Impact of hepatic steatosis on hepatitis B virus infection and antiviral treatments
Poster presentation

Presenter: Ying Zhu

Presenter: Ying Zhu

2403

Response-guided interferon add-on to bulevirtide treatment: updated real-world insights from the austrian hepatitis D cohort study
Poster presentation

Presenter: Michael Schwarz

Presenter: Michael Schwarz

2596

Patient centered-outcomes in HDV-treated patients with Bulevirtide
Poster presentation

Presenter: Daniele Mengato

Presenter: Daniele Mengato

2984

The kinetic of HBsAg isoforms predicts response to BLV and pegylated interferon alfa2a in patients with chronic hepatitis delta
Poster presentation

Presenter: Maria Pfefferkorn

Presenter: Maria Pfefferkorn

Viral Hepatitis B and D: New therapies, unapproved therapies or strategies

88

Safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7565020, a novel monoclonal antibody that targets the hepatitis B surface antigen: results from a phase 1 single ascending dose study in healthy volunteers and participants with chronic hep

Poster presentation

Presenter: Edward J. Gane

89

HBV genotype association with response to xalnesiran in nucleos(t)ide analogue treated participants with chronic hepatitis B infection in the Piranga phase 2 platform study

Poster presentation

Presenter: Rémi Kazma

290

Tissue virological response is the main predictor of hepatitis D relapses

Poster presentation

Presenter: Pavel Bogomolov

486

SOLSTICE week 24 subgroup analysis: impact of baseline viral parameters and cirrhosis status on virological and biochemical responses in participants with chronic hepatitis delta virus infection treated with tobevibart and elebsiran

Poster presentation

Presenter: Alina Jucov

493

Outcomes of 48 weeks of therapy and subsequent 24-week post-treatment period with tobevibart (VIR-3434) and elebsiran (VIR-2218) with or without pegylated interferon alfa-2a in chronic hepatitis B virus infection. Findings from the MARCH study

Oral presentation

Presenter: Edward J. Gane

509

Besifovir reduces hepatocellular carcinoma risk compared to Tenofovir Disoproxil Fumarate: large-scale cohort study

Poster presentation

Presenter: Yoon E Shin

677

Safety, tolerability and immunogenicity of GS-2829 and GS-6779, a novel arenaviral vectored therapeutic hepatitis B vaccine: results from a phase 1a study in healthy participants

Poster presentation

Presenter: Edward J. Gane

678

Entry inhibitor Hepalptide combined with pegylated interferon-alpha 2a therapy resulted in cccDNA clearance in CHB patients: a phase II randomised, double-blind, placebo-controlled trial

Oral presentation

Presenter: Fu-Sheng Wang

713

Interim results of a phase I/II study to determine the safety, immunogenicity and efficacy of therapeutic hepatitis B virus synthetic long peptide vaccination

Poster presentation

Presenter: Roel Pieterman

720

Patient characteristics and treatment patterns amongst hepatitis D patients: results from a real-world survey in Europe

Poster presentation

Presenter: Marvin Rock

747

A Randomised trial of nucleos(t)ide withdrawal vs nucleos(t)ide withdrawal with adjuvant pegylated-interferon in HBeAg-negative hepatitis B virus infection to promote HBsAg clearance (NUC-B)

Oral presentation

Presenter: Mark R Thursz

815

Safety and pharmacokinetics of bepirovirsen, delivered subcutaneously by vial, or prefilled syringe fitted with a safety syringe device in healthy adult participants, and syringe device ease of use: a randomised phase 1 trial

Poster presentation

Presenter: Poonam Shah

856

The safety and antiviral effect of oral daily 300 mg ALG-000184 in combination with Entecavir for up to 96 Weeks in untreated HBeAg-positive subjects with chronic hepatitis B virus infection

Poster presentation

Presenter: Jinlin Hou

861

Monotherapy with the novel capsid assembly modulator ALG-000184 for up to 96 weeks results in profound and sustained HBV DNA suppression in untreated subjects with chronic HBV infection

Poster presentation

Presenter: Man-Fung Yuen

1148

The safety and efficacy of PD-1 antibody combined with pegylated interferon- α therapy to promote the clinical cure in nucleoside (acid) analogues-suppressed chronic hepatitis B patients

Poster presentation

Presenter: Junliang Fu

1404

HBsAg declines, and T cell increases, observed in CHB patients: Interim results from P1b trial of VRON-0200, a novel checkpoint modifier, following prime only, and prime and boost dosing

Poster presentation

Presenter: Edward J. Gane

1596

Combination treatment of TLR7 agonist and anti-PD-L1 reconstitute protective immunity in virally suppressed chronic hepatitis B patients

Poster presentation

Presenter: Yuying Chen

1768

IM-PROVE I: characterization of chronic hepatitis B (CHB) subjects with functional cure or HBV DNA suppression after completion of imdusiran plus short courses of pegylated interferon alfa-2a (IFN) and discontinuation of nucleos(t)ide analogue (NA) therap

Poster presentation

Presenter: Man-Fung Yuen

1850

Genetic prediction of causality of immune cell-mediated plasma metabolites and acute hepatitis B: a Mendelian randomization study

Poster presentation

Presenter: Size Li

1924

Viral kinetics and sequence analysis of a phase I monotherapy study in subjects with chronic hepatitis B reveals a high barrier of resistance to the capsid assembly modulator ALG-000184

Poster presentation

Presenter: Andreas Jekle

1978

Preliminary safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of AB-101, a small-molecule PD-L1 inhibitor, in healthy and chronic hepatitis B subjects

Poster presentation

Presenter: Edward J. Gane

1979

Quality of life in HDV-infected patients prior to bulevirtide treatment: chronic hepatitis versus compensated cirrhosis

Poster presentation

Presenter: Speranta Iacob

1990

First-in-human pharmacokinetics and pharmacodynamics of oral small-molecule PD-L1 inhibitor AB-101 and correlation to preclinical models

Poster presentation

Presenter: Emily P. Thi

2043

IM-PROVE I: Rapid loss followed by transient increases in HBV RNA in chronic hepatitis B subjects during treatment with imdusiran and pegylated interferon alfa-2a is associated with HBsAg seroclearance

Poster presentation

Presenter: Emily P. Thi

2075

Achieving undetectable hepatitis delta virus RNA at end of therapy with bulevirtide 10 mg/day with or without with pegylated interferon alpha is strongly associated with post-treatment virologic response in chronic hepatitis delta

Oral presentation

Presenter: Fabien Zoulim

2224

30% of inactive HBsAg carriers achieved clinical cure at 48 weeks with Pegylated Interferon alpha-2b therapy: a multicenter real-world study (STARHB Project in China)- 2.5 years data update

Poster presentation

Presenter: Shan Ren

2559

Up to 18 months' functional cure in response to bepirovirsen therapy in B-Clear On-NA responders: B-Sure third report
Poster presentation
Presenter: Seng Gee Lim

2631

Up to 2 years' functional cure in response to bepirovirsen therapy in B-Clear Not-on-NA responders: B-Sure third report
Poster presentation
Presenter: Seng Gee Lim

Viral Hepatitis C: Clinical aspects including follow up after SVR

38

Previous hepatitis B virus infection and the risk of liver-related complications in patients after HCV cure - Data on more than 6,000 patients from the german hepatitis C-registry (DHC-R)
Poster presentation
Presenter: Laura Muana Wilhelm

374

Hepatitis C treatment in arterial hypertension is safe and highly effective: real-world study
Poster presentation
Presenter: Michał Brzdęk

390

Overweight, but not alcohol is associated with increased risk for advanced liver disease in patients with chronic hepatitis C infection- results from the german hepatitis C-registry (DHC-R)
Poster presentation
Presenter: Katharina Luise Hupa-Breier

396

Increasing risk of hepatic decompensation in patients with HCV related liver cirrhosis during long-term follow up after sustained virological response (SVR) - data from the german hepatitis C-registry (DHC-R)
Poster presentation
Presenter: Christian Niehaus

397

Hepatocellular carcinoma risk scores and incidence during and after hepatitis C therapy with direct antiviral agents - data from the german hepatitis C-registry (DHC-R)
Poster presentation
Presenter: Magdalena Hahn

441

Predictors of hepatocellular carcinoma risk after hepatitis C viral clearance - data from the german hepatitis C-registry (DHC-R)
Poster presentation
Presenter: Christian Niehaus

615

An innovative peer-led, smartphone-based intervention to enhance engagement for patients with untreated hepatitis C
Poster presentation
Presenter: Jennifer Plunkett

731

Post-treatment outcomes for patients with hepatitis C cirrhosis treated through west London operational delivery network

Poster presentation

Presenter: Ashley Brown

738

Association between sustained virological response and adverse liver-related outcomes in patients with decompensated HCV cirrhosis

Poster presentation

Presenter: Lisa M. van Velsen

798

Long-term prognosis and changes in liver function after direct-acting antiviral treatment in decompensated cirrhotic patients with hepatitis C virus

Poster presentation

Presenter: Yuki Tahata

928

Sex-related differences in patients with chronic hepatitis c virus infection treated with direct-acting antiviral drugs

Poster presentation

Presenter: Krystyna Dobrowolska

1193

PRO-Link HCV: automated detection and Re-engagement of hepatitis C patients lost to follow-up. A pilot study in southern Spain

Poster presentation

Presenter: Federico García

1194

Relinking lost to follow up patients with hepatitis C: a modeling approach to assess liver-related outcomes

Poster presentation

Presenter: Manuel Mendizabal

1278

Effectiveness of automatic alerts from microbiology laboratories to liver units for linking to hepatitis C treatment

Poster presentation

Presenter: Nuria Cañete

1423

Development of a hepatitis C infection integrated care model for prisoners in chinese population

Poster presentation

Presenter: Lung Yi Loey Mak

1690

Effectiveness and outcomes of routine opt-out screening for hepatitis C in a UK emergency department

Poster presentation

Presenter: Samuel Hey

1784

Treatment of genotype 3 chronic hepatitis C infection: age reduces the efficacy of treatment with sofosbuvir and daclatasvir but the reduction is less marked with sofosbuvir and velpatasvir

Poster presentation

Presenter: Saeed Sadiq Hamid

1827

Mortality benefits of a national program of supported, active care in the treatment of marginalised people with chronic HCV infection

Oral presentation

Presenter: Graham R Foster

2074

Clinical follow up in patients treated for hepatitis C

Poster presentation

Presenter: Arron Jones

2088

Characterising prevalence and unmet needs in the setting of funded hepatitis C therapy - automated hepatitis screening in Australian emergency departments can assist

Poster presentation

Presenter: Julia Di Girolamo

2143

Evaluation of transient elastography and platelets count for predicting hepatocellular carcinoma in patients with chronic hepatitis C and sustained virological response to direct-acting antivirals

Poster presentation

Presenter: Cristiane Villela-Nogueira

2390

A step toward eliminating recalls and follow-up testing: first Australian implementation of hepatitis C RNA reflexive testing utilising a single blood sample collected in the emergency department setting

Poster presentation

Presenter: Julia Di Girolamo

2415

HCC risk stratification scores: insights from large multi-center national cohort study

Poster presentation

Presenter: Imam Waked

2501

Long term clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective study

Oral presentation

Presenter: Gamal Shiha

2729

Implementation of a systematic hepatitis C screening program: insights from a regional approach and its impact on diagnosis and treatment outcomes

Poster presentation

Presenter: Madalena Pestana

2794

Refining HCC risk prediction in non-ACLD chronic hepatitis patients after antiviral therapy: insights from a multicenter study

Poster presentation

Presenter: Rachel Wen-Juei Jeng

2827

Systematic screening for HBV, HCV and HIV in hospitalised psychiatric patients: a feasible approach on the road towards elimination of viral hepatitis

Poster presentation
Presenter: Marie Coessens

2944

Microelimination project for HCV in patients with elevated ALT using pooling PCR technique in a health area. Preliminary results

Poster presentation
Presenter: Natalia Marcos Carrasco

2961

Impact of hepatitis C eradication with direct-acting antivirals on metabolic and liver-related outcomes in diabetic patients

Poster presentation
Presenter: Clelia Asero

Viral hepatitis C: Therapy and resistance

169

The annual incidence of HCV RNA positivity detected by rapid on-site RT PCR doesn't decrease and remains relatively high over the last 3 years among drug users

Poster presentation
Presenter: Denis Ouzan

674

Real-world efficacy and safety of universal 8-week Glecaprevir/Pibrentasvir in CHC patients with early CKD or Pre-ESRD: insights from a nationwide HCV registry in Taiwan

Poster presentation
Presenter: Ming-Lung Yu

923

Real-world outcomes in patients with Voxilaprevir (VOX)/Velpatasvir (VEL)/Sofosbuvir (SOF) treatment failure: a follow-up study

Poster presentation
Presenter: Julia Dietz

1491

The SVR10K Hepatitis C study: final results show 98.9% SVR in 7,000 patients treated with SOF/VEL in Asia, Latin America, Middle East, Nordic and Southern Europe

Poster presentation
Presenter: Soo Aleman

1691

Exploring a hepatitis C elimination model among ex-drug users in community drug rehabilitation centers insights from Guangdong, China

Poster presentation
Presenter: Hong Li

1706

Retreatment of HCV in a large metropolis – implications for WHO elimination targets? The London experience

Poster presentation
Presenter: Matthew Foxton

1758

Pharmacokinetics of bemnifosbuvir in participants with renal impairment
Poster presentation
Presenter: Xiao-Jian Zhou

1763
Efficacy and safety of Bemnifosbuvir and Ruzasvir after 8 weeks of treatment in patients with chronic hepatitis C virus (HCV) infection
Poster presentation
Presenter: Alina Jucov

1919
Pharmacokinetics of bemnifosbuvir in participants with hepatic impairment
Poster presentation
Presenter: Xiao-Jian Zhou

2030
Efficacy and safety of glecaprevir/pibrentasvir in acute HCV participants with a history of prior infection(s)
Poster presentation
Presenter: Thomas Reiberger

2062
A decade of hepatitis C virus management: insights from a large population-based cohort on treatment patterns, adherence, and outcomes
Poster presentation
Presenter: Fadi Abu Baker

2064
Glecaprevir/pibrentasvir in chronic HCV: an integrated analysis of patients on concomitant opioids, antipsychotics and cardiovascular medications
Poster presentation
Presenter: Curtis Cooper

2080
No DDI between Bemnifosbuvir/Ruzasvir and Bictegravir/Emtricitabine/Tenofovir Alafenamide
Poster presentation
Presenter: Xiao-Jian Zhou

2125
8 weeks of Glecaprevir/Pibrentasvir is highly effective in patients with genotype 3 hepatitis C related cirrhosis, irrespective of the presence of clinically significant portal hypertension
Poster presentation
Presenter: Fiona Marra

Viral Hepatitis: Experimental and pathophysiology

79
Ubiquitinated hepatitis D antigen induced specific cytotoxic T lymphocyte responses inhibited HDV replication via JAK/STAT pathway in HDV infected liver organoids
Poster presentation
Presenter: leer shen

126
STING activation suppresses viral replication but promotes liver inflammation and fibrosis in chronic hepatitis B concurrent with metabolic dysfunction-associated steatotic liver disease

Poster presentation
Presenter: Wenhui Wu

295

Epigenetic viral footprint of chronic HDV infection in HBV co-infected chimeric mice
Poster presentation
Presenter: Valerio Taverniti

499

In vitro characterization of elebsiran (VIR-2218), an investigational siRNA therapeutic targeting hepatitis B virus
Poster presentation
Presenter: Gregory Camus

596

Circulating miRNAs are downregulated in hepatitis delta patients that control viral replication
Poster presentation
Presenter: Javier Pérez Garreta

637

Novel, high-sensitive immunoassays for phosphorylated and non-phosphorylated HBcAg detection
Poster presentation
Presenter: Rene Geissler

644

Experimental HCV infection identifies ribosomal RNA 2'-O-methylation sites also affected across all etiologies and stages of chronic liver diseases
Poster presentation
Presenter: Pélagie Huchon

707

Analysis of intrahepatic cccDNA and HBV-DNA in patients with hepatocellular carcinoma attributed to non-HBV etiologies
Poster presentation
Presenter: Elena Vargas-Accarino

773

Eliminating hepatitis B with a combination of the newly revised Entecavir and Birinapant
Poster presentation
Presenter: Wu-Jyh Lin

817

Spatial profiling of HBV and HDV infection in human liver samples
Oral presentation
Presenter: Maria Saez-Palma

833

Pre-mRNA Processing Factor 4B kinase is associated with hepatitis B virus replication
Poster presentation
Presenter: Wei-Lun Tsai

987

Variability of the hepatitis delta virus and the role of the interferon I in a superinfected mice model
Poster presentation
Presenter: Maria Francesca Cortese

988

Detecting hepatocellular carcinoma by circulating cell-free DNA in patients with chronic hepatitis B

Poster presentation

Presenter: Bootsakorn Boonkaew

1022

Viral N6-methyladenosine modifications regulate hepatitis E virus infections

Poster presentation

Presenter: Mara Klöhn

1034

Hepatitis delta virus infection hotspots in Ethiopia: a multicenter study

Poster presentation

Presenter: Teklu Shiferaw Simbo

1147

Long non-coding RNA SNHG4 is regulated by hepatitis B virus and promotes hepatocarcinogenesis

Poster presentation

Presenter: BELAL AHMAD

1296

T helper 17 cell differentiation and the functional cure of chronic hepatitis B: insights from proteomic analysis and microRNA expression profiling of plasma-derived exosomes

Poster presentation

Presenter: Meng Zhao

1315

Adaptive NK cells are expanded in CMV-positive patients with chronic hepatitis B or hepatitis D and remain elevated after initiation of antiviral treatment

Poster presentation

Presenter: Gliga Smaranda

1516

Phenotypic characterization of untreated chronic hepatitis B infected individuals in an ethiopian cohort using fixed whole blood samples

Poster presentation

Presenter: Julia MacLeod

1528

Characterizing the molecular mechanism of hepatitis B virus cccDNA loss following mitosis

Oral presentation

Presenter: Yuchen Xia

1531

VDAC1-mediated lipid droplet-mitochondria tethering promotes tumorigenesis and inhibits HBV replication in CHB patients concurrent with MASLD

Poster presentation

Presenter: Zhe Dai

1577

Interferon- α induces robust neutralizing anti-HBs production by restoring the HBsAg-specific B cell immune response in nucleos(t)ide analogues experienced chronic hepatitis B patients

Poster presentation

Presenter: Zhize Yuan

1590

Identification of hepatitis B virus epitopes presented by human leukocyte antigen A*11:01 as potential targets for immunotherapy

Poster presentation

Presenter: Laura Partington

1866

A novel quintuplex long-amplicon droplet digital PCR assay reveals greater quantities of hepatitis B virus splice variants in people with HBV/HIV co-infection compared to HBV mono-infection

Poster presentation

Presenter: Tanner Grudda

1870

Description of tenofovir levels in south african adults in the EVOLVE study: a pilot project to support therapeutic drug monitoring in HBV infection

Poster presentation

Presenter: Gloria Sukali

1918

Discordance between peripheral hepatitis B surface antigen (HBsAg) titres and hepatic expression in chronic HBV infection

Poster presentation

Presenter: James Lok

1951

NTCP intronic polymorphism rs17556915 had no impact on HDV RNA levels and bulevirtide response in patients treated with bulevirtide

Poster presentation

Presenter: Yang Liu

1997

Recombinant polyclonal antibody GIGA-2339 potentially neutralizes hepatitis B and hepatitis D virus

Oral presentation

Presenter: Brett Higgins

2038

Synthetic interferon exhibits potent antiviral activity against HBV with the potential for an improved safety profile

Poster presentation

Presenter: Wade Blair

2052

Prolonged exposure to HBV suppresses the immunogenicity and antiviral efficacy of therapeutic vaccination

Poster presentation

Presenter: Anna D. Kosinska

2105

Next generation hepatitis B virus antisense oligonucleotides incorporating novel chemistries demonstrated significantly improved properties compared to current clinical candidates

Poster presentation

Presenter: Jin Hong

2116

Characterization of antigen specificity of T cell responses and HBV neutralization activity in a cohort of patients who achieved HBV HBsAg loss

Poster presentation

Presenter: Chunfeng Li

2316

Large spatial variation of intrahepatic HDV RNA levels without association with HBV core or S RNA levels in patients with HDV induced cirrhosis

Poster presentation

Presenter: Gustaf Rydell

2326

CD300A+CD8+T cells promote functional cure in patients with chronic hepatitis B under PEG-IFN- α

Poster presentation

Presenter: Wen-Xin Wang

2336

Hepatitis E virus entry requires the cholesterol transporter Niemann–Pick C1

Poster presentation

Presenter: Emely Richter

2342

A recent shift in the evolutionary dynamics of hepatitis A virus

Poster presentation

Presenter: Sanket Mukherjee

2401

Early kinetics of HBV and HDV serum and intrahepatic markers during and after liver transplantation: impact of HBIG and baseline HBsAg levels

Poster presentation

Presenter: Sara Battistella

2405

Peripheral helper CD4+ T cell functionality distinguishes between acute resolving and chronic hepatitis B

Poster presentation

Presenter: Peng Zhang

2410

CD16+ $\gamma\delta$ T cells are associated with antibody-dependent cellular cytotoxicity and viral control in chronic HBV infection

Poster presentation

Presenter: Paulina Schröter

2411

HDV infection induces cellular refractoriness to IFN- α , but not IFN- λ treatment

Poster presentation

Presenter: Claudie Eber

2445

FXR agonists as broad-acting antivirals against HBV/HDV/HEV and other hepato(cyto)tropic viruses

Poster presentation

Presenter: David Durantel

2508

No evidence for viral escape mutations in immunodominant HCV-specific CD4 T cell epitopes

Poster presentation

Presenter: Jill Werner

2544

Longitudinal analysis of viral profiles in chronic HBV/HDV coinfecting patients

Poster presentation

Presenter: Cristina Musolino

2602

Isogenic studies of basal-core promoter and precore mutations in hepatitis B genotype c

Poster presentation

Presenter: Leon Louis Seifert

2661

Persistent immune defects in innate-like CD8 T cells despite antiviral therapy in chronic hepatitis B

Poster presentation

Presenter: Lung Yi Loey Mak

2731

Inflammatory and oncogenic gene signatures in chronic hepatitis delta infection

Poster presentation

Presenter: Arshi Khanam

2742

On treatment modeling of ALT, HBVDNA and HBsAg in NUC-treated HBeAg-negative CHB patients helps to characterize the immune response and may predict clinical relapse after discontinuation

Poster presentation

Presenter: Piero Colombatto

2743

Sustained off-treatment inhibition of HBV replication and HBsAg levels after long-term treatment with ABI-4334 in differentiated HepaRG cells and primary human hepatocytes

Poster presentation

Presenter: Barbara Testoni

2746

Hepatitis B surface antigen specific CD4 T cell response in hepatitis B vaccinated individuals

Poster presentation

Presenter: Carolin Heni

2779

The nucleoside analogue NITD008 strongly suppresses viral replication in immunodeficient humanized mice stably infected with the hepatitis E virus

Oral presentation

Presenter: Maura Dandri

2784

Single-cell immune profiling of liver and blood reveals pretreatment signatures associated with treatment outcomes in young children with chronic hepatitis B

Poster presentation

Presenter: Chao Zhang

2905

Targeting hepatitis E virus with an innovative CRISPR-Cas13-based therapeutic approach

Poster presentation

Presenter: Yannick Brüggemann

2964

Early immune responses define Peg-IFN α -mediated treatment outcome in chronic hepatitis D virus infection

Poster presentation
Presenter: Helenie Kefalakes

2965
Naïve C57BL/6 mice immunized with CLB-405 and CLB-505 combined with a saponin-based adjuvant TQL-1055 exhibit a dose-dependent humoral and cellular immune
Poster presentation
Presenter: Aditi Deshpande

2993
HBV cccDNA: The molecular reservoir of hepatitis B persistence and challenges in eradication
Poster presentation
Presenter: Gulce SARI

3019
Immune response patterns in HBeAg (-) chronic hepatitis B patients during NA treatment depends on the viral activity at baseline
Poster presentation
Presenter: Miriam Frisch

3061
Developing personalised treatment pathways for hepatitis B using novel assays and fine needle liver aspirates
Poster presentation
Presenter: Mark Douglas

3099
Screening of different species reveals cat as a potential HBV infection model
Poster presentation
Presenter: Yuchen Xia